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CHAPTER I 
 
INTRODUCTION 
 
Background 
Cancer has been affecting humans for thousands of years. The first 
description of cancer was discovered in an Egyptian papyrus dated between 
3000-1500 BC (1). It referred to “tumours” of the breast. In Ancient Greece in 
about 400 BC Hippocrates, the "Father of Medicine", was the first to recognize 
the difference between benign and malignant tumors (1).  
The understanding, diagnosis and the fight against the cancer was 
progressing very slowly through the ages. The first cancer hospital was founded 
in Reims, France, in the 18th century with the belief that cancer was a contagious 
disease. The French gynecologist Recamier described the invasion of the 
bloodstream by cancer cells in 1829, coining the word metastasis (cancer 
spread) (2). 
It was not until 1953 when Francis Crick and James Watson unraveled the 
structure of DNA that allowed for a rapid development of the cellular and 
molecular biology (3). Since then the fight against the cancer has been based on 
a molecular level and has allowed for the development of anticancer therapies. 
In modern understanding, cancer is a group of diseases characterized by 
an uncontrolled growth and spread of abnormal cells. Usually cancer cells form a 
lump of tissue called a tumor, which can affect the organism severely, for 
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example by blocking blood vessels, pressing against nerves, or by releasing 
hormones that can affect the normal functions of the body. If cancerous cells 
break away from the main tumor and start growing and developing in other parts 
of the tissue this leads to its spread and the cancer becomes malignant. In order 
for the cancer cells to spread they must be able to leave their environment and 
travel through the blood or lymph system, a process called invasion. When 
cancer cells reach their new location, they must be able to make new blood 
vessels grow around them and supply them with oxygen and nutrients, a process 
known as angiogenesis. The whole process of a tumor gaining new mutations as 
it divides and then spreading to other parts of the body is called metastasis. If the 
cancer cells divide uncontrollably without being able to spread, they form a 
benign tumor, which can be removed with surgery. 
Cancer is caused by many factors including environment, lifestyle, and 
heredity. These factors may act together or in a sequence to promote the 
appearance of cancer. The uncontrolled cell division is usually a result of defects 
or damage in one or more of the genes involved in cell growth. If the damage in 
the genes is not repaired it leads to miscoding events, such as mis-pairing, 
deletion or translocation, which may result in permanent mutations. If these 
permanent mutations persist in critical regions of genes that are involved in cell 
division, this leads to multiple events that result in the appearance of cancer.   
There are four main types of gene involved in cell division - oncogenes, 
tumor suppressor genes, suicide genes and DNA-repair genes. Oncogenes are 
genes that start and accelerate the growth of a cell. If these genes are damaged, 
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the cells are permanently instructed to divide and can become cancerous. The 
tumor suppressor genes have an opposite function to the oncogenes, they stop 
the cell division. One of the most important tumor suppressor genes is p53, 
which is involved in signaling apoptosis. Most cancer cells have mutation in this 
gene. The suicide genes control apoptosis, or cell suicide. Cells are usually able 
to commit suicide whenever something goes wrong in order to prevent damage 
to the neighboring cells or passing on damaged genetic material. If these suicide 
genes become damaged, then a faulty cell can keep dividing and become 
cancerous. DNA-repair genes are encoded proteins whose function is to repair 
damaged DNA. If these genes are damaged, cell loses its ability to repair 
damaged DNA. DNA damage can then accumulate in the cell, leading to further 
mutations and ultimately cancer. 
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DNA Damage and Its Consequences 
  
Environmental and Chemical Carcinogenesis 
Humans are continuously exposed to exogenous and endogenous 
chemicals that have been shown to induce DNA mutations and cancer. Exposure 
to these chemicals occurs because they are present in food, air or water or they 
are products of cell metabolism. 
In 1761, Dr. John Hill first linked the development of nasal cancer in 
people who used tobacco snuff excessively (4). It was 14 years later when Sir 
Percival Pott related the appearance of scrotal cancer in chimney sweeps to their 
occupation (5). In 1915, Yamagiwa and Ichikawa were the first to conduct 
experimental carcinogenesis (6). They repeatedly painted coal tar on the ears of 
rabbits and succeeded in producing multiple squamous cell carcinomas in the 
painted areas. Their experiments led to the discovery of a pure carcinogenic 
chemical, 1,2,5,6-dibenzanthracene. Several years later PAH’s were discovered 
as the active carcinogens in tar by two independent research groups (7, 8). 
By the end of 1970’s many chemicals were established as carcinogens 
and a question was raised of what was the mechanism of action of these 
carcinogens in genotoxicity. Of particular importance was the work by the Millers 
(9) and others (10), who showed that most of the carcinogens were metabolized 
or bio-activated to more potent species (metabolite), which were called the 
“ultimate carcinogens”. The “ultimate carcinogen”, in its initial perception, was an 
electrophile that was formed in vivo, had finite stability, and could diffuse limited 
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distances to covalently modify DNA. This early perception of ultimate carcinogen 
led to the idea that carcinogens can be only activated in vivo by nuclear enzymes 
(11). Years later, it was shown that metabolites that react with DNA could be 
generated in hepatocytes and even trapped outside the cells (12). Moreover, it 
was established that enzymes that are involved in the detoxication of cells could 
activate chemical carcinogens. For example, gluthathione transferase can 
activate haloalkenes and 1,2-dihaloethanes, and P450 enzymes can epoxidize 
vinyl halides and polycyclic hydrocarbons by converting them to more reactive 
electrophiles (13). 
In the last 25 years the field of chemical toxicology has developed 
tremendously due to the development of more sophisticated experiments and 
methods for analysis of the action of carcinogens in vivo and in vitro. Today’s 
science relies on the use of genome modified systems, molecular biology, 
chemical synthesis of carcinogens, nuclear magnetic resonance spectroscopy 
(NMR), mass spectrometry (MS), protein crystallography, and other techniques 
to answer the questions of how the carcinogens actually induce cancer. It is 
considered that the reaction of carcinogens with DNA is the one of the earliest 
events of development of cancer. Many carcinogens react with DNA to form 
different covalent complexes referred as DNA adducts. If these DNA adducts are 
not repaired prior replication, they can cause mutations in the genes involved in 
important cellular functions as was discussed earlier. 
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Formation of Formamidopyrimidine-dGuo (FAPy-dGuo) Lesions via  
Oxidation 
DNA damage can be generated by the reaction of DNA with reactive 
oxygen species (ROS’s), such as superoxide radical anion, hydrogen peroxide, 
and hydroxyl radical (14-17). These ROS’s are products of normal cellular 
metabolism. Electron transport chains have a potential to “leak” electrons to 
oxygen which results in the formation of superoxide (18). Superoxide is also 
formed by certain enzymes. For example, phagocytes release ROS’s in order to 
destroy cells infected with viruses or bacteria. The ROS’s can react with the DNA 
resulting in the formation of strand breaks, DNA-protein cross-links, abasic sites 
and more then 20 oxidized base lesions including 8-oxo-dGuo (1.03) and FAPy 
lesions derived from dAdo and dGuo. 
The FAPy-dGuo (1.04) lesion is formed from the addition of hydroxyl 
radical to the double bond of C8 position of dGuo moieties (1.01) in DNA giving 
an intermediate guanyl radical (1.02) (Figure 1-01). One-electron oxidation of 
guanyl radical (1.02) leads to the formation of 8-oxo-dGuo (1.03). A competitive 
pathway is the one-electron reduction of this intermediate guanyl radical (1.02) 
followed by ring-opening resulting in a FAPy-dGuo (1.04) lesion. In general, 8-
oxo-dGuo (1.03) is the most abundantly formed DNA lesion; however, there is at 
least one report concerning human leukemia cells in which the ratio FAPy-dGuo 
(1.04) : 8-oxo-dGuo (1.03) is almost 3 (19).  
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Figure 1-01. Formation of 8-oxo-dGuo (1.03) and FAPy-dGuo (1.04) 
lesions via oxidation of dGuo moieties (1.01) in DNA. 
 
 
Studies on the mutagenicity and the repair of both 8-oxo-dGuo (1.03) and 
FAPy-dGuo (1.04) lesions have been conducted. The 8-oxo-dGuo (1.03) lesion is 
miscoding and results in GC→TA transversions, which have been observed in 
vivo in the ras oncogene and the p53 tumor suppressor gene in lung and liver 
cancers (18). The reason for the GC→TA transversions is that  8-oxo-dGuo 
(1.03) can adopt a syn conformation during replication or transcription of DNA, 
which can cause mis-pairing with dATP through Hoogsteen base pairing (Figure 
1-02) (20). 
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Figure 1-02. Formation of Hoogsteen base pairing between 
8-oxo-dGuo (1.03) and dAdo. 
 
 
Many in vitro replication studies of the FAPy-dGuo adduct (1.04) have 
been conducted using Klenow fragment from Escherichia coli DNA polymerase I 
exo– (Kf–). The FAPy-dGuo adduct (1.04) was efficiently bypassed and dATP was 
preferentially mis-incorporated opposite of the adduct (21). 
Interestingly, repair studies of FAPy-dGuo (1.04) showed that this adduct 
is excised by formamidopyrimidine DNA glycosylase (FPG) much more efficiently 
opposite dCyd than when it mis-pairs with dAdo (22). Several reasons were 
given to explain this observation. First, it was observed that FAPy-dGuo:dCyd 
lesion is twenty-fold more tightly bound than the FAPy-dGuo:dAdo lesion to the 
FPG protein, which suggested that the FAPy-dGuo lesion is preferentially 
recognized when it is paired with dCyd rather then with dAdo. Second, if the 
FAPy-dGuo:dAdo is repaired by FPG, this would allow the retention of the mis-
incorporated dAdo resulting in dGuo→Tyd transversion, an outcome that does 
not preserve the genomic integrity of the organism. 
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Structural insight in the binding and recognition of FAPy-dGuo’s by the 
FPG protein was provided by the work of Coste and Casting (23). Their work 
revealed that cFAPy-dGuo (G*), a carbocyclic analogue of FAPy-dGuo (Figure 1-
03) that does not undergo anomerization, is bound to FPG protein in the anti 
conformation in contrast to the 8-oxo-dGuo (1.03), which is bound in a syn 
conformation (20). The binding of the cFAPy-dGuo (G*) is established by 
interaction of all the functional groups of the cFAPy-dGuo base with the FPG 
protein (Figure 1-03). 
 
 
 
 
Figure 1-03. Interactions between the extrahelical cFAPy-dGuo (G*) and FPG 
residues inside the active site binding pocket: amino acid residues of Ll-FPG 
involved in the recognition are shown in red and the DNA are shown in blue; C, 
the cytosine opposite cFapydGuo (G*); p0 and p_1 indicate the phosphate groups 
bordering the lesion; small green circles represent the water mediated 
interactions; black dashed lines represent hydrogen bond interactions (23). 
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The pyrimidine moiety of the cFAPy-dGuo (G*) is involved in the Watson-
Crick face recognition and contribute to the proper orientation of the pyrimidine 
ring in the binding pocket. The functional groups, derived from the ring-opening 
of the imidazole ring of dGuo, are suggested to play an important role in the 
rotameric selection of FAPy-dGuo’s. 
The first repair studies of FAPy-dGuo (1.04) in mammalian cells were 
reported by Bohr and Greenberg (24). The source of the mammalian cells were 
mitochondrial and nuclear extracts from the wild type and knock-out mice lacking 
one of the major DNA glycosylases for repair of oxidative DNA damage - OGG1. 
The repair studies of FAPy-dGuo (1.04) with the mitochondrial and nuclear 
extract from the wild type mouse showed that this lesion is efficiently repaired by 
OGG1, while the repair studies of FAPy-dGuo (1.04) with the mitochondrial and 
nuclear extract from the knock-out mice showed that FAPy-dGuo (1.04) was still 
repaired but with a low efficiency. It was suggested that in the absence of OGG1, 
which repairs 8-oxo-dGuo (1.03) in mouse liver mitochondria (25), another 
enzyme NEIL1 (human homologue of E. coli endonuclease VIII) may function as 
a backup glycosylase for FAPy-dGuo (1.04). Interestingly, NEIL1 does not 
participate in the repair 8-oxo-dGuo (1.03) in mouse liver mitochondria (26). 
The repair of both 8-oxo-dGTP (1.05) and FAPy-dGTP (1.06) was 
investigated with the MTH1 protein, which is a mammalian homologue of E. coli 
MutT and is involved in the hydrolysis of 8-oxo-dGTP (1.05) in the nucleotide 
pools (Figure 1-04). The experiments showed that the FAPy-dGTP (1.06) was 
hydrolyzed more then ten-fold less efficiently then 8-oxo-dGTP (1.05). The poor 
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recognition of FAPy-dGTP (1.06) by MTH1 might be due to the loss of the two-
ring system (purine), which is necessary for the stacking interaction between the 
substrate and the enzyme, and the presence of several FAPy-dGuo (1.06) 
isomers one of which could be an inhibitor (27). 
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Figure 1-04. Structures of the 8-oxo-dGTP (1.05) and FAPy-dGTP (1.06). 
 
 
Since FAPy-dGTP (1.06) is a poor substrate for MutT, a hypothesis was 
proposed that FAPy-dGTP (1.06) could be produced in the nucleoside 
triphosphate pool as a result of oxidative stress and become a source of FAPy-
dGuo (1.04) adduct in duplex DNA (28). Experiments conducted with Klenow 
fragment showed that FAPy-dGTP (1.06) is incorporated opposite dC 1000 times 
less efficiently than is dGTP, but calculations were made that a FAPy-dGTP 
(1.06) concentration of 1% that of the dGTP concentration would yield several 
FAPy-dGuo lesions (1.04) per million base pairs of DNA, which is sufficient to 
give the levels of detected FAPy-dGuo (1.04) in cellular DNA (29, 30).  
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In mammalian cells, (cos-7), FAPy-dGuo (1.04) is mutagenic and induces 
FAPy-dGuo→T transversions (31). The levels of the mutational frequency were 
sequence dependant. For example, Fapy-dGuo (1.04) gave 30 % mutation in 5’-
T-(FAPy-dGuo)-T context compared to 8% in 5’-T-(FAPy-dGuo)-A context. 
 
 
Formation of N5-Alkylated Formamidopyrimidine-dGuo Lesions by  
Alkylating Agents 
DNA can also be damaged by alkylating agents (electrophiles), which 
react with the nucleophilic centers, such as oxygen or nitrogen atoms of the DNA 
base or backbone. When these agents react with the oxygen atoms of the DNA 
phosphodiester backbone, a phosphotriesters is formed (32, 33) and when they 
react with the DNA bases, DNA adducts are formed. The DNA adduct together 
with the opposite base is usually called a lesion. 
The N7 position of the dGuo is generally regarded as the most 
nucleophilic site of DNA (1.01) and upon alkylation results in the formation of an 
N7-alkyl cationic dGuo intermediate (1.07). The N7-alkyl cationic species (1.07) 
can readily depurinate resulting in an abasic sites (1.08) in DNA (34). Abasic 
sites are strong blocks to replication, but when bypassed they induce the 
misincorporation of dAdo (35, 36). Alternatively, addition of hydroxide to the C8-
position of the N7-cationic dGuo intermediate (1.07) followed by ring-opening 
gives raise to 2,6-diamino-4-hydroxy-N5-alkyl-formamidopyrimidine (N5-alkylated 
FAPy-dGuo) (1.09) lesion (Figure 1-05). 
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Figure 1-05. Alkylation of dGuo moieties (1.01) in DNA and formation 
of abasic site (1.08) and N5-alkyated FAPy-dGuo lesion (1.09). 
 
 
 An example of a N5-alkylated FAPy-dGuo adduct (1.09) that forms as a 
results of the N7 dGuo alkylation is aflatoxin B1 (1.10), which is produced by 
several fungal species that contaminate food supplies (37). Aflatoxin BB1 is 
metabolized by a cytochrome P450 to aflatoxin B1-8,9-exoepoxide (1.11), the 
ultimate carcinogenic species (38). This aflatoxin B1 epoxide intercalates into 
DNA and then alkylates the N7 position of dGuo moieties to form an aflatoxin B1 
N7-cationic dGuo species (39). Base catalyzed ring-opening of the imidazole ring 
produces trans-8,9-dihydro-8-(2,6-diamino-4-oxo-3,4-dihydropyrimid-5-yl-
formamido)-9-hydroxyaflatoxin B1 (AFB1-FAPy-dGuo) as a mixture of isomers 
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(1.12 and 1.13) (Figure 1-06) (40). Site-specific mutagenesis showed that the 
AFB1-FAPy-dGuo adduct(s) was more mutagenic that the N7-cationic dGuo 
species when replicated in Escherichia coli using a single-stranded DNA 
replication vector giving high levels of dGuo → dTyd transversions (34). 
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N5-Alkylated FAPy-dGuo adduct could be also formed from butadiene 
(BD) (1.14), which is a well-established carcinogen in rodents and humans (41). 
BD (1.14) is epoxidized in two steps by cytochrome P-450 to form 3,4-
epoxybutane (1.15) and 1,2,3,4-diepoxybutane (1.16), which are the ultimate 
carcinogenic species (Figure 1-07). These epoxides react with DNA to form 
several adducts of dGuo and dAdo moieties in DNA (42). In addition to those 
adducts, Elfara and coworkers reported the formation of an adduct 1.19 that 
could be formed via an N5-alkylated FAPy-dGuo intermediate (1.18) (43) (Figure 
1-08). 
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Figure 1-07. Structures of trans-butadiene (1.14), 3,4-epoxybutadiene 
(1.15) and 1,2,3,4-diepoxybutadiene (1.16). 
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Figure 1-08. Formation of adduct 1.19 via the N5-alkylated FAPy-dGuo 
intermediate 1.18. 
 
 
 There are alkylating agents that can react directly (without metabolic 
activation) with dGuo moieties in DNA to form N5-alkylated FAPy-dGuo lesions. 
In this category of alkylating agents are nor-nitrogen mustard (1.20) (44), 
aziridine (1.21) (45, 46), alkyl halides (1.22-1.26) (47-51) and mitomycin C (1.27) 
(Figure 1-09) (52). The most biological important N5-alkylated FAPy-dGuo lesions 
formed by the above mentioned alkylating agents are the mitomycin FAPy-dGuo 
(1.28) nor-nitrogen mustard FAPy-dGuo (1.29), and MeFAPy-dGuo (1.30) 
lesions, formed from mitomycin C (1.27), nor-nitrogen mustard (1.20) and methyl 
halides (1.24-1.26), respectively (Figure 1-10). 
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Figure 1-09. Structures of nor-nitrogen mustard (1.20), aziridine (1.21), alkyl 
halides (1.22 - 1.26) and mitomycin C (1.27) that are known to form N5-alkylated 
FAPy-dGuo adducts. 
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Figure 1-10. Structures of mitomycin FAPy-dGuo (1.28), not-nitrogen mustard 
FAPy-dGuo (1.29) and MeFAPy-dGuo (1.30) adducts. 
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 Mitomycin C (1.27), isolated from Streptomyces caespitosus, is a clinical 
used antitumor agent used for the treatment of bladder, rectal, pancreatic, lung 
and breast cancers. It reacts with DNA in vivo and in vitro resulting in the 
formation of several DNA adducts including mitomycin FAPy-dGuo (1.28) as a 
minor product. Interestingly this FAPy-dGuo adduct (1.28) is formed in slightly 
acidic conditions (52). 
 The other important biological N5-alkylated FAPy-dGuo lesion can be 
formed via alkylation of dGuo moieties in DNA by nor-nitrogen mustard (1.20). 
This alkylating agent is a metabolite of a family of nitrogen mustard 
chemotherapeutic agents, such as cyclophosphamide (1.31). The 
cyclophosphamide (1.31), used to treat a variety of cancers, is metabolized to the 
cytotoxic alkylating agent phosphoramide mustard (1.34), which can be 
dephosphoramidated to give nor-nitrogen mustard (1.20) (Figure 1-11). 
The DNA alkylation chemistry of nor-nitrogen mustard (1.20) is complex. It 
forms monoalkylated adducts at a number of different sites on DNA including the 
N7 position of dGuo, which can undergo hydroxide ring-opening to form the nor-
nitrogen mustard FAPy-dGuo adduct (1.29). 
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Figure 1-11. Formation of nor-nitrogen mustard (1.20) from the metabolic 
activation of cyclophosphamide (1.31). 
 
 
Methyl halides (1.24 - 1.26) and other methylating agents, such as 
dimethyl sulfate (1.35), methylmethane sulfonate (1.36), N-methyl-nitrosourea 
(1.37), N,N-dimethyl-N-nitrosoamine (1.38) (Figure 1-12), react with dGuo 
moieties of DNA to form preferentially N7 and O6-guanine adducts. The O6-
methylguanine adduct incorrectly pairs with dTTP during DNA replication, leading 
to a GC→AT base transition mutation (53). The N7-methyl dGuo cationic species 
undergo imidazole ring-opening, analogues to N7-aflatoxin B1 dGuo cationic 
adduct, in neutral or basic conditions to generate 2,6-diamino-4-hydroxy-N5-
methyl-formamidopyrimidine (MeFAPy-dGuo) lesions (1.30) (54). This important 
DNA lesion will be a main focus in Chapter II of this dissertation.  
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Figure 1-12. Structures of dimethyl sulfate (1.35), methylmethane sulfonate 
(1.36), N-methyl-N-nitrosourea (1.37) and N,N-dimethyl-N-nitrosoamine 
(1.38). 
 
 
The repair of the N5-alkylated FAPy-dGuo lesions has not been well 
studied due to the lack of convenient pathways for the preparation of 
oligonucleotides that contain these lesions at define location. Thus far, there 
have been several reports regarding the repair of AFBB1-FAPy-dGuo (1.12 and 
1.13) and MeFAPy-dGuo lesions (1.30) in which ss-DNA containing a single 
dGuo residue was alkylated with aflatoxin B1 8,9-epoxide (1.11) or dimethyl 
sulfate (1.35), respectively (55, 56). The MeFAPy-dGuo (1.30) containing 
oligonucleotides also were obtained via site-specific incorporation of N7-methyl 
dGTP by PCR (57, 58). The syntheses of oligonucleotides containing AFB1-
FAPy-dGuo (1.12, 1.13) and MeFAPy-dGuo (1.30) lesions by the afore-
mentioned methods are not convenient and have many restrictions, which will be 
discussed in Chapter II of this dissertation. 
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The repair studies on the MeFAPy-dGuo (1.30) lesion usually with respect 
to the repair of 8-oxo-dGuo (1.03), have been performed (58). In general, the 
DNA repair enzymes that repair the 8-oxo-dGuo (1.03) adduct recognize and 
repair FAPy-dGuo (1.04) and MeFAPy-dGuo (1.30) adducts. The DNA repair 
enzymes that are used in these studies are the E. coli FPGMutM, a glycosylase 
removing 8-oxo-dGuo (1.03) from 8-oxo-dGuo:dCyt pairs; MutY, a 
monofunctional glycosylase that excises dAdo form 8-oxo-dGuo:dAdo mispairs; 
and MutT, a phosphatase that degrades the triphosphate of 8-oxo-dGuo (1.05). 
Human homologues of the FPG, MutY, and MutT have been cloned and also 
used for the repair studies of MeFAPy-dGuo (1.30). Experiments with human 
MutT and FPG showed distinct preferences towards 8-oxo-dGuo (1.03) of 20 and 
12-fold, respectively, between the most (dGuo) and the least preferred base 
(dCyd) opposite the lesion. Such preferences were not observed for the 
MeFAPy-dGuo (1.30) adduct, which suggested that MeFAPy-dGuo (1.30) is most 
likely not subjected to complementary base-dependant repair. In contrary to this 
suggestion, experiments with prokaryotic and mammalian thymine glycol (Tg) 
glycosylases including E. coli endonuclease III (endonuclease III), endo VIII 
(endonuclease VIII) and the mouse endo III homologue showed that the 
recognition of MeFAPy-dGuo (1.30) was pair dependant, the highest being with 
dGuo and the lowest with dCyt (57). An explanation for this observation is the 
formation of hydrogen bonds between the 8-oxo-dGuo (1.03) or MeFAPy-dGuo 
(1.30) and dCyt in analogy to this in the G:C base pair, which does not cause 
flipping out of the corresponding DNA adducts. The flipping out of the DNA 
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adducts is suggested to be one of the reasons how the repair enzymes recognize 
the DNA damage. 
There are several reports on the repair of AFB1-FAPy-dGuo (1.12 and 
1.13) lesion in comparison to either the AFB1-N7-dGuo (N7-afaltoxin B1 alkylated 
dGuo) or MeFAPy-dGuo (1.30) lesions. It was demonstrated that E. coli uvrABC 
enzyme, which exhibits nucleotide excision repair (NER), can incise both AFB1-
FAPy-dGuo (1.12 and 1.13) and AFB1-N7-dGuo adducts with equal efficiency in 
vitro (56); however in another study the FPG protein, which exhibits BER as well, 
was only able to remove AFB1-FAPy-dGuo (1.12, 1.13) adduct but not the 
cationic AFB1-N7-dGuo adducts (59). 
Essigmann and coworkers investigated the in vitro and in vivo repair of 
AFB1-FAPy-dGuo (1.12 and 1.13) lesion. The in vitro repair of  AFBB1-FAPy-dGuo 
(1.12 and 1.13) lesion was compared to the in vitro repair of 8-oxo-dGuo (1.03) 
and MeFAPy-dG (1.30) lesions by MutM and hOGG1, and the in vivo repair of 
AFB1-FAPy-dGuo (1.12 and 1.13) lesion was compared to the in vivo repair of 
AFB1-N -dGuo lesion (55). The in vitro repair experiments showed that the 8-oxo-
dGuo (1.03) and MeFAPy-dGuo (1.30) adducts were excised, whereas the AFB
7
1-
FAPy-dGuo (1.12 and 1.13) adduct was comparatively less efficiently excised. 
This observation was contrary to what was previously observed for AFB1-FAPy-
dGuo (1.12 and 1.13) by Chetsanga (59) and Oleykowski (56) probably due to 
the use of shorter oligonucleotides, which may not have been optimal for FPG 
and hOGG1 enzymes. 
 22
The in vivo repair experiments with the AFB1-FAPy-dGuo (1.12 and 1.13) 
and AFB1-N7-dGuo lesions were conducted with wild-type, nucleotide excision 
repair (NER) deficient, BER-deficient (MutM) and NER/BER double deficient 
mutants of E. coli. The repair experiments showed that both AFB1-FAPy-dGuo 
(1.12 and 1.13) and AFB1-N7-dGuo lesions are preferentially repaired by NER 
(55). 
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DNA Replication 
 DNA replication is needed to pass on genetic information from the 
parental cells to daughter cells. The DNA replication occurs in a semi-
conservative fashion where each strand of the parental duplex serves as a 
template for the newly generated strands. The DNA replication begins with the 
binding of T-antigen (helicase) to the replication origin and causes a partial 
unwinding of the double helix at an area known as the “replication fork” (Figure 1-
13) (60, 61). As the DNA is unwound specific single stranded DNA binding 
proteins (replication factor A) prevent the strands from re-annealing. The 
replication fork is a Y-shaped structure that moves steadily along the parental 
DNA duplex. The replication of DNA is performed by DNA polymerases, which 
catalyze the synthesis of DNA in the 5’ to 3’ direction. The two strands of the 
DNA double helix are not replicated in the same manner, because they run anti-
parallel to one another. The lagging strand is synthesized in the 5’ to 3’ direction 
by a series of short Okazaki fragments. These fragments are stretches of 100 to 
200 nucleotides in humans (1000 to 2000 in bacteria) and are stitched together 
by a DNA ligase to create a continuous strand. 
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 Figure 1-13. Illustration of DNA replication fork (37). 
 
 
 
DNA Polymerases 
 
Replicative Enzymes 
DNA replication is catalyzed by replicative enzymes that form a bond 
between the 5'-phosphate of the incoming nucleotide (the other two phosphate 
groups from the nucleotide triphosphate serve as a leaving group during 
phosphodiester formation) and the 3'-OH group of the nucleotide at the end of 
the growing DNA chain with high fidelity. The error rate of these enzymes is 
about one in 108 – 1012 nucleotide copying events. This low rate of mis-
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incorporation is achieved by several factors. The active sites of these enzymes 
are tight and do not allow incorporation of an incorrect nucleotide. Another 
hypothesis states that DNA polymerase may also discriminate against the 
incorrect triphosphate by an induced-fit conformational change (62, 63). After 
incorporation of the correct base, the replicative enzyme undergoes 
conformational changes in the active site to bring certain residues into alignment 
to provide transition-state stabilization for the catalysis of phosphodiester bond 
formation. Following a mis-incorporation event, the enzyme selects against the 
resultant mismatched DNA by a slow, rate-limiting chemistry step (Figure 1-14). 
This process allows the polymerase to release the mismatched DNA from its 
active site by excision. In addition, most replicative enzymes possess this 
intrinsic 3’ to 5’-exonuclease activity, or proofreading capabilities. 
 
 
EpDNAn EpDNAn+1ExDNAn-1 + dNMP
KpnextKx
exc
 
Figure 1-14. Illustration of the induced-fit mechanism for exclusion of mis-
incorporated dNTP: EpDNAn - enzyme-DNA complex, EpDNAn+1 - enzyme-DNA 
complex with the next correct dNTP, ExDNAn-1 - enzyme-DNA complex with the 
excluded mismatched base. 
 
 
Based of sequence similarities, DNA polymerases are classified in three 
groups: type A, type B and type C, which have homology to pol A (pol I), pol B 
(pol II) and pol C (pol III) from E. coli, respectively. The eukaryotic polymerase δ 
belongs to type B. The role of polymerase δ in replication however is not clear 
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although there is evidence that it participates in post-replicational DNA repair 
(64). 
 
Translesion Synthesis (Bypass) Polymerases 
The translesion (bypass) DNA polymerases are able to synthesize past 
DNA lesions that block DNA replication by replicative DNA polymerases (65, 66). 
These enzymes are classified in two groups - the Y-family and B-family. The 
human Y-family consists of human pol η, κ and ι and Rev1, while human pol ξ is 
a part of the B-family. Several other bypass DNA polymerases were also 
discovered, but their role in translesion synthesis has not been very well 
established. The bypass DNA polymerases have low fidelity (103-104) that results 
in the mis-incorporation of nucleotides. One of the reasons for this is that the 
active site is larger than those of replicative polymerases. For example, the 
active site of the Y-family polymerase Dpo4, isolated from archaeal aerobic 
thermophile Sulfolobus solataricus can allow the accommodation of two 
nucleotides, which results in the misincorporation of the same nucleotide across 
the adduct and the first base past the adduct, respectively. In contrast to the 
replicative polymerases, the Y-family DNA polymerases lack any intrinsic 
exonucleolase activity and replicate DNA in a distributive manner where the 
enzyme dissociates from the DNA after the addition of only a few nucleotides. It 
was observed that proliferating cell nuclear antigen (PCNA) stimulates the 
efficiency of nucleotide incorporation by Y-family polymerases opposite 
undamaged as well as damaged templates (67). The exact mechanism of the 
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action of PCNA is not known, but it was suggested that monoubiquitination of 
PCNA disrupts the binding of the replicative polymerases to the template-primer 
complex, which enables the binding of the TLS polymerase to PCNA and to the 
other components of the replication ensemble (68, 69). 
 
 
Dissertation Aims 
 The aim of this dissertation is to study the chemistry of two important DNA 
lesions, MeFAPy-dGuo (1.30) and 2-oxoethyl-FAPy-dGuo (1.39) (Figure 1-15). 
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Figure 1-15. Structures of the MeFAPy-dGuo (1.30) and  
2-oxoethyl-FAPy-dGuo (1.39) lesions. 
 
 
In Chapter II, an efficient four step synthesis of the MeFAPy-dGuo 
phosphoroamidite was developed, which allowed the preparation of 
oligonucleotides containing the MeFAPy-dGuo lesion (1.30). The aims of Chapter 
II are: 
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1. Synthesis of MeFAPy-dGuo phosphoroamidite reagent required for solid-
phase synthesis of MeFAPy-dGuo (1.30) containing oligonucleotides. 
2. NMR structural determination of the furanose and pyranose forms of 
MeFAPy-dGuo adduct (1.30) in trinucleotides. 
3. Examination of the mis-incorporation profile of MeFAPy-dGuo (1.30) 
catalyzed by prokaryotic (Klenow fragment exo– of E. coli, pol II–, and 
Dpo4) and eukaryotic (human pol η, κ and ι) DNA polymerases. 
4. Determine the steady-state kinetics for the base incorporation opposite the 
MeFAPy-dGuo adduct (1.30) catalyzed by prokaryotic and eukaryotic DNA 
polymerases. 
5. Examination of the full-length extension products past the MeFAPy-dGuo 
lesion (1.30) catalyzed by prokaryotic and eukaryotic DNA polymerases. 
The sequence of the full-length extension products was determined by an 
LC-ESI/MS/MS method. 
 
In Chapter III, it was hypothesized that (2-oxoethyl)-FAPy-dGuo (1.39) 
adduct could be formed from the N7-dGuo alkylation of DNA with 2-chlorooxirane 
and related oxiranes, such as the other halooxiranes, 2-acetoxyoxirane and 2-
cyanooxirane, followed by hydroxide ring-opening of the corresponding N7-
alkylated dGuo cationic species. The (2-oxoethyl)-FAPy-dGuo adduct (1.39) was 
synthesized, its spectral properties characterized, and used as a standard to 
identify its formation in the reaction of 2-acetoxyoxirane with dGuo and DNA. 
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This epoxide was used as model for the reactivity of 2-chlorooxirane and the 
related oxiranes listed above. The aims of Chapter III are: 
1. Synthesis and spectral characterization of (2-oxoethyl)-FAPy-dGuo (1.39). 
2. Examination of the reactivity of 2-acetoxyoxirane towards dGuo. 
3. Examination of the formation of (2-oxoethyl)-FAPy-dGuo adduct (1.39) in 
oligonucleotides treated with 2-acetoxyoxirane. 
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CHAPTER II 
 
SYNTHESIS, SITE-SPECIFIC INCORPORATION AND TRANSLESION 
SYNTHESIS PAST THE MeFAPy-dGuo ADDUCT IN DNA  
 
Introduction 
 
Formation of MeFAPy-dGuo (2.05) Lesion, Endogenous and Exogenous 
 Methyl Sources
MeFAPy-dGuo (2.05) is not only an important biological lesion, but 
also a useful probe for investigating specific protein-DNA interactions (1, 2). It 
is formed upon initial methylation at the N7-position of dGuo moieties (2.01) in 
DNA by methylating agents followed by hydroxide ring-opening of the 
imidazole ring as described in Chapter I (Figure 2-01). The major endogenous 
source of the cationic N7-methyl-dGuo species (2.02) is from the reaction of 
dGuo moieties (2.01) of DNA and S-adenosyl-L-methionine (2.06) (SAM) 
(Figure 2-02); SAM is present in high concentrations in the nucleous and is 
used to methylate dCyt and dAdo in DNA, which play an important role in the 
regulation of gene expression (3-5). Other endogenous methyl sources are 
betaine (2.07), choline (2.08), and N-nitroso compounds (Figure 2-02) (6).  
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Figure 2-01. Alkylation of dGuo moieties (1.01) in DNA and formation 
of abasic site (2.03) and MeFAPy-dGuo lesion (2.05). 
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Figure 2-02. Structures of endogenous and exogenous methylating agents: 
SAM (2.06), betaine (2.07), choline (2.08), N-methylnitrosourea (2.09), 
methyldiazohydroxide (2.10) and NNK (2.11). 
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For example, N-methylnitrosourea (2.09) (Figure 2-02) can be formed 
by nitrosation of methylurea, which is a product of the reaction of the 
catabolite methylamine and carbamyl phosphate, the latter is a precursor of 
pyrimidines (7, 8). 
The major exogenous methyl sources are the N-nitrsoamines that are 
present in food, tobacco smoke, or are part of the environmental pollutants. 
The N-nitrosoamines undergo metabolic activation to yield 
methyldiazohydroxide (Figure 2-02) (2.10), which is the methylating agent (9, 
10). Analysis of laboratory animals treated with 4-(methylnitrosoamino)-1-3-
pyridyl)-1-butanone (2.11) (NNK) (Figure 2-02), the most abundant and the 
strongest carcinogen in tobacco (11, 12), showed the following distribution of 
adducts in their lungs: N7-methylguanine, O6-methylguanine and to lesser 
extend of O4-methylthymine. 
 
 
Formation of MeFAPy-dGuo (2.05) Lesions and Abasic Sites (2.03) 
There are a number of factors that govern the partitioning between the 
abasic site (2.03) and the MeFAPy-dGuo (2.05) from the cationic N7-methyl-
dGuo intermediate (2.02) (Figure 2-01). In general, the formation of abasic 
sites (depurination) (2.03) is favored at neutral or acidic pH, and the formation 
of MeFAPy-dGuo (2.05) lesion in basic conditions. For example, the 
depurination of the cationic N7-methyl-dGuo species (2.02) occurs with t1/2 = 
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4.4 h at pH 4.4 and 24 °C, whereas the ring-opening occurs with t1/2 = 4.3 h at 
pH 10 and 24 °C (13). 
The structure of duplex DNA also plays role in the depurination and the 
ring-opening of the cationic N7-methyl-dGuo species (2.02) (Figure 2-01). 
Usually depurination is faster in single-stranded (ss) than double stranded 
(ds) DNA, while similar dependence has not been clearly observed for the 
ring-opening (14). In ds-DNA, under physiological conditions, the depurination 
of 2.02 is predominant and the formation of MeFAPy-dGuo (2.05) is very slow 
(15, 16). In spite of this slow formation of MeFAPy-dGuo (2.05) in vitro, 
experiments with rats treated with methylating agents showed that MeFAPy-
dGuo  (2.05)  was formed in significant amounts (17, 18). 
The structural environment of the cationic N7-methyl-dGuo (2.02) and 
the N7-methyl-Guo (2.12) species affects the rate of formation of the 
corresponding MeFAPy-dGuo (2.05) and MeFAPy-Guo (2.13) lesions. In 
polymeric systems, such as poly-7-methyl-dGuo and poly-7-methyl-dGuo-
dCyt sequences, the ring-opening occurs very slowly and these systems were 
described as “remarkably resistant to ring opening at pH 8.9 and 37 °C (19). It 
was also found that in RNA, the depurination of 2.12 is slow and the formation 
of MeFAPy-Guo (2.13) lesion is about 2-3 times greater then in DNA (19, 20). 
Presumably, the reason why the depurination is very slow in RNA is the affect 
of the hydroxyl group at the 2’-position of the sugar moiety. The electron-
withdrawing hydroxyl group destabilizes the oxocarbenium ion-like transition 
state (2.14) of the depurination reaction (Figure 2-03). 
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Figure 2-03. Effect of the structural context on the rate of ring-opening: 
Formation of MeFAPy-Guo (2.13) lesion and oxocarbenium ion 2.14. 
 
 
At the nucleoside level, the rate of formation of FAPy-dGuo is 
dependent on the substituent at the 5’-position. For example, the presence of 
a 5’-phosphate group of N7-methyl-Guo decreases the rate of ring-opening, 
presumably by electrostatic repulsion of the upcoming hydroxide anion (19, 
21). 
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Anomerization and Stability of N5-Alkylated FAPy-dGuo Adducts 
MeFAPy-dGuo nucleoside exists as a complex mixture of isomers. The 
MeFAPy-dGuo nucleoside labeled as the β-anomer (2.15) can undergo ring 
opening of the ribose to form C1’-N9 imine intermediate (2.16); re-closure of 
2.16 can occur to give the β  (2.15) or α-anomer (2.17) (22) . Additionally, ring 
closure reaction can also occur with the 5’-hydroxyl group to give the 
pyranose form as either the β (2.18) or α-anomer (2.19) (Figure 2-04) (23). 
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Figure 2-04. Anomerization of MeFAPy-dGuo nucleoside (2.15). 
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The six-membered pyranose form of the sugar is favored (24, 25). In 
DNA the formation of the six-membered ring is not possible, because of the 
5’-hydroxyl group is involved in a phosphodiester bond (26). However, the 
anomerization is possible in DNA leading to the formation of α or β-furanose, 
which are separable by HPLC (24, 27, 28). MeFAPy-dGuo nucleoside (2.15) 
and other N5-alkylated FAPy-dGuo’s can also exist as atropisomers due to 
restricted bond rotations about formyl group and sometime the C5-N7 bond. 
For example, isomers of the β-ribofuranose triacetate (2.20 a-d) derivative 
exhibit rotation about N7-C8 bond (24), and the MeFAPy-Gua (2.21a and 
2.21b) exhibit slow rotation about C5-N7 bond (29, 30) (Figure 2-05). 
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Figure 2-05. Formation of atropisomers of β-ribofuranose triacetate (2.20 a-d) 
and the MeFAPy-Gua (2.21a and 2.21b). 
 
 
The N5-alkylated FAPy-dGuo adducts, as well as the unsubstituted 
FAPy-dGuo adduct, have been reported to be stable at physiological 
conditions and unstable in acidic and basic conditions (31, 32). This means 
that FAPy-dGuo’s are not spontaneously lost from cellular DNA. It was found 
that FAPy-dGuo’s are more stable in duplex DNA. For example, Chetsanga 
and coworkers reported that only 4% of the MeFAPy-Gua (2.21a and 2.21b) 
is lost from duplex DNA after 240 h in pH 7.4 at 37 °C (31), whereas 
Greenberg and coworkers showed that the declycosylation of the 
unsubstituted FAPy-dGuo in single stranded DNA has a half-life time of lost 
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about 1500 h at 37 °C (22). The lost of N5-alkylated FAPy-dGuo’s from DNA 
or nucleosides is accelerated in acidic conditions, such as 0.1 N HCl or 75 % 
formic acid 24 -100 °C, 15 min to 72 h (31, 33). Interestingly under slightly 
acidic conditions some N5-alkylated FAPy-dGuo’s may undergo re-closure of 
the imidazole ring to yield the corresponding substituted guanine (34). Acid 
conditions can also deformylate N5-alkylated FAPy-dGuo lesions (31, 35, 36). 
Deformylation of N5-alkylated FAPy-dGuo’s is also observed when they are 
treated with strong bases. For example, when MeFAPy-dGuo (2.15) 
nucleoside was treated with 0.2 N NaOH at 37 °C for 4 h, this led to the 
formation of the corresponding deformylated MeFAPy-dGuo (2.15) nucleoside 
(31). 
 
 
Synthesis of FAPy-dGuo and N5-alkylated FAPy-dGuo Oligonucleotides 
The development of synthetic strategies for N5-alkylated FAPy-dGuo 
adducts and their subsequent incorporation into oligonucleotides is very 
challenging because of the N5-alkylated FAPy-dGuo chemistry discussed 
above. Oligonucleotides containing N5-alkylated FAPy-dGuo lesions, 
including the MeFAPy-dGuo (2.05) lesion, can be synthesized by treatment of 
ss-DNA with the corresponding alkylating agent followed by treatment with 
base (19, 37-41). However, there are several restrictions for such a synthesis 
of MeFAPy-dGuo (2.05) containing oligonucleotides. First, the ss-DNA must 
have only one dGuo residue and second, methylating agents can also react 
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with other bases. For example, ss-DNA was methylated by dimethyl sulfate 
(DMS) and then treated with 0.2 M NaOH to perform the ring-opening of the 
cationic N7-methyl-dGuo (2.02) adduct. The methylation occurred also at the 
N1 and N3-positions of dAdo giving the following distribution of products: 
MeFAPy-dGuo (2.05) 59%, 1-methyladenine (2.22) 21% , 3-methyladenine 
(2.23) 6% and other as minor lesions (Figure 2-06) (42). 
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Figure 2-06. Structures of the DNA lesions - MeFAPy-dGuo (2.05), 
1-methyladenine (2.22) and 3-methyladenine (2.23). 
 
 
Oligonucleotides containing MeFAPy-dGuo (2.05) adduct could be 
prepared by enzymatic ligation of N7-methyl-dGTP (m7 dGTP) into duplex 
oligonucleotide (43) followed by base treatment in order to perform the 
hydroxide ring-opening of the cationic N7-methyl-dGuo species. The strategy 
to utilize ligation has not been used to obtain oligonuleotides containing 
MeFAPy-dGuo (2.05) adduct due to several drawbacks. The ligation strategy 
requires the preparation of complimentary strand for each of the target 
oligonucleotides containing the cationic N7-methyl-dGuo (2.02) species 
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(Figure 2-07). If the reaction had occurred, ideally in good yield, the 
oligonucleotide containing the cationic N7-methyl-dGuo (2.02) species had to 
be purified from the mixture of other oligonucleotides, which would result in 
partial depurination of the cationic N7-methyl-dGuo (2.02) species as 
discussed earlier. If the isolation the oligonucleotide containing the cationic 
N7-methyl-dGuo (2.02) adduct had been successful, the modified 
oligonucleotide had to be subjected to base treatment which subsequently 
required one more step of purification. 
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Figure 2-07. Synthesis of a Dickerson/Drew dodecamer containing the 
cationic N7-methyl-dGuo (2.02) species by ligation (33). 
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Oligonucleotides containing the MeFAPy-dGuo (2.05) lesion can be 
obtained by use of a DNA polymerase chain reaction (PCR). This method 
was developed by Asagoshi and coworkers, who introduced MeFAPy-dGuo 
(2.05) into DNA by incorporation of N7-methyl-dGTP followed by base 
treatment in order to perform the hydroxide ring-opening of the cationic N7-
methyl-dGuo moiety (44-46). The utilization of this method for the synthesis of 
MeFAPy-dGuo (2.05) containing oligonucleotides has several complications, 
which makes it inconvenient. The main complications are the multiple 
incorporation of N7-methyl-dGTP’s unless the template has one dCyd and the 
potentially difficult purification of the end product. In addition, this method 
does not allow the preparation of large amounts of MeFAPy-dGuo (2.05) 
containing oligonucleotide. 
The best method for obtaining oligonucleotides containing MeFAPy-
dGuo (2.05) adduct or any other FAPy’s (dGuo derivatives) adducts, is by 
solid-phase synthesis, which requires a suitable phosphoroamidite reagents. 
This aproach allows for the site-specific incorporation of the corresponding 
FAPy-dGuo adducts into oligonucleotides in any desired sequence and scale. 
Thus far, Greenberg and our group have achieved syntheses of the FAPy-
dGuo (2.30) (26, 47, 48) and MeFAPy-dGuo (2.36) phosphoroamidites, 
respectively. The syntheses of these two phosphoroamidites differ in many 
aspects. Greenberg and coworkers synthesized a FAPy-dGuo (2.30) 
phosphoroamidite as a dinucleotide in which the 3′-nucleotide is the desired 
FAPy-dGuo moiety. The use of this dinucleotide 2.30 prevents the 
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isomerization of the desired furanose form of the FAPy-dGuo to the undesired 
pyranose form during DNA synthesis. Although a well-conceived strategy, the 
need for a dinucleotide phosphoroamidite also represents a synthetic 
drawback. The synthesis of FAPy-dGuo dinucleotide phosphoroamidite (2.30) 
is a twelve step synthesis and involves several very low yield reactions 
(Figure 2-08 and 2-09). Additionally, in order to synthesize a full range of 
potential DNA sequences there is a need for four different dinucleotide 
phosphoroamidite reagents. 
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Figure 2-08. Greenberg’s synthesis of 2.27a and 2.27b (48). 
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Figure 2-09. Synthesis of FAPy-dGuo phosphoroamidite dinucleotide (2.30) 
(48). 
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Biological Consequences of the Formation of MeFAPy-dGuo (2.05) 
  Lesion  
The mutagenicity of the MeFAPy-dGuo (2.05) lesion has not been well 
studied due to the lack of suitable method for site-specific incorporation of the 
MeFAPy-dGuo (2.05) adduct into oligonucleotides. Generally, it was accepted 
that MeFAPy-dGuo (2.05) was a non-mutagenic, but lethal lesion (40, 46, 49, 
50). Asagoshi and coworkers, who used PCR to incorporate N7-methyl-dGTP 
into oligonucleotides, reported that MeFAPy-dGuo (2.05) was a strong, but 
not absolute, block to DNA replication catalyzed by Klenow fragment exo– 
(46). The blocking of the extension was due to the mis-incorporation of dATP 
and dGTP opposite the MeFAPy-dGuo (2.05) adduct. The preferred insertion 
opposite this lesion was dCTP, which represents a non-mutagenic bypass. It 
was also found that the efficiency of the bypass was dependant on the 
position of the MeFAPy-dGuo (2.05) adduct; when MeFAPy-dGuo (2.05) 
adduct was placed in a terminal position the full-length extension was more 
efficient (46). 
Laval and coworkers reported in vitro DNA polymerase and 
transfection studies with DNA containing MeFAPy-dGuo (2.05) adduct (49, 
50). The modified DNA was obtained by methylation with dimethyl sulfate 
(DMS) of single-stranded M13mp18 DNA, followed by treatment with 0.2 M 
NaOH to perform the ring-opening of the imidazole ring of the cationic N7-
methyl-dGuo moiety (2.02). When Klenow fragment exo– or T4 DNA 
polymerases were used, the DNA synthesis stopped one base prior to the 
MeFAPy-dGuo (2.05) adduct as well as the other methyl-dAdo and methyl-
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dCyt generated lesions. The transfection studies with the MeFAPy-dGuo 
(2.05) containing DNA showed that in the progeny phage the most frequent 
mutation was observed at adenine sites (A→G transitions), rather than the 
MeFAPy-dGuo (2.05) sites, which was attributed to the presence of coexisting 
base lesions that are formed during the treatment of DNA with DMS. 
 
 
Results and Discussion 
 
Site-specific Synthesis of Oligonucleotides Containing MeFAPy-dGuo 
 (2.05) Lesion 
The synthesis of a MeFAPy-dGuo phosphoroamidite is probably 
possible by adopting Greenberg’s strategy for the synthesis of the FAPy-
dGuo (2.30) phosphoroamidite, but will have the same drawbacks as 
described above. The strategy we utilized to obtain the MeFAPy-dGuo 
phosphoroamidite 2.36 was to methylate at the N7-position a dGuo derivative 
2.33 that was suitably protected for solid-phase oligonucleotide synthesis 
(Figure 2-10).  
The synthesis of 2.33 from dGuo (2.31) was accomplished using a 
previously described method (51). Protected dGuo derivative 2.33 was 
treated with an excess of methyl iodide in dry degassed DMSO for 45 min at 
room temperature to produce the cationic N7-methyl-dGuo (2.34), which was 
not isolated. After removals of the excess methyl iodide, the solution 
containing 2.34 was briefly treated with 1M NaOH, and then neutralized with 
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0.1 M HCl to afford pure 2.35 as a white precipitate. The protected MeFAPy-
dGuo nucleoside (2.35) was isolated by filtration and converted to the desired 
MeFAPy-dGuo phosphoroamidite (2.36) without further purification using 
standard conditions (52). 
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Figure 2-10. Synthesis of MeFAPy-dGuo phosphoroamidite (2.36). 
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The synthesis of the MeFAPy-dGuo phosphoroamidite (2.36) was 
accomplished in only four steps and 25% percent overall yield, compared to 
twelve steps and 0.17% (without considering the preparation of 2.24 and 2-
amino-6-chloro-4-hydroxy-5-nitropyrimidine in Figure 2-08) for the FAPy-
dGuo phosphoroamidite (2.30). In addition, 2.36 is the only phosphoroamidite 
required for a synthesis a full range of potential DNA sequences compared to 
four different FAPy-dGuo dinucleotide phosphoroamidites from the 
Greenberg’s synthesis. 
Phosphoroamidite 2.36 was used for the preparation of 
oligonucleotides containing the MeFAPy-dGuo (2.05) lesion at a defined 
location. Incorporation of the modified nucleotide was performed off-line, 
using a manual coupling protocol. The crucial step of the oligonucleotide 
synthesis was the deprotection of the 5′-hydroxy group of the MeFAPy-dGuo 
nucleotide, since the ribose ring can undergo a rearrangement to the 
pyranose form under acidic conditions. Initially a 6-mer, 5′-CTT-(MeFAPy-
dGuo)-TT-3′ (2.37a, b) was synthesized at two deprotection times. When the 
5′-DMTr group was removed using a “short” deprotection cycle that consisted 
of using 160 µL of Deblock reagent (3% Cl3CCO2H in methylene chloride) for 
20 sec, followed by incorporation of the subsequent nucleotide under 
standard conditions (on line), fives products were observed by HPLC analysis 
(Figure 2-11, Panel A). Each component was separated, and then re-
analyzed by HPLC. Component 1 (2.37a) did not change composition upon 
re-analysis. However, when components 2-5 (2.37b) were individually re-
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analyzed, it was found that they had all equilibrated to the same four 
component mixture (Figure 2-11, Panel D). The MALDI-TOF-MS analysis of 
component 1 (2.37a) and components 2-5 (2.37b) showed that they all 
possess the correct mass for the desired oligonucleotide. We tentatively 
assigned component 1 (2.37a) as the pyranose forms of the MeFAPy-dGuo 
(2.05) and components 2-5 (2.37b) as the furanose forms from this limited 
information. In addition to the furanose and pyranose form of the ribose unit, 
α- and β-anomers and antropisomers of each due to restricted rotation about 
C5-N7 bond are also possible for N5-alkylated FAPy-dGuo adducts. We 
reasoned that the MeFAPy-dGuo (2.05) would exist largely in the equatorial 
conformation of the pyranose form leaving two possible atropisomers. We 
subsequently found that component 1 (2.37a) actually consisted of two 
products, consistent with this prediction. The furanose form of the MeFAPy-
dGuo adduct (2.05) should exist as a mixture of two atropisomers of the α- 
and β-anomers, giving a total of four interconverting isomers. A similar 
behavior was observed for the more extensively studied FAPy-dGuo adduct 
of aflatoxin B1 (AFB1-FAPy-dGuo) and is in accord with the present 
observations as well. We also predicted that more of the pyranose form would 
be produced during longer deprotection cycles. 
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 Figure 2-11. HPLC analysis of the 5′-CTT-(MeFAPy-dGuo)-TT-3′ (2.37a and 
b) oligonucleotides. A. Analysis of the oligonucleotide synthesis with a “short” 
deprotection cycle. B. Analysis of the oligonucleotide synthesis with a “long” 
deprotection cycle. C. Analysis of peak 1 (2.37a), identified as the pyranose 
form of the MeFAPy-dGuo lesion, after initial purification. D. Analysis of 
interconverting peaks 2-5 (2.37b), identified as the furanose form of the 
MeFAPy-dGuo lesion, after each peak was individually purified. 
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When a longer deprotection time cycle (320 µL of Deblock reagent for 
50 sec plus an additional 3 min in standby mode) for removing the 5’-DMTr 
group nucleotide was utilized, a larger percentage of the pyranose form was 
observed (Figure 2-11, Panel B), (Table 2-01). 
 
 
Table 2-01. Yields of the 5′-CTT-(MeFAPy-dGuo)-TT-3′ (2.37a and b) 
oligonucleotides depending on the deprotection cycle: “short”-160 µL of 
Deblock reagent (3% Cl3CCO2H in methylene chloride) for 20 sec, 
“mediate”- 240 µL of Deblock reagent for 50 sec, and “long”- 320 µL of 
Deblock reagent for 50 sec plus an additional 3 min in standby mode. 
 
Deprotection cycle 
Total yield 
(OD's) 2.27a (%) 2.27b (%) 
"short" 20 9 91 
"mediate" 28 16 84 
"long" 18 90 10 
 
 
Synthesis and NMR Studies of the Trinucleotide 5′-A-(MeFAPy-dGuo)-C- 
3′ (2.38a and 2.38b) 
The NMR spectrum of the proposed furanose and pyranose forms of 
the 5′-CTT-(MeFAPy-dGuo)-TT-3′ oligonucleotides (2.37a and 2.37b) was 
very complex due to the presence of many inter-converting species. We 
therefore synthesized the trinucleotide 5′-A-(MeFAPy-dGuo)-C-3′ (2.38a and 
2.38b) using the “short” and “long” deprotection cycles. The trinucleotide 
(2.38a) obtained via the “short” deprotection protocol consisted of three 
interconverting species, while the trinucleotide (2.38b) obtained via the “long” 
deprotecion cycle consisted of two interconverting species (Figure 2-12).  
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Figure 2-12. HPLC analysis of the 5′-A-(MeFAPy-dGuo)-C-3′ oligonucleotides 
(2.38a and b). A. Analysis of inter-converting peaks 3-5 (2.38a), identified as 
the furanose form of the MeFAPy-dGuo lesion, after each peak was 
individually purified. B. Analysis of peak 1 and 2 (2.38b), identified as the 
pyranose form of the MeFAPy-dGuo lesion, after initial purification. C. 
Analysis of peaks 1 and 2 (2.38b) after 24 h. 
 
 
The high mobility of the trinucleotide prevented the evolution of inter-
residue NOE’s for use in sequence specific resonance assignment. The spin 
systems of the individual 2′-deoxyribose units were identified from TOCSY 
spectra; the assignment of the 2′-deoxyribose proton resonances was based 
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on connectivity and chemical shift. The carbon resonance of the 2′-
deoxyribose units were correlated from the proton assignments by HSQC 
spectra. Inter-residue connectivity was established by 3JPH3' and 3JPH5" scalar 
couplings. Multiple conformations were observed for the furanose (2.38a) and 
pyranose (2.38b) samples precluding a full characterization the trinucleotides. 
However, the pyranose (2.38b) and furanose (2.38a) forms could be 
distinguished from the available data.  Multiplicity edited HSQC data showed 
that the 4′-position of the MeFAPy-dGuo residue is a methine (CH) for the 
pyranose (2.38b) form and a methylene (CH2) for the furanose (2.38a) form. 
A three-bond 31P-1H coupling is observed from the phosphate that bridges the 
5′-dAdo and the MeFAPy-dGuo residue. A one-bond 1H-13C HSQC identified 
the MeFAPy-dGuo carbon resonance involved in the phosphate bridge as a 
methylene (furanose form, 2.38a) or methane (pyranose form, 2.38b). The 
carbon resonances of the MeFAPy-dGuo 2′-deoxyribose unit were also 
compared to the model 2′-deoxyribosides (Figure 2-13). We observed a 
significant change in chemical shift for the 4′-carbon resonance of the 
MeFAPy-dGuo residue depending on the ring size. The 4′-carbon chemical 
shifts for the MeFAPy-dGuo residue were 82.4 ppm for the furanose (2.38a) 
form and 69.6 ppm in the pyranose (2.38b) form in the 5′-A-(MeFAPy-dGuo)-
C-3′ trinucleotide. The furanose value is compared to that of the 3′,5′-
dibutarate of the AFB1-FAPy-dGuo nucleoside (2.39) (53), and methyl 2′-
deoxyribofuranoside 3,5-dimethyleher (2.41) (54), which have C4 carbon shift 
of 83.7 and 82.4 ppm, respectively. The C4′ carbon chemical shifts of the 
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MeFAPy-dGuo pyranose (2.38b) form compares favorably with the pyranose 
form of the AFB1-FAPy-dGuo nucleoside (2.40) (55) and methyl 2′-
deoxyribopyranose 3,5-diacetae (2.42) (56) (66.6 and 69.0, respectively).  
The NMR experiments with the trinucleotides 2.38a and 2.38b showed 
that our initial tentative assignments, based on the FAPy-dGuo’s conversions 
were correct. This means that through the use of the “short” or “long” 
deprotection cycle, we were able to synthesize MeFAPy-dGuo containing 
oligonucleotides having predominantly furanose or pyranose form, 
respectively. 
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Figure 2-13. Comparison of the 13C chemical shifts for furanose  
and pyranose forms of 2′-deoxyribose units. 
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Oligonucleotide Sequences Containing the MeFAPy-dGuo (2.05) Lesion 
Phosphoroamidite 2.36 was used for the preparation of several 
oligonucleotides containing the MeFAPy-dGuo (2.05) lesion at a defined 
location (Table 2-02). The modified oligonucleotides were characterized by 
MALDI-TOF-MS spectrometry. The presence of the MeFAPy-dGuo (2.05) 
was confirmed by enzymatic digestion and analysis of the modified 
nucleoside by HPLC (Appendix); the modified oligonucleotides were also 
sequenced by MALDI-TOF analysis using controlled exonuclease digestions 
with nucleases PI and PII (Appendix).  
 
 
Table 2-02. Characterization of the oligonucleotides containing the MeFAPy-
dGuo (furanose and pyranose forms) (2.05) lesion by MALDI-TOF-MS 
spectrometry; a-positive LC-ESI/MS.  
 
              M/z (Da)
Oligonucleotide Ring Observed Calculated 
 3'-C-(MeFAPy-dGuo)-A-5' furanose 900.2a 899.2
pyranose 900.2a
 3'-TT-(MeFAPy-dGuo)-TTC-5' furanose 1803.8 1803.6
pyranose 1803.1
  3'-CTCTC-(MeFAPy-dGuo)-CTTCTCC-5' furanose 3842.9 3841.6
pyranose 3843.4
3'-CCCCCTTCCTAG-(MeFAPy-dGuo)-TACT-5' furanose 5401.9 5401.2
pyranose 5101.3
 3'-CCCCCGCTACGAGCATTCCTAAG-(MeFAPy-dGuo)-TACT-5' furanose 8498.1 8497.3
pyranose 8495.2  
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Stability of the Oligonucleotides Containing the MeFAPy-dGuo (2.05)  
Lesion 
The stability of ss-DNA containing the Me-FAPy-dGuo (2.05) adduct 
was investigated in water and buffer at pH 6.5 and 7.0. The ss-DNA's used to 
assess the stability of MeFAPy-dGuo (2.05) adduct were the 5′-CCTCTTC-
(MeFAPy-dGuo)-CTCTC-3′ (2.43a and b) oligonucleotides, which were 
obtained via “short” (2.43a) and “long” (2.43b) deprotection cycles (see 
supplementary for HPLC and CZE traces). We initially used MALDI-TOF MS 
spectrometry to perform the stability assays due to the length of the 
oligonucleotides. The oligonucleotides 2.43a and 2.43b were dissolved in 
water or pH 7.0 phosphate buffer at room temperature and 95 °C. Aliquots 
were then taken periodically and analyzed by MALDI-TOF MS spectrometry. 
The MS analysis showed that oligonucleotides 2.43a and 2.43b were stable 
in pH 7.0 phosphate buffer, but underwent degradation in water by releasing 
the MeFAPy-Gua (2.21a and 2.21b) followed by cleavage of the resulting 
abasic oligonucleotides to yield oligonucleotides 2.44a, 2.45a, 2.44b, 2.45b 
and 2.46 (Figure 2-14). The percentage of decomposition of oligonucleotides 
2.43a and 2.43b was determined by the ratio between the corresponding 
abasic sites (2.44a and 2.45b) and the starting oligonucleotides (2.43a and 
2.43b) in the MALDI-TOF MS spectra (see Appendix for MALDI-TOF MS 
spectra) (Table 2.03). 
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Figure 2-14. Stability of the MeFAPy-dGuo oligonucleotide 2.43a and 2.43b 
in water. A. Oligonucleotide 2.43a undergoes lost of MeFAPy-Gua (2.21a and 
2.21b) to give the abasic site oligonucleotide 2.44a, which decomposes to 
oligonucleotides 2.45a and 2.46. B. Oligonucleotide 2.43b undergoes lost of 
MeFAPy-Gua (2.21a and 2.21b) to give the abasic site oligonucleotide 2.44b, 
which decomposes to oligonucleotides 2.45b and 2.46.   
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Table 2-03. Percent of decomposition of the oligonucleotides 2.42a and 
2.42b in water and phosphate buffer pH 7.0 at 25 °C and 95 °C. 
 
      Decomposition (%)
Temperature (°C) Medium Time (days) 2.42a 2.42b 
25 water 2 50 30
5 90 50
90 water 1 hour 100 100
25 pH 7 2 stable stable
5 stable stable
90 pH 7 10 min stable —
30 min 10% —
1 hour 20% —  
 
 
The stability of the oligonucleotides 2.43a and 2.43b in pH 7.0 buffer 
was important observation to establish, because it was critical for translesion 
DNA polymerase studies, which require annealing of the MeFAPy-dGuo 
containing oligonucleotides with their complementary strands by heating at 95 
°C for 5 min followed by slow cooling to room temperature. 
We also performed assays on the stability of several other MeFAPy-
dGuo containing oligonucleotides in pH 7.0 buffer and the results confirmed 
that MeFAPy-dGuo containing oligonucleotides were stable under these 
conditions even at high temperature.  
A reasonable explanation for the degradation of oligonucelotides 2.43a 
and 2.43b in deionized water is the lack of any buffer capacity of the 
deionized water, which may allow the pH to vary depending on the analyte; 
the analyte may cause the pH to become acidic or basic. We hypothesized 
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that most likely the oligonucleotides 2.43a and 2.43b caused the pH of water 
to become acidic, since the release of N5-alkylated FAPy-Gua from N5-
alkylated FAPy-dGuo oligonucleotides is known to occur in acidic conditions. 
We also hypothesized that the release of the MeFAPy-Gua (2.21a and 2.21b) 
occurs via formation of carbinolamine species, which are formed in acidic 
conditions. In order to explore our hypothesis, we investigated the stability of 
oligonucleotide 2.43a in pH 6.5 phosphate buffer. The LC-ESI/MS analysis of 
oligonucleotide 2.43a after 24 h at pH 6.5 showed that MeFAPy-dGuo (2.05) 
adduct was completely lost resulting in abasic site oligonucleotide 2.44a 
(Figure 2-15, Panel C). After additional 24 hours the LC-ESI/MS analysis 
showed full conversion of the abasic site 2.44a to the oligonucleotides 2.45a, 
2.46 and the MeFAPy-Gua (2.21a and 2.21b) (Figure 2.14, Panel A) (Figure 
2-15). 
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 Figure 2-15. LC-ESI/MS analysis of the stability of oligonucleotide 5′-
CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.43a) in phosphate buffer pH 6.5. A. 
Total ion current (TIC). B. Select ion profile of 2.43a with m/z =1280.5 ([M-
3H]). C. Select ion profile of 2.44a with m/z =1225.2 ([M-3H]). D. Select ion 
profile of 2.45a with m/z = 1091.3 ([M-2H]). E. Select ion profile of 2.44a as 
hydrated form with m/z =1100.9 ([M-2H]). F. Select ion profile of 2.46 with m/z 
=747.2 ([M-2H]). 
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Oligonucleotide 2.43a was then heated at 90 °C for 1 h and the 
changes in its composition were monitored by HPLC (Figure 2.16). After all of 
the starting material was converted to the abasic site oligonucleotide 2.44a 
(Figure 2-16, Panel C), an aliquot was taken and added to a solution of T4-
pdg (Endo V), which cleaves abasic sites. The T4-pdg reaction mixture was 
set at 37 °C for 24 h, while the remaining solution of oligonucleotide 2.44a 
was heated at 90 °C for additional 1.5 h. The HPLC analysis of both of the 
above reaction mixtures showed (HPLC traces of the T4-pdg (Endo V) 
reaction mixture are not shown) that oligonucleotide 2.44a decomposed to 
oligonucleotides 2.45a and 2.46 (Figure 2-16, Panel D). In a control 
experiment, oligonucleotide 2.43a was incubated with T4-pdg (Endo V) in pH 
7.0 buffer and after 24 h aliquot was taken and analyzed by LC-ESI/MC, 
which showed that no degradation of oligonucleotide 2.43a. This further 
confirms that the MeFAPy-dGuo (2.05) containing oligonucleotides are stable 
in pH 7.0. 
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 Figure 2-16. HPLC analysis of the stability of MeFAPy-dGuo oligonucleotide 
2.43a in water at 90 °C. A. Analysis of the oligonucleotide 2.43a as pure 
material; B. Analysis of the oligonucleotide 2.43a after 2 days at 25 °C, 2.44a 
is the abasic site oligonucleotide; C. Analysis of the oligonucleotide 2.43a 
after 1 h heating at 90 °C, 2.44a is the abasic site oligonucleotide, 2.21a and 
2.21b are the MeFAPy-Gua. D. Analysis of the oligonucleotide 2.43a after 2.5 
h heating at 90 °C, 2.44a is the abasic site oligonucleotide, 2.21a and 2.21b 
are the MeFAPy-Gua. 
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Oligonucleotide 2.43a was incubated in deionized water and treated 
with Na(CN)BH3 in order to trap the imine of the ring-opened MeFAPy-dGuo 
nucleotide 2.47, a likely intermediate in the degradation of the MeFAPy-dGuo 
(2.05) containing nucleotides (Figure 2-17). 
 
 
2.43a
N
NHHN
O
5'-CCTCTTC-OPO3
3'-CTCTC-OPO3
ONH3C
CHO
NH2
2.43a
H2O
2.47
N
NHNOH
5'-CCTCTTC-OPO3
3'-CTCTC-OPO3
ONH3C
CHO
NH2
NaB(CN)H3
2.21a,b
N
NH
H
NOH
5'-CCTCTTC-OPO3
3'-CTCTC-OPO3
ONH3C
CHO
NH2
2.48  
 
Figure 2-17. Formation of the oligonucleotide 2.48 via reduction of the imine 
oligonucleotide 2.47 with Na(CN)BH3. 
 
 
After 48 h, the reaction mixture was analyzed by MALDI-TOF-MS and 
then subjected to acid hydrolysis and alkaline enzyme digest. The MOLDI-
TOF-MS analysis of the reaction mixture did not show the formation of 2.45a 
and 2.46, which was otherwise observed when 2.43a was kept in water for 48 
h (see Appendix for MALDI-TOF MS spectra). Acid hydrolysis of the 
Na(CN)BH3 reaction mixture (containing the oligonucleotide 2.48) was 
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performed with 0.1 M HCl at 37 °C for overnight, which are the optimal 
conditions for hydrolysis of N5-alkylated FAPy-dGuo oligonucleotides (31, 33). 
The HPLC analysis of the acid hydrolysis did not show the release of 
MeFAPy-Gua (2.21a and 2.21b) (Figure 2-18, Panel B), which are products of 
acid hydrolysis of MeFAPy-dGuo (2.05) containing oligonucleotides. In a 
control experiment, the acid hydrolysis of oligonucleotide 2.43a resulted in the 
formation of 2.21a and 2.21b (Figure 2-18, Panel A). 
 
 
 
Figure 2-18. HPLC analysis of the acid hydrolysis of: A. oligonucleotide 
2.43a. B. the oligonucleotide 2.48 formed via reduction of 2.43a with 
Na(CN)BH3. 
 
 
The enzyme digestion of the Na(CN)BH3 reaction mixture was 
analyzed by LC-ESI/MS/MS. The MS analysis showed the formation of dTyd, 
dCyt, one unknown species, but not a formation of the MeFAPy-Gua (2.21a 
and 2.21b) which are otherwise formed when 2.43a is subjected to enzyme 
digest (30) (Figure 2-19). The unknown species, m/z 591.1, was identified as 
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a dinucleotide (2.49) being the reduced MeFAPy-dGuo (2.05) nucleoside and 
dCyd (Figure 2-20). The lack of digestion of this nucleotide by alkaline 
phosphatase is probably due to the enzymes not being able to recognize the 
ring-opened reduced sugar and consequently unable to digest the 
dinucleotide.  
 
 
 
Figure 2-19. LC-ESI/MS analyses of the enzyme digest of oligonucleotide 
2.48. A. UV traces B. Total ion current. C. Select ion profile of dinucleotide 
2.49 with m/z 591.1 ([M-H]). D. Select ion profile of dTyd with m/z 242.8 ([M-
H]). E. Select ion profile of dCyt with m/z 227.9 ([M-H]). 
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Figure 2-20. The structure of dinucleotide 2.49. 
 
 
Based on the analysis of the reduction reaction mixture by MALDI-
TOF-MS, acid hydrolysis and enzyme digest, it was concluded that the ring- 
opened imine of the MeFAPy-dGuo containing oligonucleotide 2.47 was 
successfully reduced to oligonucleotide 2.48. 
Our success in trapping the oligonucleotide imine 2.47 motivated us to 
attempt to trap the imine 2.16, which is involved in the anomerization of 
MeFAPy-dGuo nucleoside 2.15 (Figure 2-04). A mixture of six- and five-
membered MeFAPy-dGuo nucleoside was dissolved in water and 100 eq. 
Na(CN)BH3 was added in equal portions (33 times of 3.03 eq.) for a period of 
one month. The resulting mixture was purified by HPLC to afford compound 
2.50, which arises from reduction of imine 2.16 (Figure 2-21). Interestingly, 
the MS fragmentations of the mixture of six- and five-membered MeFAPy-
dGuo nucleoside (2.15) and the compound 2.50 were very different, which 
also help to identify the structure of 2.50 (Figure 2-22). Fragmentation of the 
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MeFAPy-dGuo nucleoside (2.15), m/z of 299.9, at 25 % relative energy (RE) 
gave a product ion with m/z 184.2, which is assigned as lost of sugar. 
Furthermore, product ion with m/z 184.2 at 25 % RE gave a product ion m/z 
156.2, which is assigned as loss of CO. The compound 2.50, m/z of 302.0, at 
27 % relative energy gave a product ion with m/z 274.1, which is assigned as 
a los of CO. Product ion with m/z 274.1 at 25 % RE gave a product ion with 
m/z 256.2, which is assigned as a loss of H2O. 
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Figure 2-21. Formation of 2.50 by reduction of imine 2.16 with 
Na(CN)BH3. 
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Figure 2-22. MS fragmentation of a mixture of 5- and 6-membered  
ring MeFAPy-dGuo (2.15) nucleoside and compound 2.50. 
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Polymerase Bypass of the MeFAPy-dGuo (2.05) Adduct in 
 Oligonucleotides 
The in vitro bypass and extension of the MeFAPy-dGuo (2.05) adduct 
was examined with prokaryotic and eukaryotic DNA polymerases. The 
prokaryotic enzymes were E. coli DNA polymerase I Klenow fragment exo– 
(Kf–), E. coli DNA polymerase II exo– (Pol II–) and S. solfataricus P2 DNA 
polymerase IV (Dpo4). Kf– and Pol II– are highly conserved proteins that have 
roles in translesion synthesis across specific DNA adducts in the bacterial 
chromosome. Klenow fragment has two distinct enzymatic activities, a 5’→3’ 
polymerase and a 3’→5’ exonuclease activity. Kf– has significantly diminished 
3’→5’ exonuclease activity through a mutations in the 3’→5’-exonuclease 
active site. DNA polymerase II is a prototype of the B-family of polymerases 
and is SOS-inducible (57, 58). Dpo4 is phylogenetically related to DinB 
polymerases and is a useful model for Y-family (lesion bypass) polymerase 
(59, 60). It is a thermostable enzyme and is active up to 70 °C, but can also 
synthesize DNA at 37 °C (60). Dpo4 exhibits misinsertion fidelities in the 
range of 8 x 10–3 to 3 x 10–4 and can facilitate translesion replication on 
damaged DNA templates containing an abasic site, a cis-syn thymine–
thymine dimer, the C-8 acetylaminofluorene adduct and cis-platin-guanine 
(60). 
The eukaryotic DNA polymerases examined were the human DNA 
polymerases pol δ, η, κ and ι. Pol δ is a replicative DNA polymerase that 
replaces pol α, which starts the DNA replication, and completes leading 
synthesis. It consists of three subunits of 125, 55 and 40 kDa. The 125 kDa 
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subunit exhibits 3'→5' exonuclease activity and the 40 kDa subunit interacts 
with PCNA (61). 
Human pol η replicates through a cis-syn dTyd-dTyd dimer by inserting 
two dATP’s opposite the two dTyd’s of the dimer with nearly the same 
efficiency and fidelity as opposite the two undamaged dTyd’s (62). Defects in 
the gene coding the human pol η are responsible for a cancer predisposition 
disorder, the xeroderma pigmentosum variant (XPV) (63, 64). Human pol η 
also plays an important role in efficient and accurate replication through the 8-
oxoguanine (8-oxo-dGuo) lesion (65, 66), incorporating a dCTP opposite the 
lesion; however, a low but significant level of dATP is also inserted. 
Human pol κ misincorporates nucleotides with a frequency of about 
10−3 to 10−4 opposite all four template bases (67). Human pol κ inserts dATP 
opposite an 8-oxo-dGuo lesion more efficiently than dCTP, and it can extend 
with an about 20-40-fold reduction in efficiency (68). Interestingly, human pol 
κ can extend from a dCyt incoporated opposite past N2- dGuo adducts by 
human pol ι (69). 
Human pol ι incorporates nucleotides opposite template purines with a 
much higher efficiency and fidelity than opposite template pyrimidines (70-
72). In some cases, pol ι incorporates nucleotides opposite the DNA adduct, 
but is unable to carry out the subsequent extension step (70). Human pol ι 
plays an important role in the bypass of γ-HO-PdGuo (69), an N2-dGuo 
adduct that arise from the reaction of dGuo with acrolein, which is an end 
product of lipid peroxidation. Human pol ι incorporates dCTP opposite the γ-
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HO-PdGuo adduct, but is unable to extend past the adduct; the extension is 
performed by pol κ. The sequential action of pols ι and κ may provide cells 
with an efficient pathway for the error-free bypass of the various N2-dG 
adducts that are formed by products of lipid peroxidation. 
The MeFAPy-dGuo (2.05) adduct was incorporated at position-5 of 
28mer oligonucleotide (2.52a); this oligonucleotide was annealed to a 
complementary 23mer (2.53) (-1) primer strand which was 5′-labeled with 32P. 
An oligonucleotide (28mer) (2.52b) containing the pyranose form of the 
MeFAPy-dGuo was also synthesized using the “long” deprotection cycle 
(Figure 2-23). 
 
 
3’-CCCCCGCTACGAGCATTCCTAAGGTACT-5’ unmodified oligonucleotide (2.51)
3’-CCCCCGCTACGAGCATTCCTAAG-(MeFAPy-dGuo)-TACT-5’ (2.52a) (furanose form)
3’-CCCCCGCTACGAGCATTCCTAAG-(MeFAPy-dGuo)-TACT-5’ (2.52b) (pyranose form)
5’-GGGGGCGATGCTCGTAAGGATTC-3’ primer (-1) (2.53)  
Figure 2-23. The oligonucleotide sequences used for running in vitro DNA 
bypass and extension of the MeFAPy-dGuo (2.05) lesion with 32P imaging. 
 
 
The steady-state insertion rates for each individual dNTP’s were 
determined. Reaction times, enzyme concentrations and dNTP 
concentrations were chosen so that the maximium product formation would 
be ∼ 20% of the substrate concentration. The steady-state rates versus dNTP 
concentration were fit using nonlinear regression (hyperbolic fits) in GraphPad 
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Prism (version 4.0, GraphPad, San Diego, CA) for the estimation of kcat and 
Km values (Figure 2-24). The nonlinear regression (hyperbolic fits) has the 
equation: Y=kcat x X/(km + X), which describes the binding of a ligand to a 
receptor that follows the law of mass action. kcat is the turnover number and 
Km is the concentration of ligand required to reach half-maximal rate. 
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Figure 2-24. Example of steady-state kinetic curve: the incorporation of dCTP 
opposite the MeFAPy-dGuo adduct (2.05) in the oligonucleotide 2.52a 
catalyzed by Dpo4.  
 
 
 
 
 
 
. 
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LC-ESI/MS/MS Sequencing of the Full-length Extension Products Past 
the MeFAPy-dGuo Lesion (2.05) in Oligonucleotides Using Biotinated  
Primers 
The full-length extension assays were performed in a similar manner to 
a previously published procedure with the following modifications (73). The 
MeFAPy-dGuo oligonucleotide (2.52a) was annealed to a complementary 
23mer (2.54) (-1) primer, which was 5′-biotinated. Ten dTyd’s were used as a 
spacer between the biotin and the complementary sequence (Figure 2-25); a 
dUrd was incorporated at position 21. After the extension reaction took place, 
the extended primer was added to a solution of streptavidin coated beads. 
After gentle shaking for 2 h, the streptavidin beads were thoroughly washed 
to remove the other components of the reaction mixture. The streptavidin 
coated beads were incubated with uridine DNA glycosylase (UDG) for three 
hours, than washed extensively. The UDG treatment results in the removal of 
the dUrd and the formation of abasic site of the extended primer. The 
depurinated oligonucleotides were treated with piperidine to form two strands, 
one being the 3′-end of the primer with 5′-phosphate and the other being the 
5′-end of the primer. The 3′-fragment contains the sequence information of 
interest from the extension reaction. The beads were removed from the liquid 
containing the extension product(s) and washed several times with water, 
which was added to the filtrate. The collected solution was lyophilized to 
dryness, dissolved in water and analyzed by LC-ESI/MS/MS. The 3′-fragment 
of the extended primer was sequenced by collision-induced dissociation (CID) 
and mass analysis of the fragments.  
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Biotin-5’(dT10)-GGGGGCGATGCTCGTAAGGAUTC (2.54)
3’-CCCCCGCTACGAGCATTCCTAAG-X-TACT-5’ (2.52a)
1. DNA polymerase, 4 dNTP’s
2. Streptavidin coated beads
Streptavidin(  )-5’(dT10)-GGGGGCGATGCTCGTAAGGAUTC-YYYYY-3
YYYYY-3’
’
3’-CCCCCGCTACGAGCATTCCTAAG-X-TACT-5’
1. wash
2. UDG hydrolysis 
3. wash
4. piperdine
5’-pTC-
X = MeFAPy-dGuo
LC-ESI/MS/MS analysis
5’-pCTTACGAGCCCCC-3 (2.55)
 
Figure 2-25. LC-ESI/MS/MS sequencing of the full-length extension adduct 
past the MeFAPy-dGuo adduct (2.05) in oligonucleotides. 
 
 
After the fragments were identified, the proposed oligonucleotide 
sequence was purchased from Midland Certified Reagents as an authentic 
standard and subjected to the same LC-ESI/MS/MS analysis. The CID’s of 
the commercially obtained products were compared with those of the reaction 
product(s) to show the same pattern of fragmentation. To establish the 
percentage of formation of the full-length extension product(s) another 
oligonucleotide, 5′-pCTTACGAGCCCCC-3′ (2.55), was used as an internal 
standard. This standard was added prior to the LC-ESI/MS/MS analysis. The 
standard had molecular ion peak with m/z 1310.5 ([M-3H]). The standard 
calibration curves were constructed using seven concentrations of the 
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corresponding analyte (purchased from Midland Certified Reagents) versus a 
fixed amount of the standard. 
The use of biotinated primers allowed the clean up of the extension 
products from other components, such as salts, dNTP’s and enzymes, and 
improved the sensitivity of the LC-ESI/MS/MS method. The use of the 13mer 
(2.55) allowed the calculation of the absolute percentage of formation of the 
full-length extension products. 
 
 
DNA Bypass of MeFAPy-dGuo Adduct (2.05) Catalyzed by Prokaryotic  
DNA Polymerases 
The MeFAPy-dGuo containing oligonucleotide (2.52a) was annealed to 
a complimentary 23mer (2.54) (-1) primer strand, which was 5’-labeled with 
32P. The single nucleotide insertion and the full length extension reactions in 
the presence of all four dNTP’s using prokaryotic DNA polymerases were run 
at fixed amount of the enzyme and increasing dNTP(s) concentration(s). The 
single nucleotide incorporation and the full-length extension reactions 
catalyzed by prokaryotic DNA polymerases with the unmodified sequence 
(2.51) were performed, in the same manner as the adducted sequence, but 
with two-fold less concentration of the enzyme and the reaction time. 
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Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in the  
Oligonucleotide 2.52a Catalyzed by Kf– 
The Klenow fragment exo– (Kf–) inserted all four dNTP’s opposite the 
MeFAPy-dGuo adduct (2.05) (Figure 2-26, Panel A), which is in accordance 
with previously published data (45, 49, 50). In contrast, Kf– incorporated only 
dCTP in the unmodified oligonucleotide (Figure 2-26, Panel B). To measure 
the mis-incorporation frequencies by Kf– of the MeFAPy-dGuo containing 
oligonucleotide 2.52a relative to the unmodified oligonucleotide, a steady-
state kinetic assay was performed. While the insertion efficiencies for dCTP 
and dATP opposite the MeFAPy-dGuo adduct were about 8 and 1.4 times 
lower, respectively, the insertion efficiencies for dGTP, dTTP were about 3.7 
and 25 times higher, respectively, than for the unmodified template (Table 2-
04). 
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A: MeFAPy-dGuo (furanose)
Ext.T G C
0   25     50    100 0    25     50    100 0      25    50   100 0     25     50     100 0   10     50   100 nM (dNTP)
A
A T G C Ext.
0   25   50   100 0  25   50   100 0    25   50   100 0    25   50   100 0   25   50  100 nM (dNTP)
B: MeFAPy-dGuo (pyranose)
0   25   50  100 0   25   50   100 0    25    50   100 0    25   50  100 0    25    50  100 nM (dNTP)
A T G C Ext.
C: Unmodified
 
 
Figure 2-26. Single and full-length incorporation assays catalyzed by Kf–: A. 
Incorporation across the MeFAPy-dGuo adduct (furanose form) in 
oligonucleotide 2.52a; B. Incorporation across the MeFAPy-dGuo adduct 
(pyranose form) in oligonucleotide 2.52b; C. Incorporation of dNTP(s) in the 
unmodified oligonucleotide (2.51). 
 
 
Table 2-04. Steady-state kinetics parameters for Kf–. 
 
kcat kcat/km
Template dNTP Km (μM) (s-1 x 10-3) (μM-1 x s-1x 10-3) fa
C 0.07 ± 0.02 2.0 ± 0.1 30 1
MeFAPy-dGuo T 0.33 ± 0.09 2.8 ± 0.3 8 0.28
G 0.19 ± 0.02 1.7 ± 0.1 9 0.29
A 1.1 ± 0.7 1.6 ± 0.2 1.5 0.05
C 0.013 ± 0.001 3.3 ± 0.1 260 1
dGuo T 3.4 ± 0.2 1.2 ± 0.3 0.4 0.002
G 2.11 ± 0.02 5.2 ± 0.3 2.4 0.009
A 2.8 ± 0.9 5.5 ± 0.5 2 0.007
af - misincorporation frequency = (kcat/Km) incorporated dNTP/(Kcat/Km) correct dNTP (dCTP)  
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In the presence of all four dNTP's, Kf– extended past the MeFAPy-
dGuo adduct, although there were a significant pause after incorporation of 
one nucleotide past the lesion. Experiments with 0-primers with Ado (2.56), 
Tyd (2.57) and Guo (2.58) showed that the full-length extension was blocked 
following the mis-incorporation of dGTP, dTTP and dATP opposite the adduct 
(Figure 2-27). The inhibition of the extension after mis-incorporation of dATP 
and dGTP opposite the MeFAPy-dGuo adduct was also reported by Asagoshi 
and coworkers (46). 
 
 
0      25    50   100 nM (dNTP)
Ado (2.56) Tyd (2.57) 2.53
0     25     50   1000   25   50  100 0    25     50   100
Guo (2.58)  
Figure 2-27. Full-length incorporation assays with the MeFAPy-dGuo 
containing oligonucleotide (2.52a) catalyzed by Kf– and 0-primers with Ado 
(2.56), Tyd (2.57), Guo (2.58) and -1 primer 2.53 in the presence of the four 
dNTP’s; 5’-GGGGGCGATGCTCGTAAGGATTCA-3’ (2.56); 5’-GGGGGC 
GATGCTCGTA-AGGATTCT-3’ (2.57); 5’-GGGGGCGATGCTCGTAAGG 
ATTCG-3’ (2.58); 5’-GGGGGCGATG-CTCGTAAGGAT TC-3’ (2.53). 
 
 
In contrast to the polymerase reactions with the MeFAPy-dGuo 
(furanose form) oligonucleotide (2.52a), Kf– incorporated only dCTP opposite 
to the MeFAPy-dGuo (pyranose form) adduct in oligonucleotide 2.52b but 
further extension was completely blocked (Figure 2-26, Panel B). 
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The product(s) of the extension reaction catalyzed by Kf– was analyzed 
by the LC-ESI/MS/MS method described above. The ESI mass spectrum of 
the reaction mixture showed a molecular ion peaks with m/z of 719.2 and 
1078.8 (Figure 2-28). This two molecular ion peaks correspond to M-3H and 
M-2H ions of the same oligonucleotide, of m/z 2159.6 Da (calculated for M-
2H). The possible composition of the m/z 1078.8 ± 2 Da (M-2H) 
oligonucleotide was 1 phosphate, 2 dCyd’s, 2 dTyd’s, 2 Ado’s and 1 dGuo. 
Given the composition and the sequence of the template, the most likely 
extension product was 5′-pTCCATGA-3′. 
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Figure 2-28. TIC spectrum of the LC-ESI/MS/MS analysis of the Kf– 
extension reaction product past the MeFAPy-dGuo lesion in oligonucleotide 
2.52a and the biotinated primer 2.54; molecular ion peaks with m/z 719.2 and 
m/z 1078.8 correspond to M-3H and M-2H, respectively, of the extension 
product with mass 2159.6 Da identified as the 5′-pTCCATGA-3′. 
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The CID of the molecular ion peak m/z 1078.8 matched well with the 
predicted CID spectrum for the sequence 5′-pTCCATGA-3′, which represents 
an error-free bypass and extension (Figure 2-29, Table 2-05). The predicted 
CID spectrum was obtained from the “Mongo Oligo Mass Calculator” v2.06 
maintained by the Department of Medicinal Chemistry at the University of 
Utah, which is available online at http://library.med.utah.edu/masspec/ mongo 
.htmpthe. 
An authentic standard of the oligonucleotide 5′-pTCCATGA-3′ was 
purchased from Midland Certified Reagents and subjected to LC-ESI/MS/MS 
analysis under similar conditions as the sample from the extension reaction 
(Appendix). 
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Figure 2-29. CID spectrum of the molecular ion peak m/z 1078.8 of the Kf– 
extension product, identified as the 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleoitde 2.52a. 
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Table 2-05. Observed and theoretical fragmentation for the Kf– 
extension product m/z 1078.83, identified as the 5′-pTCCATGA-3′, 
past the MeFAPy-dGuo lesion in the oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481.0 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCC (a4-B) 1059.2 1059.1 
5'-pTCCAT (a6-B) 1677.3 1676.2 
                  (a6-B, -2) 837.7 837.6 
        pCCATGA-3' (w6, -2) 926.8 926.7 
          pCATGA-3' (w5) 1565.2 1565.2 
             pATGA-3' (w4) 1276.3 1276.2 
               pTGA-3' (w3) 963.2 963.1 
                 pGA-3' (w2) 659.2 659.1 
 
 
The CID of the sequence was identical to the one found in the Kf– full-
length extension, thereby proving its sequence (Table 2-05). 
To establish the yield of the error-free bypass product the 
oligonucleotide, 5′-pCTTACGAGCCCCC-3′ (2.55), was used as internal 
standard, which was added prior to MS analysis. The TIC spectrum is shown 
in Figure 2.30 with m/z 982.9 and 1310.5 being the M-4H and M-3H, 
respectively, of the internal standard. A calibration curve for the 5′-
pTCCATGA-3′ and the standard 2.55 was constructed and showed good 
linearity (R2 = 0.997) (Figure 2-31).  
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Figure 2-30 TIC spectrum of the LC-ESI/MS/MS analysis of the Kf– extension 
product, identified as the 5′-pTCCATGA-3′, past the MeFAPy-dGuo lesion in 
the oligonucleotide 2.52a in the presence of internal standard 5′-
pCTTACGAGCCCCC-3′ (2.55); molecular ion peaks with m/z 719.0 and m/z 
1078.7 correspond to M-3H and M-2H, respectively, of the extension product 
with mass 2159.5 Da; molecular ion peaks with m/z 982.9 and m/z 1310.5 
correspond to M-4H and M-3H, respectively, of the internal standard 5′-
pCTTACGAGCCCCC-3′ (2.55). 
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Figure 2-31. The calibration curve for the 5′-pTCCATGA-3′ and the internal 
standard 5′-pCTTACGAGCCCCC-3′ (2.55). 
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The estimated yield of the error-free bypass product 5′-pTCCATGA-3′ was 
26%. This low yield is due to the inefficient extension of the product after 
initial insertion of dCTP and the fact that the extension is blocked after the 
initial mis-incorporation of dATP, dTTP and dGTP. 
 
 
Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in the  
Oligonucleotide 2.52a Catalyzed by Pol II– 
Pol II– incorporated all four dNTP's opposite the MeFAPy-dGuo lesion 
in the oligonucleotide 2.52a while only dCTP was inserted for the unadducted 
oligonucleotide (Figure 2-32). 
 
0  25    50  100 0     25   50   100 0   25   50   100 0    25    50  100 0    25    50 100 nM (dNTP)
A T G C Ext.
A: MeFAPy-dGuo
B: Unmodified
A T G C Ext.
0  25   50  100 0  25 50 100 0  25   50   100 0   25   50  100 0   25  50  100 nM (dNTP)
 
Figure 2-32. Single and full-length incorporation assays catalyzed by Pol II–: 
A. Incorporation across the MeFAPy-dGuo adduct in oligonucleotide 2.52a; 
B. Incorporation of dNTP(s) in the unmodified oligonucleotide 2.51. 
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Steady-state kinetic assays were performed to obtain more quantitative 
information about the tendency for pol II– to misincorporate nucleotides 
opposite the MeFAPy-dGuo lesion. The insertion efficiency for dCTP opposite 
the MeFAPy-dGuo was nearly the same as the unmodified template, whereas 
the insertion efficiencies for dTTP, dGTP and dATP were 7, 14 and 80 times 
higher, respectively, than the unmodified template (Table 2-06). 
 
 
Table 2-06. Steady-state kinetics parameters for Pol II–. 
 
kcat kcat/km
Template dNTP Km (μM) (s-1 x 10-3) ( M-1 x s-1x 10-3)  fa
C 0.016 ± 0.005 1.1 ± 0.3 69 1
MeFAPy-dGuo T 4.8 ± 0.3 7.7 ± 0.8 2 0.02
G 7.2 ± 0.1 5.1± 0.5 0.7 0.01
A 3.9 ± 0.4 6.4 ± 0.5 1.6 0.02
C 0.012 ± 0.002 0.91 ± 0.07 76 1
dGuo T 3.3 ± 0.2 0.82 ± 0.07 0.2 0.003
G 13.7 ± 0.2 0.75 ± 0.09 0.05 0.001
A 15.0 ± 0.6 0.29 ± 0.03 0.02 0.0002
af - misincorporation frequency = (kcat/Km) incorporated dNTP/(Kcat/Km) correct dNTP (dCTP)  
 
 
Pol II– was able to extend past the MeFAPy-dGuo in the 
oligonucleotide 2.52a in the presence of all four dNTP’s, but there was 
blocking product(s) after incorporation of the base opposite the MeFAPy-
dGuo adduct. The full-length extension was examined with the 0-primers Ado 
(2.56), Tyd (2.56), and Guo (2.58) opposite the MeFAPy-dGuo adduct and 
showed that the extension was completely blocked (Figure 2-33). 
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0     25     50   100  nM (dNTP)
Ado (2.56) Tyd (2.57) Guo (2.58) 2.53
0      25    50    1000    25    50   100 0    25     50   100
 
Figure 2-33. Full-length incorporation assays with MeFAPy-dGuo containing 
oligonucleotide (2.52a) by pol II– and 0-primers Ado (2.56), Tyd (2.57),Guo 
(2.58) and -1 primer 2.53 in the presence of the four dNTP’s; 5’-
GGGGGCGAT-GCTCGTAAGGATTCA-3’ (2.56); 5’-GGGGGCGATGCTCG 
TAAGGATTCT-3’ (2.57); 5’-GGGGGCGATGCTCGTAAGGATTCG-3’ (2.58); 
5’-GGGGGC-GATGCTCGTAAGGATTC-3’ (2.53). 
 
 
The nucleotide sequences of the full-length extension product(s) of pol 
II– were determined using the LC-ESI/MS/MS method described for the 
extension with Kf–. The ESI mass spectrum of the full-length extension 
reaction showed a molecular ion peaks with m/z 719.1 and 1079.0 (Figure 2-
34), which correspond to M-3H and M-2H ions of the same oligonucleotide. 
The molecular mass of the oligonucleotide calculated based on the mass of 
the molecular ion peak M-2H was 2160.1 Da. The analysis of the 
oligonucleotide with m/z 1079.0, performed in a similar manner as that for the 
Kf– extension reaction product, suggested that the pol II– full-length extension 
product was 5′-pTCCATGA-3′. The CID of molecular ion peak m/z 1079.0 is 
shown in Figure 2-35 and the comparison of the molecular mass of the 
observed and theoretical values of the fragments is shown in Table 2-07.  
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Figure 2-34. TIC spectrum of the LC-ESI/MS/MS analysis of the pol II– 
extension reaction product, past the MeFAPy-dGuo lesion of the 
oligonucleotide 2.52a and the biotinated primer 2.54; molecular ion peaks 
with m/z 719.1 and m/z 1079.0 correspond to M-3H and M-2H, respectively, 
of the extension product with mass 2160.1 Da identified as the 5′’-
pTCCATGA-3′. 
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Figure 2-35. CID spectrum of the molecular ion peak m/z 1079.0 of the pol II– 
extension product, identified as the 5′’-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in the oligonucleotide 2.52a. 
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Table 2-07. Observed and theoretical fragmentation for the pol II– extension 
product m/z 1079.0, identified as the 5′-pTCCATGA-3′, past the MeFAPy-
dGuo lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.1 481.0 
5'-pTC (a3-B) 770.2 770.8 
5'-pTCC (a4-B) 1059.1 1059.1 
5'-pTCCAT (a6-B) 1676.0 1676.2 
                   (a6-B, -2) 837.6 837.6 
        pCCATGA-3' (w6, -2) 926.9 926.7 
          pCATGA-3' (w5) 1565.3 1565.2 
             pATGA-3' (w4) 1276.2 1276.2 
               pTGA-3' (w3) 963.2 963.1 
                pGA-3'  (w2) 659.0 659.1 
 
 
The yield for the formation of the free error bypass product, 5′-
pTCCATGA-3′, was determined using the internal standard 2.55 and the 
calibration curve shown in Figure 2-31. The yield of error-free bypass was 
18%. Possible reasons for this low yield are the inefficient extension of the 
product after initial insertion of dCTP and the fact that the extension from the 
initial mis-incorporation of dATP, dTTP and dGTP are completely inhibited. 
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Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide 
 2.51a Catalyzed by Dpo4. 
The ability of the Y-family of DNA polymerases to bypass the MeFAPy-
dGuo adduct was examined with Dpo4. Dpo4 inserted all four dNTP's 
opposite the MeFAPy-dGuo adduct in oligonucleotide 2.52a (Figure 2-36, 
Panel A). At higher dNTP concentrations incorporations of second dATP, 
dTTP and dCTP were observed. Dpo4 inserted all four dNTP's in unmodified 
oligonucleotide 2.51 and at higher dNTP(s) concentration an incorporation of 
second dNTP was observed. The incorporation of second dNTP is not 
unusual for Dpo4 because the enzyme has a larger active site compared to 
the Kf– and pol II– and may allow the accommodation of a second molecule of 
dNTP (74). 
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A T G C Ext.
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A: MeFAPy-dGuo
B: Unmodified
 
Figure 2-36. Single and full-length incorporation catalyzed by Dpo4: A. 
Incorporation across the MeFAPy-dGuo adduct in oligonucleotide 2.52a; B 
Incorporation of dNTP(s) in the unmodified oligonucleotide 2.51. 
 
 
Steady-state kinetic experiments were run in order to investigate the 
rate of incorporation of the four dNTP’s by Dpo4.  While the insertion 
efficiencies for dCTP and dATP opposite the MeFAPy-dGuo were 2.5 and 10 
times less, respectively, than the unmodified template, while the insertion 
efficiencies for dGTP and dTTP were the same as the unmodified template 
(Table 2-08). 
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Table2-08. Steady-state kinetics parameters for Dpo4. 
 
kcat kcat/km
Template dNTP Km (μM) (s-1 x 10-3) ( M-1 x s-1x 10-3)  fa
C 0.015 ± 0.002 0.6 ± 0.1 40 1
MeFAPy-dGuo T 0.105 ± 0.09 0.34 ± 0.06 3 0.08
G 0.39 ± 0.04 1.5 ± 0.4 4 0.1
A 0.52 ± 0.02 0.21 ± 0.09 0.4 0.01
C 0.09 ± 0.01 9.6 ± 0.3 100 1
dGuo T 2.0 ±  0.3 8.12 ± 0.05 4 0.04
G 1.7 ± 0.4 10.3 ± 1.2 6 0.06
A 2.4 ± 0.8 9.3 ± 0.4 4 0.04
af - misincorporation frequency = (kcat/Km) incorporated dNTP/(Kcat/Km) correct dNTP (dCTP)  
 
Full-length extension product was observed for Dpo4 when all four 
dNTP's were added. The extension was efficient and there were no significant 
pause sites as observed with Kf– and Pol II–. Subsequently, full-length 
extensions were examined with 0-primers Ado (2.56), Tyd (2.56), and Guo 
(2.58) were run in the presence of all four dNTP’s in order to investigate if the 
initial mis-incorporation products could be extended (Figure 2-37). The 
extension assays showed that the 0-primers were extended with low 
efficiency. 
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Ado (2.56) Tyd (2.57) Guo (2.58) 2.53
0      25   50   100 0     25    50   100 nM (dNTP)0       25    50   100 0     25     50   100
 
Figure 2-37. Full-length incorporation assays with MeFAPy-dGuo containing 
oligonucleotide (2.52a) by Dpo4 and 0-primers Ado (2.56), Tyd (2.57), Guo 
(2.58) and -1 primer 2.53 in the presence of the four dNTP’s; 5’-
GGGGGCGATGCTCG-TAAGGATTCA-3’ (2.56); 5’-GGGGGCGATGCTCGT 
AAGGATTCT-3’ (2.57); 5’-GGGGGCGATGCTCGTAAGGATTCG-3’ (2.58); 
5’-GGGGGCGATGCT-CGTAAGGATTC-3’ (2.53). 
 
 
Full-length extension reaction with the corresponding biotinated -1 
primer 2.54 and the MeFAPy-dGuo containing oligonucleotide 2.52a was run 
and analyzed by LC-ESI/MS/MS. The ESI spectrum of the reaction product(s) 
obtained from the biotinated primer 2.54 showed two molecular ion peaks 
with m/z 718.8 and 1078.5 (Figure 2-38), which correspond to M-3H and M-
2H ions of the same oligonucleotide. The molecular peak with m/z 1078.8 
was used to calculate the molecular mass of the extension product, which is 
2160.1 Da. This molecular mass was close to the molecular mass of the 
identified extension products of Kf– and pol II–, which suggested that probably 
the Dpo4 extension product was the oligonucleotide 5′-pTCCATGA-3′. The 
CID of molecular ion peak 1078.5, shown in Figure 2-39, matched very well 
with the CID spectrum of 5′-pTCCATGA-3′ (Table 2-09), which represents an 
error-free bypass and extension. 
  105
400 600 800 1000 1200 1400 1600 1800 2000
m/z
0
10
20
30
40
50
60
70
80
90
100
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
1078.5
718.8
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
R
el
at
iv
e 
A
bu
nd
an
ce
 
 
Figure 2-38. TIC spectrum of the LC-MS/MS/MS analysis of the Dpo4 
extension reaction product past the MeFAPy-dGuo lesion in oligonucleotide 
2.52a using primer 2.53; molecular ion peaks with m/z 718.8 and m/z 1078.5 
correspond to M-3H and M-2H, respectively, of the extension product with 
mass 2159.1 Da, identified as the 5′-pTCCATGA-3′. 
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Figure 2-39. CID spectrum of the molecular ion peak m/z 1078.5 of the Dpo4 
extension product, identified as the 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
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Table 2-09. Observed and theoretical fragmentation for the Dpo4 extension 
product m/z 1078.5, identified as the 5′-pTCCATGA-3′, past the MeFAPy-
dGuo lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.1 481.0 
5'-pTC (a3-B) 770.2 770.8 
5'-pTCC (a4-B) 1059.2 1059.1 
5'-pTCCAT (a6-B) 1676.1 1676.2 
                   (a6-B, -2) 837.7 837.6 
      pCCATGA-3' (w6, -2) 926.7 926.7 
        pCATGA-3' (w5) 1565.2 1565.2 
           pATGA-3' (w4) 1276.2 1276.2 
             pTGA-3' (w3) 963.2 963.1 
                 pGA-3' (w2) 659.2 659.1 
 
 
The yield of formation of the free error bypass product, 5′-pTCCATGA-
3′, was determined by using the internal standard 5′-pCTTACGAGCCCCC-3′ 
(2.56) and the calibration graph curve shown in Figure 2-31. The yield of the 
error-free bypass was 72%, indicating the more efficient bypass and 
extension of the primer after initial incorporation of dCyt opposite the 
MeFAPy-dGuo adduct by Dpo4 then Kf– and pol II–. 
Although the extension assays with primers 2.56, 2.57 and 2.58 
showed that Dpo4 can extend products that are formed after initial mis-
incorporation of dGTP, dTTP, and dATP, the full-length extension products 5′-
pTCGATGA-3′, 5′-pTCTATGA-3′ and 5′-pTCAATGA-3′, respectively, were not 
detected for the bypass of oligonucleotide 2.52a. This suggests that the rate 
of mis-incorporation of the dATP, dTTP and dGTP is low compared to the rate 
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of incorporation and extension past dCTP opposite the MeFAPy-dGuo adduct 
(Table 2-08). 
Full-length extension reactions were run with the corresponding 
biotinated primers of Ado (2.56), Tyd (2.57) and Guo (2.58). The LC-
ESI/MS/MS analyses of the extension products showed that the biotinated 
primers were extended in an error-free manner. The CID spectra and 
fragmentation tables of the corresponding extension products can be found in 
the Appendix. 
 
 
DNA Bypass of MeFAPy-dGuo Adduct (2.05) Catalyzed by Eukaryotic 
 DNA Polymerases 
The MeFAPy-dGuo containing oligonucleotide (2.52a) was annealed to 
a complementary 23mer (2.54) (-1) primer strand, which was 5’-labeled with 
32P. The single nucleotide insertion and the full length extension reactions in 
the presence of all four dNTP’s using eukaryotic DNA polymerases were run 
at fixed amount of the enzymes and increasing dNTP(s) concentration(s). The 
same reactions with unmodified oligonucleotide 2.51 were run at two-fold less 
concentration of eukaryotic DNA polymerases but with the same reaction time 
as the adducted oligonucleotide 2.52a 
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Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide  
2.51a Catalyzed by Human Pol δ. 
Human pol δ inserted only dCTP opposite the MeFAPy-dGuo adduct in 
oligonucleotide 2.52a (Figure 2-40, Panel A) and only dCTP in the unmodified 
oligonucleotide 2.51 (Figure 2-40, Panel B). The full-length extension past the 
MeFAPy-dGuo adduct in oligonucleotide 2.52a catalyzed by human pol δ was 
blocked, which was expected since the replicative human pol δ does not 
replicate through DNA damaged lesions. 
 
 
A T G Ext.C
0 120 250 1000 0 120 250 1000 0 120 250 1000 0 120 250 1000 0 120 250 1000 nM (dNTP)
A: MeFAPy-dGuo
B: Unmodified
A T G Ext.C
0 120 250 1000 0 120 250 1000 0 120 250 1000 0 120 250 1000 0 120 250 1000 nM (dNTP)
 
Figure 2-40. Single and full-length incorporation assays catalyzed by a 
human pol δ: A. Incorporation across the MeFAPy-dGuo adduct in 
oligonucleotide 2.52a; B Incorporation of dNTP(s) in the unmodified 
oligonucleotide 2.51.  
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Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide 
 2.51a Catalyzed by Human Pol η. 
Human pol η inserted all four dNTP's opposite the MeFAPy-dGuo 
adduct in oligonucleotide 2.52a (Figure 2-41, Panel A). At higher dNTP 
concentrations incorporations of second dATP, dGTP and dCTP were also 
observed. 
The gel analysis of the single nucleotide insertion in unmodified 
oligonucleotide 2.51 showed that the human pol η preferentially inserted 
dCTP, over dATP, dGTP and dTTP, and no subsequent incorporations of a 
second dNTP was observed (Figure 2-41, Panel B). 
 
 
A T G Ext.C
0  120 250  1000 0  120  250  1000 0  120   250   1000 0  120 250  1000 0 120 250 1000 nM (dNTP)
A: MeFAPy-dGuo
B: Unmodified
A T G Ext.C
0   120  250  1000 0  120 250 1000 0   120 250 1000 0   120 250 1000 0   120  250 1000 nM (dNTP)
 
Figure 2-41. Single and full-length incorporation assays catalyzed by a 
human pol η: A. Incorporation across the MeFAPy-dGuo adduct in 
oligonucleotide 2.52a; B Incorporation of dNTP(s) in the unmodified 
oligonucleotide 2.51.  
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The rates of nucleotide incorporation opposite the MeFAPy-dGuo 
lesion catalyzed by human pol η were determined and the steady-state 
kinetics parameters are listed in Table 2-10. The insertion efficiency for dCTP 
opposite the MeFAPy-dGuo was 6.4 times less than the unmodified template, 
whereas the insertion efficiencies for dTTP, dGTP and dATP were 1.5, 3.6 
and 3 times higher, than the unmodified template, respectively. 
 
 
Table 2-10. Steady-state kinetics parameters for pol η. 
 
 kcat kcat/km
Template dNTP Km (μM) (s-1 x 10-3) (μM-1 x s-1x 10-3) fa
C 8 ± 2 26 ± 1 3 1
MeFAPy-dGuo T 23 ± 3 17 ± 2 0.7 0.7
G 9 ± 1 3.8 ± 0.3 0.4 0.1
A 29 ± 8 14 ± 1 0.5 0.1
C 1.9 ± 0.5 40 ± 3 21 1
dGuo T 4 0± 10 20 ± 3 0.5 0.02
G 110 ± 40 13 ± 1 0.1 0.005
A 140 ± 30 20 ± 2 0.1 0.005
af - misincorporation frequency = (kcat/Km) incorporated dNTP / (Kcat/Km) correct dNTP (dCTP)  
 
 
The full-length extension reaction of MeFAPy-dGuo oligonucleotide 
and the biotinated primer 2.54 catalyzed by pol η was run and analyzed by 
LC-ESI/MS/MS. The ESI spectrum of the extension reaction showed three 
molecular ion peaks with m/z 1078.8, 1086.8 and 1099.2 (Figures 2-42 and 2-
43), which correspond to oligonucleotides with masses 2159.6, 2175.2 and 
2200.4 Da (M-2H), respectively. The oligonucleotides with masses 2159.6 
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and 2175.2 were identified as the 5′-pTCCATGA-3′ and 5′-pTCTATGA-3′ 
based on possible oligonucleotide compositions, the sequence of the 
template and the corresponding CID’s (Figures 2-43 and 2-44, Tables 2-11 
and 2-12). 
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Figure 2-42. TIC spectrum of the LC-MS/MS/MS analysis of the pol η 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using the primer 2.54; molecular ion peaks with m/z 
719.0 and m/z 1078.8 correspond to M-3H and M-2H, respectively, of the 
extension product with mass 2159.6 Da identified as 5′-pTCCATGA-3′. 
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Figure 2-43. TIC spectrum of the LC-MS/MS/MS analysis of the pol η 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using the primer 2.54; molecular ion peaks with m/z 
724.6 and m/z 1086.9 correspond to M-3H and M-2H, respectively, of the 
extension product with mass 2175.8 Da identified as 5′-pTCTATGA-3′; 
molecular ion peaks with m/z 732.4 and m/z 1099.2 correspond to M-3H and 
M-2H, respectively, of the extension product with mass 2200.4 Da identified 
as 5′-pTCGATGA-3′. 
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Figure 2-44. CID spectrum of the molecular ion peak m/z 1078.8 of the pol η 
extension product, identified as 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
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Table 2-11. Observed and theoretical fragmentation for the pol η extension 
product m/z 1078.8, identified as 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCC (a4-B) 1059 1059.1 
5'-pTCCAT (a6-B) 1676 1676.2 
                  (a6-B, -2) 837.5 837.6 
        pCATGA-3' (w5) 1565 1565.2 
          pATGA-3' (w4) 1276 1276.2 
            pTGA-3' (w3) 963.1 963.1 
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Figure 2-45. CID spectrum of the molecular ion peak m/z 1086.8 of the pol η 
extension product, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
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Table 2-12. Observed and theoretical fragmentation for the pol η extension 
product m/z 1086.8, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCT (a4-B) 1074.2 1074.1 
5'-pTCTAT (a6-B) 1690.2 1691.2 
                  (a6-B, -2) 845.6 845.1 
        pTATGA-3' (w5) 1581.3 1580.2 
          pATGA-3' (w4) 1276.3 1276.2 
             pTGA-3' (w3) 963.2 963.1 
               pGA-3' (w2) 659.1 659.1 
 
 
The possible composition of the oligonucleotide with m/z 2200.46 (M-
2H) was 1 phosphate, 1 dCyd, 2 dTyd’s, 2 dAdo’s, and 2 dGuo’s. Analysis of 
the CID spectrum suggests that the sequence was 5′-pTCGATGA-3′, which 
represents a mis-insertion of dGTP followed by an error-free extension. The 
CID of the molecular ion m/z 2200.4 matched very well with the predicted CID 
(Figure 2-46, Table 2-13). 
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Figure 2-46. CID spectrum of the molecular ion peak m/z 1099.2 of the pol η 
extension product, identified as 5′-pTCGATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
 
Table 2-13. Observed and theoretical fragmentation for the pol η extension 
product m/z 1099.2, identified as 5′-pTCGATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481 
5'-pTC (a3-B) 770 770.8 
5'-pTCGAT (a6-B) 1716.1 1716.2 
                  (a6-B, -2) 857.6 587.6 
        pGATGA-3' (w5) 1605.3 1605.2 
           pATGA-3' (w4) 1276.4 1276.2 
              pTGA-3' (w3) 963.2 963.1 
                pGA-3' (w2) 659.5 659.1 
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The yields of the 5′-pTCCATGA-3′, 5′-pTCTATGA-3′ and 5′-
pTCGATGA-3′ extension products were determined by using the internal 
standard 5’-pCTTACGAGCCCCC-3′ (2.55) and the calibration curves shown 
in Figures 2-31, 2-47 and 2-48. The yields for the extension products 5′p-
TCCATGA-3′, 5′-pTCTATGA-3′ and 5′-pTCGATGA-3′ were 54%, 5% and 8%, 
respectively.  
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Figure 2-47. The calibration curve for the 5′-pTCTATGA-3′ and the internal 
standard 5′-pCTTACGAGCCCCC-3′ (2.55). 
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Figure 2-48. The calibration curve for the 5′-pTCGATGA-3′ and the internal 
standard 5′-pCTTACGAGCCCCC-3′ (2.56). 
 
 
Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide  
2.52a Catalyzed by Human Pol ι. 
Human pol ι did not catalyze any dNTP incorporation across the 
MeFAPy-dGuo adduct with good efficiency (Figure 2-49, Panel A). The gel 
analysis of the single nucleotide insertion in unmodified oligonucleotide 2.51 
showed that the human pol ι did not incorporate any dNTP (Figure 2-49, 
Panel B). 
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A: MeFAPy-dGuo
B: Unmodified
 
Figure 2-49. Single and full-length incorporation assays catalyzed by human 
pol ι: A. Incorporation across the MeFAPy-dGuo adduct in oligonucleotide 
2.52a; B Incorporation of dNTP(s) in the unmodified oligonucleotide 2.51. 
 
 
Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide 
 2.52a Catalyzed by Human Pol κ. 
Human pol κ inserted dTTP, dGTP and dCTP opposite the MeFAPy-
dGuo adduct in oligonucleotide 2.52a (Figure 2-50, Panel A), while dCTP and 
at higher concentration dGTP was inserted in the unmodified oligonucleotide 
(Figure 2-50, Panel B).  
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B: Unmodified
 
Figure 2-50. Single and full-length incorporation assays catalyzed by human 
pol κ: A. Incorporation across the MeFAPy-dGuo adduct in oligonucleotide 
2.52a; B Incorporation of dNTP(s) in the unmodified oligonucleotide 2.51. 
 
 
The rates of incorporation of the three dNTP’s by human pol k were 
determined by steady-state kinetic experiments. The insertion efficiency for 
dCTP opposite the MeFAPy-dGuo was 6 times less than the unmodified 
template, whereas the insertion efficiencies for dGTP and dTTP were the 
same and 2.8 higher than the unmodified template, respectively (Table 2-14). 
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Table 2-14. Steady-state kinetics parameters for pol κ. 
 kcat kcat/km
Template dNTP Km (μM) (s-1 x 10-3) (μM-1 x s-1x 10-3) fa
C 9 ± 2 49 ± 2 5.5 1
MeFAPy-dGuo G 220 ± 70 27 ± 5 0.1 0.02
T 45 ± 9 27 ± 2 0.6 0.11
C 2.1 ± 0.8 75 ± 6 35 1
dGuo G 300 ± 89 42 ± 4 0.1 0.003
T 150 ± 20 32 ± 2 0.2 0.006
af - misincorporation frequency = (kcat/Km) incorporated dNTP/(Kcat/Km) correct dNTP (dCTP)  
 
Full-length extension reaction with biotinated (-1)-primer 2.54 and the 
MeFAPy-dGuo oligonucleotide 2.52a catalyzed by human pol κ was run and 
analyzed by LC-ESI/MS/MS. The ESI spectrum of the extension reaction 
showed two molecular ion peaks with m/z 1078.5 and 1086.9 (Figure 2-51 
and 2-52), which were assumed to correspond to oligonucleotides with 
masses 2159.6 and 2175.8 Da (M-2H), respectively. The possible 
composition of the 2159.6 Da oligonucleotide was 1 phosphate, 2 dCyd’s, 2 
dTyd’s, 2 dAdo’s and 1 dGuo, whereas the possible composition of the 
2175.8 Da oligonucleotide was 1 phosphate, 1 dCyt, 2 dTyd’s, 3 dAdo’s and 1 
dGuo. Considering these compositions and the sequence of the template, the 
only possible extensions products were 5′p-TCCATGA-3′, which represents 
an error free bypass and extension and 5′-pTCAATGA-3′, which represents 
mis-insertion of dATP opposite the adduct followed by error-free extension. 
The CIDs of the molecular ions peaks m/z 1078.5 (Figure 2-53) and m/z 
1086.9 (Figure 2-54) matched very well with the predicted CID spectra of an 
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authentic (Appendix), commercially purchased oligonucleotides (Table 2-15, 
2-16). 
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Figure 2-51. TIC spectrum of the LC-MS/MS/MS analysis of the pol κ 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using primer 2.54. Molecular ion peaks with m/z 718.8 
and m/z 1078.7 correspond to M-3H and M-2H, respectively of 
oligonucleotide with mass 2159.6 Da, identified as 5′-pTCCATGA-3′. 
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Figure 2-52. TIC spectrum of the LC-MS/MS/MS analysis of the pol κ 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using primer 2.54. Molecular ion peaks with m/z 724.3 
and m/z 1089.9 correspond to M-3H and M-2H, respectively of 
oligonucleotide with mass 2175.8 Da, identified as 5′-pTCTATGA-3′. 
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Figure 2-53. CID spectrum of the molecular ion peak m/z 1078.8 of the pol κ 
extension product, identified as 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
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Figure 2-54. CID spectrum of the molecular ion peak m/z 1086.9 of the pol κ 
extension product, identified as 5’-pTCTATGA-3’, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
 
Table 2-15. Observed and theoretical fragmentation for the pol κ extension 
product m/z 1078.8, identified as 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCC (a4-B) 1059.2 1059.1 
5'-pTCCAT (a6-B) 1676.2 1676.2 
                   (a6-B, -2) 837.7 837.6 
     pCCATGA-3' (w6, -2) 926.7 926.7 
        pCATGA-3' (w5) 1565.2 1565.2 
           pATGA-3' (w4) 1276.3 1276.2 
             pTGA-3' (w3) 963.2 963.1 
               pGA-3' (w2) 659.2 659.1 
 
 
  124
Table 2-16. Observed and theoretical fragmentation for the pol κ extension 
product m/z 1086.9, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
   
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481 481 
5'-pTC (a3-B) 770 770.8 
5'-pTCT (a4-B) 1074.2 1074.1 
5'-pTCTAT (a6-B) 1692.2 1691.2 
                  (a6-B, -2) 845.1 845.1 
      pCTATGA-3' (w6, -4) 466 466.5 
         pTATGA-3' (w5) 1580.2 1580.2 
           pATGA-3' (w4) 1276.1 1276.2 
              pTGA-3' (w3) 963.1 963.1 
                pGA-3' (w2) 659.2 659.1 
 
 
The yields for the formation of the 5′-pTCCATGA-3′ and 5′-
pTCTATGA-3′ extension products were determined using the internal 
standard 2.55 and the calibration graphs shown in Figures 2-31 and 2.47. The 
yield of formation of the error-free product 5′p-TCCATGA-3′ was 55%, 
whereas the yield of formation of error-prone product 5′-pTCTATGA-3′, was 
5%. 
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Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide 
 2.52a Catalyzed by a Combination of Human Pols κ/ι. 
The human pols κ/ι were used in equimolar amounts and their 
concentration was kept fixed for the single nucleotide insertion assays. 
The single nucleotide insertion catalyzed by a combination of human 
pols κ/ι seemed to occur at higher dNTP concentrations (Figure 2-55). The 
preferable nucleotide incorporated opposite the MeFAPy-dGuo lesion was 
dCTP, which represents the correct incorporation. Human pols κ/ι also 
inserted dGTP and dTTP at higher dNTP’s concentrations. In contrast to pol 
κ, which favored the misinsertion of dTTP over dGTP, the combination of pols 
κ/ι favored the misinsertion of dGTP more than dTTP (Figures 2-50 and 2-
55). This change in the preference for the incorporation of the second 
nucleotide when a combination of pols κ/ι is used is perhaps due to the tight 
binding of human pol ι to the template/primer with T more than to the 
template/primer with G; if the binding is tight, the human pol ι does not 
dissociate, which prevents pol κ from extending the products. Human pol ι 
alone did not catalyzed any nucleotide incorporation across the MeFAPy-
dGuo adduct with a good efficiency (Figure 2.49, Panel A). 
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Figure 2-55. Single and full-length incorporation assays catalyzed by a 
combination human pols κ/ι: A. Incorporation across the MeFAPy-dGuo 
adduct in oligonucleotide 2.52a; B Incorporation of dNTP(s) in the unmodified 
oligonucleotide 2.51.  
 
 
The single nucleotide incorporation assays with the combination of 
human pols κ/ι and the unmodified sequence 2.51 showed that only dCTP is 
incorporated in contrast to human pol κ, which not only incorporated dCTP 
but also dGTP at higher dNTP concentration (Figure 2-55, Panel B and 
Figure 2-50, Panel B). 
The full-length extension reaction with the MeFAPy-dGuo containing 
oligonucleotide 2.52a and the biotinated primer 2.54 catalyzed by a 
combination of pols κ/ι was run and analyzed by LC-ESI/MS/MS. The ESI 
spectrum of the extension reaction showed two molecular ion peaks with m/z 
1078.8 and 1086.9 (Figures 2-56 and 2-57), which correspond to 
oligonucleotides with masses 2159.6 and 2175.8 Da, respectively. Since 
these two oligonucleotides had the same molecular masses as the extension 
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products of pol κ, 5′-pTCCATGA-3′ and 5′’-pTCTATGA-3′, it was initially 
assumed that they are identical to the afore-mentioned sequences. This was 
tested by examining the MS/MS (CID) spectra of the molecular ions with m/z 
1078.8 and 1086.9 (Figures 2-58 and 2-59). The CID spectra of the molecular 
ions with masses 2159.6 and 2175.8 Da showed fragmentation patterns 
indicative for the 5′-pTCCATGA-3′ and 5′-pTCTATGA-3′ (Tables 2-17 and 2-
18).  
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Figure 2-56. TIC spectrum of the LC-ESI/MS/MS analysis of the pols κ/ι 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using primer 2.54; molecular ion peaks with m/z 718.8 
and m/z 1078.8 correspond to M-3H and M-2H, respectively, of the extension 
product with mass 2159.6, identified as 5′-pTCCATGA-3′; molecular ion 
peaks with m/z 983.1 and m/z 1310.6 correspond to M-4H and M-3H, 
respectively, of the internal standard 5′-pCTTACGAGCCCCC-3′ (2.55). 
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Figure 2-57. TIC spectrum of the LC-ESI/MS/MS analysis of the pols κ/ι 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using primer 2.54; molecular ion peaks with m/z 724.3 
and m/z 1086.9 correspond to M-3H and M-2H, respectively of 
oligonucleotide with mass 2175.8, identified as 5’-pTCTATGA-3’; molecular 
ion peaks with m/z 982.3 and m/z 1310.9 correspond to M-4H and M-3H, 
respectively, of the internal standard 5′-pCTTACGAGCCCCC-3′ (2.55). 
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Figure 2-58. CID spectrum of the molecular ion peak m/z 1078.8 of the pols 
κ/ι extension product, identified as 5′-pTCCATGA-3′, past the MeFAPy-
dGuo lesion in oligonucleotide 2.52a. 
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Table 2-17. Observed and theoretical fragmentation for the pol κ/ι extension 
product m/z 1078.8, identified as 5′-pTCCATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.1 481.0 
5'-pTC (a3-B) 770.2 770.8 
5'-pTCC (a4-B) 1059.2 1059.1 
5'-pTCCAT (a6-B) 1676.1 1676.2 
                  (a6-B, -2) 837.7 837.6 
      pCCATGA-3' (w6, -2) 926.3 926.7 
         pCATGA-3' (w5) 1565.2 1565.2 
            pATGA-3' (w4) 1276.2 1276.2 
              pTGA-3' (w3) 963.2 963.1 
                pGA-3' (w2) 659.2 659.1 
                  pA-3' (w1) 330.1 330 
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Figure 2-59. CID spectrum of the molecular ion peak m/z 1086.9 of the pols 
κ/ι extension product, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.51a. 
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Table 2-18. Observed and theoretical fragmentation for the pols κ/ι extension 
product m/z 1086.9, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.1 481.0 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCT (a4-B) 1074.2 1074.1 
5'-pTCTAT (a6-B, -2) 845.6 845.1 
        pTATGA-3' (w5) 1581.1 1580.2 
          pATGA-3' (w4) 1276.2 1276.2 
            pTGA-3' (w3) 963.8 963.1 
              pGA-3' (w3) 659.2 659.1 
 
 
The yields of for the extension products 5′-pTCCATGA-3′ and 5′-
pTCTATGA-3′ by the combination of human pols κ/ι were determined using 
the internal standard 5′-pCTTACGAGCCCCC-3′ (2.55) and the calibration 
curve shown in Figures 2-31 and 2.47. The yield of formation of the 
oligonucleotide 5′-pTCCATGA-3′ was 20%, whereas the yield of formation of 
the oligonucleotide 5′-pTCAATGA-3′ was 5%. The yield of formation of the 
error free bypass product, 5′-pTCCATGA-3′, was by a factor of two lower than 
the yield of the same extension product formed by human pol κ, while the 
yield of the error prone bypass, 5′-pTCTATGA-3′, was the same as the yield 
of the same extension product formed by human pol κ. 
A possible explanation for the difference in the yields of the reaction 
products formed by a combination of human pols κ/ι and human pol κ is 
alone that pol κ is primarily involved in the extension past the MeFAPy-dGuo 
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adduct and that pol ι is affecting the rate with which pol κ 
incorporates/misincoporates dNTP across the MeFAPy-dGuo lesion (2.05). 
 
 
Polymerase Bypass of the MeFAPy-dGuo Adduct (2.05) in Oligonucleotide 
 2.51a Catalyzed by a Combination of Human Pols η/ι. 
The human pol η/ι were used in equimolar amounts and their 
concentration was kept fixed for the single nucleotide insertion assays. 
The combination of human pols η/ι inserted all four dNTP's opposite 
the MeFAPy-dGuo adduct in oligonucleotide 2.52a (Figure 2-60, Panel A) 
with less efficiency than the pol η alone (Figure 2-41, Panel A). At higher 
dATP concentration incorporation of second dATP was also observed. 
The gel analysis of nucleotide insertion in unmodified sequence 2.51 
showed that the human pols η/ι preferentially inserted dCTP over dGTP 
(Figure 2-60, Panel B); in the analogous reactions with only human pol η all 
four dNTP’s were incorporated (Figure 2-41, Panel B). 
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Figure 2-60. Single and full-length incorporation assays catalyzed by a 
combination of human pols η/ι: A. Incorporation across the MeFAPy-dGuo 
adduct in oligonucleotide 2.52a; B Incorporation of dNTP(s) in the unmodified 
oligonucleotide 2.51.  
 
 
The product(s) of the full-length extension reaction with MeFAPy-dGuo 
oligonucleotide 2.52a and -1 biotinated primer 2.54 catalyzed by a 
combination of pols η/ι was examined by LC-ESI/MS/MS. Similarly to the 
extension reaction catalyzed by pol η, the ESI spectrum of the extension 
reaction catalyzed by pols η/ι showed three molecular ion peaks with m/z 
1078.5, 1086.9 and 1099.2 (Figures 2-61 and 2-62). These three molecular 
ion peaks correspond to three oligonucleotides with masses 2159.1, 2175.8 
and 2200.5 Da. It was assumed that these three oligonucleotides have the 
same composition as those identified as the extension products of pol η. The 
CID spectra for the molecular ions with m/z 1078.5, 1086.9 and 1099.2 
(Figures 2-63, 2-64 and 2-65) were examined and showed fragmentation 
patterns indicative for the 5′-pTCCATGA-3′, 5′-pTCTATGA-3′, 5′-pTCGATGA-
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3′, respectively, (Tables 2-19, 2-20 and 2-21), which confirmed our 
assumption. 
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Figure 2-61. CID spectrum of the molecular ion peak m/z 1086.8 of the 
combination pols η/ι extension product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a and the primer 2.54; molecular ion peaks with m/z 
718.8 and m/z 1078.5 correspond to M-3H and M-2H, respectively, of the 
extension product with mass 2159.1, identified as 5′-pTCCATGA-3′. 
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Figure 2-62. TIC spectrum of the LC-ESI/MS/MS analysis of the pols η/ι 
extension reaction product(s) past the MeFAPy-dGuo lesion in 
oligonucleotide 2.52a using primer 2.54; molecular ion peaks with m/z 724.6 
and m/z 1086.9 correspond to M-3H and M-2H, respectively, of the extension 
product with mass 2175.8, identified as 5′-pTCTATGA-3′, molecular ion peaks 
with m/z 1099.2 correspond to M-2H of the extension product with mass 
2200.4, identified as 5′-pTCGATGA-3′. 
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Figure 2-63. CID spectrum of the molecular ion peak m/z 1078.8 of the 
combination pols η/ι extension product, identified as 5′-pTCCATGA-3′, past 
the MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
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Table 2-19. Observed and theoretical fragmentation for the combination pols 
η/ι extension product m/z 1078.83, identified as 5′-pTCCATGA-3′, past the 
MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.0 481.0 
5'-pTC (a3-B) 769.9 770.8 
5'-pTCC (a4-B) 1058.9 1059.1 
5'-pTCCAT (a6-B) 1675.7 1676.2 
                  (a6-B, -2) 837.5 837.6 
         pCATGA-3' (w5) 1565 1565.2 
           pATGA-3' (w4) 1275.9 1276.2 
              pTGA-3' (w3) 962.3 963.1 
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Figure 2-64. CID spectrum of the molecular ion peak m/z 1086.8 of the 
combination pols η/ι extension product, identified as 5′-pTCTATGA-3′, past 
the MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
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Table 2-20. Observed and theoretical fragmentation for the combination pols 
η/ι extension product m/z 1086.8, identified as 5′-pTCTATGA-3′, past the 
MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.0 481.0 
5'-pTC (a3-B) 770.1 770.8 
5'-pTCT (a4-B) 1074.2 1074.1 
5'-pTCTAT (a6-B) 1691.2 1691.2 
                  (a6-B, -2) 845.6 845.1 
         pTATGA-3' (w5) 1581.3 1580.2 
           pATGA-3' (w4) 1276.8 1276.2 
             pTGA-3' (w3) 963.2 963.1 
               pGA-3' (w2) 659.1 659.1 
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Figure 2-65. CID spectrum of the molecular ion peak m/z 1099.2 of the 
combination pols η/ι extension product, identified as 5′-pTCGATGA-3′, past 
the MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
  137
Table 2-21. Observed and theoretical fragmentation for the combination pols 
η/ι extension product m/z 1099.2, identified as 5′-pTCGATGA-3′, past the 
MeFAPy-dGuo lesion in oligonucleotide 2.52a. 
 
Fragment assignment Observed Theoretical  
5'-pT (a2-B) 481.0 481.0 
5'-pTC (a3-B) 770.0 770.8 
5'-pTCGAT (a6-B) 1715.6 1716.2 
                  (a6-B, -2) 857.5 587.6 
          pGATGA-3' (w5) 1605.0 1605.2 
             pATGA-3' (w4) 1276.0 1276.2 
               pTGA-3' (w3) 963.0 963.1 
                 pGA-3' (w2) 659.6 659.1 
 
 
The yields of formation of the extension products 5′-pTCCATGA-3′, 5′-
pTCTATGA-3′ and 5′-pTCGATGA-3′ were determined by using the internal 
standard 5′-pCTTACGAGCCCCC-3′ (2.55) and the calibration curves shown 
in Figures 2-31, 2-47 and 2-48. The yields of formation of the extension 
products 5′-pTCCATGA-3′, 5′-pTCTATGA-3′ and 5′-pTCGATGA-3′ were 14%, 
0.6% and 0.1%, respectively. The yields of the extension products by the 
combination of pols η/ι are low compared to the yields of the corresponding 
extension products of pol η. A possible explanation for this difference is the 
inability of pol ι to efficiently bypass and extend past the MeFAPy-dGuo 
adduct in oligonucleotide 2.52a (Figure 2-49, Panel A).  
If pol ι binds tightly to DNA before pol η , this would prevent a dNTP 
incorporation across the MeFAPy-dGuo adduct, or if pol ι binds to DNA right 
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after pol η have incorporated a certain dNTP across the MeFAPy-dGuo 
adduct this would prevent further extension of the products.  
 
 
Summary 
We have synthesized a MeFAPy-dGuo phosphoroamidite for the first 
time. This phosphoroamidite was synthesized in four steps and 25% overall 
yield and was used for the preparation of oligonucleotides containing the 
MeFAPy-dGuo lesion (2.05) at a defined location. The crucial step of the 
oligonucleotide syntheses was the acid deprotection of the 5’-hydroxy group 
of the MeFAPy-dGuo nucleotide, since such conditions can cause the ribose 
ring to undergo a rearrangement to the pyranose form. The NMR experiments 
of a trinucleotide containing the MeFAPy-dGuo adduct (2.05), established that 
the removal of the 5’-hydroxyl group of the MeFAPy-dGuo nucleotide under 
the “short” and “long” deprotection cycles results in oligonucleotides 
containing the MeFAPy-dGuo furanose and pyranose forms of the MeFAPy-
dGuo adduct (2.05), respectively. 
Examination of the stability of MeFAPy-dGuo containing 
oligonucleotides showed that MeFAPy-dGuo adduct (2.05) persists in ss and 
ds-DNA at neutral pH but deglycosylation of the MeFAPy-dGuo 
oligonucleotides was observed in water or acidic buffer followed by cleavage 
of the resulting abasic site oligonucleotides. The deglycosylation of MeFAPy-
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dGuo nucleotides occurs through a ribose ring-opened imine intermediate, 
which can be trapped by reduction with Na(CN)BH3. 
The in vitro bypass and full length-extension of the MeFAPy-dGuo 
adduct (2.05) was examined with prokaryotic and eukaryotic DNA 
polymerases. The MeFAPy-dGuo adduct (2.05) was found to be highly 
miscoding; in addition to the correct insertion of dCTP opposite the lesion, all 
three prokaryotic DNA polymerases, Kf–, pol II– and Dpo4, mis-inserted dATP, 
dGTP and dTTP with varying efficiencies. The kcat/km values for dCTP 
insertion opposite the MeFAPy-dGuo lesion (2.05) with Kf– was 8 times lower 
than the insertion opposite an unmodified dGuo, while the misincorporation 
frequencies (f) for the other dNTP's ranged from ∼ 5 to 30 percent (Table 2-
22). 
 
 
Table 2-22. Comparison of the for Kf– insertion efficiencies for the four dNTP’s 
opposite the MeFAPy-dGuo (2.05), FAPy-dGuo (2.59) and 8-oxo-dGuo 
adducts (2.60). 
 
dNTP              Insertion efficiency (modified/dGuo)
MeFAPy-dGuo MeFAPy-dGuo
(a) FAPy-dGuo (b)
C < 8 < 66 < 50
T > 25 < 3.4 < 6.7
G > 3.7 < 0.0003 < 1.4
A < 1.4 >12.5 > 17
           a) ref.46; b) ref. 75, 76  
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The insertion efficiency for the dCTP opposite the MeFAPy-dGuo 
lesion, obtained by Asagoshi and co-workers using Kf– (46), was 66 times 
lower than the insertion efficiency opposite an unmodified dGuo base (Table 
2-21). In contrast to our observations that the insertion efficiency for dTTP 
opposite MeFAPy-dGuo adduct (2.05) was the highest (>25), Asagoshi and 
coworkers reported that the insertion efficiency for dATP was the highest; 
however, the extension of this product was not efficient. Similarly, we 
observed that the extension followed the misincoporation of dATP was 
blocked. Although in our bypass experiments with Kf– the insertion effciencies 
for dGTP and dTTP were high, the full-length extension of these products 
were not observed, suggesting the misinsertion of dGTP and dTTP 
completely inhibits the extension reaction. 
Greenberg and coworkers (75, 76) reported that dATP was 
preferentially incorporated opposite the unsubstituted FAPy-dGuo (2.59) with 
an insertion efficiency 17 times higher, than the insertion opposite the 
unmodified sequence for Kf–  (Figure 2-66, Table 2-22). Moreover, the 
preferential insertion of dATP was observed in mammalian cells, which 
resulted in a high level of FAPydGuo→dTyd conversions (66). 
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Figure 2-66. Structures of the MeFAPy-dGuo (2.05), FAPy-dGuo (2.59) and 
8-oxo-dGuo (2.60) lesions. 
 
 
The kcat/km values for dCTP insertion opposite the MeFAPy-dGuo 
lesion (2.05) with Dpo4 was 2.5 times lower than the insertion opposite an 
unmodified dGuo, while insertion of dCTP by pol II– was nearly equally 
efficient opposite the modified and unmodified base. Misincorporation 
frequencies (f) for the other dNTP's ranged from 1-2 and 11-10 percent for pol 
II– and Dpo4, respectively. 
The MeFAPy-dGuo adduct (2.05) was also found to be a complete 
block to replication catalyzed by human replicative DNA polymerase pol δ and 
highly miscoding to the human DNA polymerases pols κ, η, and ι, and the 
combinations of human pols η/ι and pols η/ι. Human pol κ inserted dCTP, 
dGTP and dTTP, while human pol η inserted all four dNTP's opposite the 
MeFAPy-dGuo adduct (2.05). The same trends of dNTP incorporation of 
opposite the MeFAPy-dGuo adduct (2.05) were observed for the 
combinations of human pols η/ι and η/ι but with lower efficiency. The kcat/km 
values for dCTP insertion opposite the MeFAPy-dGuo lesion (2.05) with pol κ 
and pol η were 6 and 6.4 times lower than the insertion opposite an 
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unmodified dGuo. Misincorporation frequencies (f) for the other dNTP's 
ranged from ∼ 2-11 and 13-73 percent for pol κ and pol η, respectively. 
The ability of the prokaryotic and eukaryotic translesion DNA 
polymerases to extend the MeFAPy-dGuo adduct (2.05) was also examined 
in the presence of all four dNTPs. Starting with the -1 primer, full-length 
extension products were observed for all polymerases. Kf– and pol II– showed 
significant pauses, which are due to the mis-incorporation of dGTP, dTTP and 
dATP opposite the MeFAPy-dGuo adduct (2.05). Dpo4 appeared to be the 
most efficient prokaryotic enzyme. The human polymerases extended past 
the MeFAPy-dGuo adduct (2.05) with different efficiency; the efficiency of pol 
ι was very low and the efficiencies of human pol κ and pol η alone were 
greater then the combinations of human pols η/ι or human pols η/ι. The 
products of the extension reactions catalyzed by the prokaryotic and 
eukaryotic DNA polymerases were sequenced by LC-ESI/MS/MS. The primer 
used for the full-length extension reaction had dUrd incorporated at position 
21 and a biotin attached at the 5’-end through a linker of ten dTyd’s. The 
extension reaction of the biotinated primer was carried out in the presence of 
all four dNTP’s and each of the DNA polymerases. The extended primer was 
bound to streptavidin coated beads, which allowed the clean up of the 
extension products and the UDG reaction from undesirable components, such 
as salts and enzymes. The use of biotinated primers improved greatly the 
sensitivity of the LC-ESI/MS/MS method.  
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The yields of formation of the full-length extension products were 
determined using an internal standard (Table 2-23). The prokaryotic DNA 
polymerases bypassed and extended past the MeFAPy-dGuo (2.05) in error-
free manner. Dpo4 was the most efficient polymerase with 72% formation of 
the free-error extension product. The eukaryotic DNA polymerases, pol κ, pol 
η, and combinations of pols η/ι and pols κ/ι, bypassed and extended the 
MeFAPy-dGuo lesion (2.05) in both error-free and error-prone manner.  
Human pol κ and pol η bypassed and extended the MeFAPy-dGuo (2.05) 
lesion more efficiently than the combinations of pols η/ι and pols κ/ι. 
The error-prone products of the bypass and extension of MeFAPy-
dGuo lesion (2.05) were identified as the 5′p-TCGATGA-3′ and 5′p-
TCTATGA-3′. We did not detect the formation of the full-length extension 
product 5′p-TCAATGA-3′, which was expected to be formed, since in 
mammalian cells the FAPy-dGuo (2.59) induced high levels of FAPy-
dG→dTyd transversions with a mutation frequency 30% (66). A reasonable 
explanation is either that the extension following the mis-insertion of A is not 
efficient or the efficiency of misinsertion of A is sequence dependant as was 
observed for FAPy-dGuo (2.59) in mammalian cells (66). 
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Table 2-23. Summary of the yields of formation of the full-length extension 
product(s) of the MeFAPy-dGuo (2.05) lesion in oligonucleotide 2.52a by 
prokaryotic and eukaryotic DNA polymerases. 
 
Enzyme 
Inserted 
dNTP Extension Products Yield (%) Comments 
  C 5'-pTCCATGA-3' 26 error free manner 
Kf– A, G, T — — —  — — —  blocking 
          
  C 5'-pTCCATGA-3' 18 error free manner 
Pol II– A, G, T — — —  — — —  blocking 
          
  C 5'-pTCCATGA-3' 72 error free manner 
Dpo4 T — — —  — — —  — — —  
  G — — —  — — —  — — —  
  A — — —  — — —  — — —  
          
  C 5'-pTCCATGA-3' 55 error free manner 
Pol κ T 5'-pTCTATGA-3' 5 error prone manner 
  G — — —  — — —  — — —  
  A — — —  — — —  — — —  
          
  C 5'-pTCCATGA-3' 20 error free manner 
Pols κ/ι T 5'-pTCTATGA-3' 5 error prone manner 
  G — — —  — — —  — — —  
  A — — —  — — —  — — —  
          
  C 5'-pTCCATGA-3' 54 error free manner 
Pol η T 5'p-TCGATGA-3' 5 error prone manner 
  G 5'-pTCTATGA-3' 8 error prone manner
  A — — —  — — —  — — —  
          
  C 5'-pTCCATGA-3' 14 error free manner 
Pols η/ι T 5'p-TCGATGA-3' 0.6 error prone manner 
  G 5'-pTCTATGA-3' 0.1 error prone manner
  A — — —  — — —  — — —  
          
Pol ι  G, A, C — — —  — — —  blocking 
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Experimental Procedures 
 
General Methods 
1H NMR spectra were recorded at 400 or 500 MHz on a Brucker AM 
Series NMR spectrometers in DMSO-d6. All chemicals were the best available 
quality and used as received. Thin-layer chromatography was performed on 
silica gel glass plates (Merck, Silica Gel 60 F254, layer thickness 250 μm). The 
chromatograms were visualized under UV light (254 nm) or by staining with 
an anisaldehyde/H2SO4 solution, followed by heating. Column 
chromatography was performed using silica gel (Merck, 70-230 mesh). 
 
Mass Spectrometry  
Low and high-resolution FAB mass spectra were obtained at the 
University of Notre Dame Mass Spectrometry Facility (Notre Dame, IN) using 
a matrix of nitrobenzyl alcohol. Mass spectra (MALDI-TOF) of 
oligonucleotides were obtained at the Vanderbilt University MS Resource 
Laboratory on a Voyager STR instrument (Perseptive Biosystem). The 
system was operated in negative ion mode using a matrix of 3-
hydroxypicolinic acid and ammonium hydrogen citrate. 
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Experimental Procedures for the Synthesis of MeFAPy-dGuo 
phosphoroamidite (2.36) 
 
N2-((Dimethylamino)methylene)-2’-deoxyguanosine (2.32) (51) 
dGuo.H2O (3 g, 0.01 mol) was co-evaporated with dry pyridine (3 x 150 
mL) and then dried overnight under high vacuum. The dry dGuo was 
suspended in dry methanol (100 mL) and N,N-dimethylformamide dimethyl 
acetal (3.43 mL, 0.02 mmol) was added. The reaction mixture was heated at 
60 °C for 2 h. After cooling to ambient temperature, a white powder was 
precipitated. The powder was collected by suction filtration and washed with 
dry methanol to afford the pure 2.32 (2.4 g, 75%). 1H NMR (DMSO-d6) 8.58 
(s, 1H, N=CH), 8.12 (s, 1H, H-8), 6.25 (t, J = 8 Hz, 1H, H-1’), 5.35 (d, J = 3 
Hz, 1H, OH-3’), 4.38-4.30 (m, 1H, H-3’), 4.20-4.00 (m, 1H, H-4’), 3.32-3.25 
(m, 2H, H-5’), 3.15 (s, 3H, N-CH3), 3.06 (s, 3H, N-CH3), 2.82-2.68 (m, 1H, H-
2’), 2.48-2.32 (m, 1H, H-2’). 
 
5’-O-Dimethoxytrityl-N2-[(dimethylamino)methylidene]-2’-deoxyguanosine 
(2.33) (51). 
Compound 2.32 (2 g, 0.006 mol) was suspended in dry pyridine (100 
mL) in cooled to 10 °C; dimethoxytrityl chloride (2.23 g, 0.0066 mol) was 
added in three equal portions over a period of 1 h. After the addition of the 
last portion, the cooling bath was removed and the reaction mixture was 
stirred at room temperature for 5 h. After this time, the reaction was quenched 
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by addition of 1 mL of methanol and then the pyridine removed in vacuo with 
rotary evaporator. The resulting gummy product was dissolved in solvent, 
then silicagel was added and the solvent was removed. The dry silicagel was 
applied on the top of a packed column and the product was then eluted with a 
mixture of CH2Cl2 : methanol : pyridine 97 : 2 : 1, followed by an eluent 
mixture with 1% increasing gradient of methanol. The product 2.33 (2.35 g, 
63%) was obtained as a white powder. 1H NMR (DMSO-d6) 8.58 (s, 1H, 
N=CH), 8.12 (s, 1H, H-8), 7.40-6.83 (m, 13H, ArH), 6.28 (t, J = 6 Hz, 1H, H-
1’), 5.37 (d, J = 3 Hz, 1H, OH-3’), 4.41-4.30 (m, 1H, H-3’), 4.00-3.90 (m, 1H, 
H-4’), 3.72 (s, 6H, 2-OCH3), 3.20-3.00 (m, 2H, H-5’), 3.12 (s, 3H, N-CH3), 3.02 
(s, 3H, N-CH3), 2.80-2.60 (m, 1H, H-2’), 2.40-2.20 (m, 1H, H-2’). 
 
N-3-[(Dimethylamino)methylene]-(5’-O-[bis(4-methoxyphenyl)phenylmethyl-2’-
deoxy-β-D-erythro-pentofyranosyl)amino]-3,4-dihydro-4-oxo-5-pyrimidinyl]-N-
(methyl)-formamide (2.35) 
Methyl iodide (1.5 mL, 24 mmol) was added dropwise to a stirred 
solution of 2.32 (1 g, 1.60 mmol) in dry, degassed dimethyl sulfoxide (DMSO) 
(8 mL) at room temperature. After 45 min, the excess methyl iodide was 
removed in vacuo using rotary evaporator, the remaining DMSO was dilluted 
with 10 mL of distilled water and aqueous NaOH (1 mL, 1 M) was added 
dropwise over 1 min. The resulting clear solution was immediately neutralized 
by the dropwise addition of aqueous HCl (0.1 M). The change in the pH was 
monitored by pH paper. A precipitate was formed upon neutralization, which 
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was collected by suction filtration to give pure 2.35 (0.79 g, 75%). 1H NMR 
(DMSO-d6) mixture of isomers: δ 11.10 (broad s, 0.5H, NHCO), 10.95 (broad 
s, 0.5H, NHCO), 8.37 (s, 0.5 H, CHO), 8.29 (s, 0.5H, CHO), 7.82 (s, 0.5H, 
N=CH), 7.74 (s, 0.5H, N=CH), 7.77-7.19 (m, 9H, ArH), 6.87-6.80 (m, 5H, NH 
+ ArH), 6.32-6.29 (m, 1H, H’-1), 5.39 (d, 0.5H, OH-3’, J = 10 Hz) 5.32 (d, 
0.5H, OH-3’, J = 10 Hz ), 4.31-4.22 (m, 1H, H’-3), 3.95-3.85 (m, 1H, H’-4), 
3.71 (s, 6H, 2CH3O), 3.03-2.95 (m, 1H, H-5’), 2.80-2.75 (m, 1H, H-5’), 2.89 (s, 
1.5H, CH3N-CHO), 2.86 (s, 1.5H, CH3-N-CH=), 2.84 (s, 1.5H, CH3N-CHO), 
2.79 (s, 3H, CH3-N-CH=),  2.08-1.87 (m, 1H, H-2’), 2.33-2.15 (m, 1H, H-2’). 
HRMS (FAB+) m/z calcd for C35H40N6O7 [M + H]+ 656.2985, found 656.2990. 
 
N-3-[(Dimethylamino)methylene]-3’O-[(2-cyanoethyl)-(N,N-
diisopropyl)phosphoroamidite-(5’-O-[bis(4-methoxyphenyl)phenylmethyl -2’ -
deoxy-β-D-erythro-pentofyranosyl)amino]-3,4-dihydro-4-oxo-5-pyrimidinyl]-N-
(methyl)-formamide (2.36) 
Compound 2.35 (100 mg, 0.15 mmol) was dried by co-evaporation with 
anhydrous pyridine (3 x 10 mL) and dried overnight at high vacuum. The 
gummy residue was dissolved in dry methylene chloride (10 mL) and a 
solution of anhydrous 1H-tetrazole (12.60 mg, 0.18 mmol) was added, 
followed by the addition of 2-cyanoethyl-N,N,N’,N’-tetraisopropylphosphoro-
diamidite (63.29 mg, 0.21 mmol). This reaction mixture was stirred at room 
temperature for 2 h. After this time, the solvent was removed in vacuo with a 
rotary evaporator. The crude product was purified by flash chromatography 
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on silica gel eluting with methylene chloride : methanol : pyridine (97 : 2 : 1) to 
give 2.36 as a mixture of stereoisomers (100 mg, 78%). 1H NMR (CD2Cl2) 
mixture of isomers: δ 11.69 (bs, 0.5H, NHCO), 11.52 (bs, 0.5H, NHCO), 8.58 
(s, 0.5H,CHO), 8.56 (s, 0.5H, CHO), 8.00 (s, 0.5H, N=CH), 7.95 (s, 0.5H, 
N=CH), 7.38-7.15 (m, 9H, aromatic), 6.90-6.75 (m, 4H, aromatic), 6.51-6.29 
(m, 1H, H-1’), 6.01 (d, 0.5H, NH, J = 12 Hz), 5.92 (d, 0.5H, NH, J = 12 Hz), 
4.74-4.51 (m, 1H, H-3’), 4.31-4.15 (m, 1H, H-4’), 3.78 (s, 6H, 2-CH3O), 3.70-
3.63 (m, 2H, POCH2), 3.63-3.43 (m, 2H, isopropyl CH), 3.20-3.03 (m, 2H, H-
5’), 3.04 (s, 3H, CH3-N-CH=), 3.02 (s, 3H, CH3-N-CH=), 3.00 (s, 1.5H, CH3N-
CHO), 2.83 (s, 1.5H, CH3N-CHO), 2.65 (t, 2H, OCH2-CN), 2.17-2.02 (m, 1H, 
H-2’), 2.02-1.89 (m, 1H, H-2’), 2.84 5.89), 1.22-1.01 (m, 12H, isopropyl CH3). 
31P NMR (CD2Cl2 121 MHz) δ 150.47, 150.22, 149.74, 149.62, 149.59, 
148.80. HRMS (FAB+) m/z calcd for C44H58N8O8P [M + H]+ 857.4115, found 
857.4143. 
 
Oligonucleotide Synthesis 
The oligonucleotides were synthesized on a Perseptive Biosystems 
Model 8909 DNA synthesizer on a 1-μmol scale using manufacturer’s 
Expedite reagents with the standard synthetic protocol for the coupling of the 
unmodified bases. The coupling of the MeFAPy-dGuo phosphoroamidite 
(2.36) was performed off-line manually. The column was removed from the 
DNA synthesizer and sealed with two syringes, one of which contained the 
1H-tetrazole activator solution (100 µL, 1.9–4.0% in CH3CN, w/v, Applied 
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Biosystems, Foster City, CA) and the other contained the MeFAPy-dGuo 
(2.36) phosphoroamidite (7 mg in 100 µL of amidite diluent (Applied 
Biosystems, Foster City, CA)). The 1H-tetrazole and the phosphoramidite 
solutions were sequentially drawn through the column (1H-tetrazole first), and 
this procedure was repeated periodically over 30 min. After this time, the 
column was washed with the manufacturer’s amidite diluent and returned to 
the instrument for the capping, oxidation, and detritylation steps (52, 77). The 
DMTr group of the MeFAPy-dGuo was removed on line with protocol 10/20 
(160 µL of Cl3CCOOH for 20 s, short deprotection) for MeFAPy-dGuo 
furanose form and with protocol 20/50 (320 µL of Cl3CCOOH for 50 s, long 
deprotection) plus an additional 3 min at standby mode for MeFAPy-dGuo 
pyranose form. The remainder of the synthesis was performed on-line using 
standard protocols. The modified oligonucleotides were cleaved from the solid 
support and the exocyclic amino groups were deprotected in a single step 
using aqueous NaOH (1.2 mL, 0.1 M) at room temperature for overnight. 
 
Nucleoside and Oligonucelotide Purifications 
For reaction monitoring and purification, a YMC ODS-AQ column (250 
х 4.6 mm, flow rate 1.5 mL/min, 250 х 4.6 mm, flow rate 10 mL/min) or 
Phenomenex Gemini-C18 column (250 х 4.6 mm, flow rate 1.5 mL/min, 250 х 
4.6 mm, flow rate 5 mL/min) monitored at 254 nm were used. HPLC analyses 
and purifications were carried out on a HPLC (Beckman Instruments; System 
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Gold Software) equipped with pump module 125 and photodiode array 
detector module 168.  
For the purification of nucleosides a mobile phase consisting of H2O 
(A) and CH3CN (B) was used. For oligonucleotide purification a mobile phase 
consisting of 100 mM aqueous ammonium formate (A) and CH3CN (B) was 
used. The following HPLC gradients were employed. 
Gradient 1: initially 1% B; 15 min linear gradient to 10% B; 5 min linear 
gradient to 20% B; isocratic at 20% B for 5 min; 2 min linear gradient to 80% 
B; isocratic at 80% B for 3 min; 3 min linear gradient to 1% B (initial 
conditions). 
Gradient 2: initially 1% B; 5 min linear gradient to 5% B; 15 min linear 
gradient to 12% B; 2 min linear gradient to 80% B; isocratic at 80% B for 2 
min; 3 min linear gradient to 1% B (initial conditions). 
Gradient 3: 1% initially B; 10 min linear gradient to 5% B; 5 min linear 
gradient to 10% B; 2 min linear gradient to 80% B; isocratic at 80% B for 2 
min; 3 min linear gradient to 1% B (initial conditions). 
The gel purification of the oligonucleotides  was conducted on 
denaturing gel containing 8.0 M urea and 16% acrylamide (w/v) (from a 19:1 
acrylamide/bis-acrylamide solution (AccuGel, National Diagnostics, Atlanta, 
GA) with 80 mM Tris borate buffer (pH 7.8) containing 1 mM EDTA. 
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Enzymatic Analysis of the MeFAPy-dGuo (2.05) Containing Oligonucleotides 
Enzymatic hydrolysis of the MeFAPy-dGuo (2.05) containing 
oligonucleotides was carried out in one step as follows: oligonucleotide (0.5 
A260 units) was dissolved in 70 μL of buffer (pH 7, 0.01 M Tris-HCl, 0.01 M 
MgCl2). DNase I (5 units), alkaline phosphatase (1.7 units), and snake venom 
phosphodiesterase I, Type II (0.02 units) were added and the solution was 
incubated at 37 °C for 1.5 h. HPLC analysis  was carried out on a HPLC using 
gradient 1. 
 
Synthesis of 5′-CTT-(MeFAPy-dGuo)-TT-3′ (2.37a and 2.37b) 
Purified by HPLC gradient 1. MALDI-TOF MS (HPA) m/z calcd for 
2.37a [M-H] 1803.3, found 1803.8; m/z calcd for 2.37b [M-H] 1803.3, found 
1803.1. 
 
Synthesis of 5′-A-(MeFAPy-dGuo)-C-3′ (2.38a and 2.38b)  
These oligonucleotides were synthesized by the “trityl-on” method in 
which the 5′-end dimethoxytrityl (DMTr) group was not removed during solid-
phase oligonucleotide synthesis. The cleavage from the solid support and the 
removal of the protecting groups were performed with conc. ammonia at room 
temperature overnight. After filtration through filter (MillexTM, Milipore 
Corporation, Bedford, MA) and drying in vacuo, the oligonucleotide was 
passed through a Poly-Pak cartridge (Glen Research Co., Ltd.) with 2% 
trifluoroacetic acid (TFA) to remove the 5’-end DMTr group. The 
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oligonucleotide was eluted with 20% acetonitrile in water and purified by 
reverse phase chromatography using gradient 1. ESI/MS for 2.38a calcd m/z 
900.2; found 900.1; for 2.38b cacld m/z 900.2, found 900.1. 
 
Synthesis of 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a and 2.42b) 
Purified by HPLC gradient 2. MALDI-TOF MS (HPA) m/z calcd for 
2.42a (M-H) 3841.6, found 3842.9; m/z calcd for 2.42b (M-H) 3841.6, found 
3843.4. 
 
Synthesis of 5′-TCAT-(MeFAPy-dGuo)-GAATCCTTACGAGCATCGCCCCC-
3′ (2.52a and 2.52b) 
Purified by gel electrophoresis. MALDI-TOF MS (HPA) m/z calcd for 
2.51a (M-H) 8496.4, found 8498.1; m/z calcd for 2.51b (M-H) 8496.4, found 
8495.2. 
 
Synthesis of 5′-TCAT-(MeFAPy-dGuo)-GATCCTTCCCCC-3′ (2.61a and 
2.62b) 
Purified by gel electrophoresis. MALDI-TOF MS (HPA) m/z calcd for 
2.56a (M-H) 5401.2, found 5401.9, m/z calcd for 2.56b (M-H) 5401.2, found 
5401.3. 
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Capillary Zone Electrophoresis (CZE) 
Electrophoretic analyses were carried out on a Beckman P/ACE MDQ 
Capillary Electrophoresis System 5500 Series monitored at 260 nm. The 
P/ACE instrument used a 31.2 cm x 100 µm eCAP capillary with samples 
applied at 10 KV and run at 9 KV. The column was packed with the 
manufactured 100-R gel using a tris-borate buffer system containing 7.0 M 
urea. 
 
MALDI-TOF MS Sequencing of Oligonucleotides 
The modified oligonucleotides (0.3 A260 units) were treated with 2 
milliunits of phosphodiesterase I (PI) in ammonium hydrogen citrate buffer 
(pH 9.4, 24 µl, 20 mM MgSO4) at 37 °C. Aliquots of 4 µL were taken before 
enzyme addition and at 1, 8, 18, 28 and 38 min time points after enzyme 
addition. The aliquots were combined in the same, which was kept frozen on 
dry ice. A complementary experiment was performed in which the modified 
oligonucleotides (0.3 A260 units) were incubated with 2 milliunits of 
phosphodiesterase II (PII) in ammonium acetate (20 mM, pH 6.6). The 
aliquots were taken in at the same manner. The two digested mixtures were 
desalted using Millipore C18 Ziptips and eluted onto a MALDI plate on a matrix 
of 3-hydroxypicolinic acid and ammonium hydrogen citrate. 
 
  155
NMR Spectroscopy of Trinucleotide 5’-A-(MeFAPy-dGuo)-C-3’ (2.38a and 
2.38b) 
Two-dimensional techniques (1H-1H double quantum filtered correlated 
spectroscopy (DQF-COSY) (78), 1H-1H nuclear Overhauser effect 
spectroscopy (NOESY) (79, 80), 1H-1H total correlated spectroscopy 
(TOCSY) (81), and multiplicity edited 1H-13C heteronuclear single quantum 
correlation spectroscopy (HSQC) (82) experiments) were performed at a 1H 
frequency of 500 MHz on a Bruker Avance spectrometer with a 5 mm CP-
TCI-Z cryoprobe. Heteronuclear 1H-31P COSY (83) experiments were 
performed at a 1H frequency of 600 MHz on Bruker Avance spectrometer with 
a QXI-XYZ probe. Experiments were conducted at 15 ± 0.5 ºC. 1H and 31P 
spectra were referenced to internal 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt (3-TMSP) and external 85% H3PO4 (capillary in H2O) 
respectively. Typical acquisition parameters for homonuclear experiments 
were as follows: 2K complex data points with 512 increments, 32 scans per 
FID, sweep width of 5250 Hz in both dimensions, relaxation delay of 2.0 s, 
States-TPPI mode. Presaturation was sufficient for water suppression. 
NOESY and TOCSY spectra were recorded with mixing times of 300 and 80 
ms respectively. Acquisition parameters for heteronuclear 13C-1H HSQC 
experiments were as follows: 1K complex data points (sweep width = 5250 
Hz), 360 increments (sweep width = 90000 Hz), 32 scans per FID, garp 
decoupling, relaxation delay of 1.8 s, Echo-Antiecho acquisition mode, pulses 
were optimized for 1JCH coupling constants (140 Hz). Acquisition parameters 
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for heteronuclear 31P-1H COSY experiments were as follows: 1K complex 
data points (sweep width = 6000 Hz) with 256 increments (sweep width = 
3000 Hz), 128 scans per FID, relaxation delay of 1.8 seconds, STATES 
mode, pulses were optimized for 3JPH coupling constants (12 Hz). Carrier 
frequencies were set at 4.7 ppm for 1H, 80 ppm for 13C, and 0 ppm for 31P. 
XWINNMR (v 3.5 patch level 6, Bruker Inc., Karlsruhe, Germany) was used 
for data processing. Apodization was attained using a skewed sinebell-
squared function with a 90 degree shift in both dimensions (180 degrees for 
COSY experiments); zero-filling and linear prediction was applied in the 
indirect dimension. Resonance assignments and peak integration was 
performed using the program SPARKY (84). 
 
Stability of 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a and  b) in Water 
and Phosphate Buffer pH 7.0 
The oligonucleotides 2.42a and 2.42 b (5′-CCTCTTC-(MeFAPy-dGuo)-
CTCTC-3′) (0.5 A260 units) were dissolved in water (350 µL) or 100 mM 
phosphate buffer pH 7.00 (350 µL) and stirred at room temperature or heated 
at 95 °C. Aliquots (10 µL) were taken periodically for analyses. The 
oligonucleotides dissolved in the water were analyzed by MALDI-TOF-MS 
without purification, whereas the oligonucleoitdes dissolved in phosphate 
buffer were desalted through a Millipore C18 Ziptips and then eluted onto a 
MALDI plate using 3-hydroxypicolinic acid and ammonium hydrogen citrate as 
the matrix. 
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Stability of 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a) in Phosphate 
Buffer pH 6.5  
The oligonucleotide 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a) 
(0.5 A260 units) was dissolved in 100 mM phosphate buffer pH 6.5 (350 µL) 
and stirred at room temperature. Aliquots (10 µL) were taken after 24 h and 
48 h, and analyzed by the LC-ESI/MS/MS method as described for the 
analysis of the full-length extension products from the DNA polymerases 
bypass studies. 
 
Stability of 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a) in water at 95 
°C, Followed by Treatment with T4-pdg (Endo V)  
The oligonucleotide 5’-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3’ (2.42a) 
(1 A260 units) was dissolved in water (350 µL). After heating at 95 °C for 1 h, 
the reaction mixture was analyzed by HPLC using gradient 2. The HPLC 
analysis showed that all of the starting material was converted to the abasic 
site oligonucleotide 2.43a. The reaction mixture was spilt in two portions. The 
first portion was heated at 95 °C for additional 1.5 h and analyzed by HPLC, 
while the second portion was lyophilized. The lyophilized sample was 
dissolved in buffer containing 100 mM NaCl, 10 mM EDTA, 10 mM Tris (pH 8) 
and 100 µg BSA, followed by addition of 1:10 diluted solution of T4-pdg (Endo 
V). This reaction mixture was set at 37 °C for 24 h and then analyzed by 
HPLC using gradient 2.  
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Reduction of 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a) in Water with 
NaB (CN)H3
The oligonucleotide 5′-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3′ (2.42a) 
(1 A260 units) was dissolved in water (500 µL) and Na(CN)BH3 (9.4 mg, 0.15 
mmol) was added in 5 equal portions over 48 h. Aliquot (15 µL) was taken, 
desalted through a Millipore C18 Ziptips, and then eluted onto a MALDI plate 
using matrix of 3-hydroxypicolinic acid and ammonium hydrogen citrate as a 
matrix. Another aliquot (125 µL) was taken and aqueous HCl (25 µL, 0.5 N) 
was added. After stirring at room temperature for overnight, the acidic 
reaction mixture was analyzed by the HPLC method using gradient 2. 
An aliquot (125 µL) of the Na(CN)BH3 reaction mixture was desalted 
and lyophilized. The lyophilized sample was subjected to enzyme digestion 
for 24 h according to the procedure used for the digestion of MeFAPy-dGuo 
containing oligonucleotides. The enzyme digestion was analyzed by the LC-
ESI-MS/MS method described for the analysis of the full-length extension 
products from the DNA polymerases.  
 
Synthesis of the Reduced MeFAPy-dGuo (2.50): N-[(1,2-dideoxy-D-erythro-
pentitol)2-amino]-3,4-dihydro-4-oxo-5-pyrimidinyl]-6-amino-N-(methyl)-
formamide 
MeFAPy-dGuo nucleoside (2.16) (2 mg, 0.0066 mmol) was dissolved 
in water and Na(CN)BH3 (41 mg, 0.66 mmol) were added in equal portions for 
a period of 30 days. The reaction was monitored and the product was purified 
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by HPLC with Phenomenex Gemini-C18 column (250 х 4.6 mm, flow rate 1.5 
mL/min, 250 х 4.6 mm, flow rate 5 mL/min) using gradient 3. The HPLC 
purification afforded pure 2.49 (0.5 mg, 25%). 1H NMR (DMSO-d6) δ 10.18 
(brs, 1h, NH) 7.68 (s, 1H, CHO), 6.50 (bs, 2H, NH2), 6.37 (m, 1H, NH), 4.55 
(m, 1H, OH-4’), 4.46 (m, 1H, OH-5’), 4.32 (m, 1H, OH-3’ ), 3.49-3.47 (m, 2H, 
H-3’), 3.45-3.30 (m, 4H, H-1’, H-4’), 3.24-3.23 (m, 2H, H-5’), 2.76 (m, 3H, 
CH3), 1.80-1.78 (m, 1H, H-2’), 1.39-1.36 (m, 1H, H-2’), 13C NMR (125 MHz, 
DMSO-d6): δ 165.66, 163.32, 160.38, 154.51, 94.01, 74.86, 69.56, 63.36, 
37.67, 33.11, 31.22; HRMS (FAB+) m/z calcd for C11H20N5O5  [M + H]+ 
302.1464, found 302.245 
 
Experimental Procedures for DNA Polymerase Bypass Assays 
 
Enzymes and Materials 
Kf–, Pol II–, and Dpo4 were expressed and purified as previously 
described (85, 86). Human DNA polymerases pol δ, η, κ, and ι were 
purchased from Enzymax (Lexington, KY). Uracil DNA glycosylase (UDG) 
was obtained from Sigma Chemical Co. (St. Louis, MO). Piperidine was 
purchased from Aldrich and used as received. dNTP solutions (100 mM) were 
purchased from GE Healthcare (formerly Amersham Biosciences, 
Piscataway, NJ). Unmodified oligonucleotides and primers were purchased 
from Midland Certified Reagents (Midland, TX). Streptavidin coated beads 
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(Streptavidin SepharoseTM High Performance) were purchased from GE 
Healthcare (Piscataway, NJ, USA). 
 
Labeling and Annealing of Oligonucleotides  
The primer was 5’-end-labeled with [γ-32P]-ATP (specific activity 3000, 
PerkinElmer Life Sciences) using T4 polynucleotide kinase (New England 
Biolabs, Ipswich, MA) according to the manufacturer’s instructions and 
purified on a Biospin column (BioRad, Hercules, CA). Template and 32P-
labeled primer (1:1 molar ratio) were annealed in 50 mM Tris-HCl buffer (pH 
7.8) by heating at 90 °C for 5 min and then slowly cooling to 30 °C. 
 
Single-Nucleotide Incorporation Assays 
32P-labeled primers were annealed to either the unmodified or the 
modified (adducted) template, and extension reactions were then carried out 
in the presence of single dNTP’s. The reactions with Kf–, pol II–, and Dpo4 
were initiated by the addition of the dNTP (final dNTP concentration was 25, 
50, and 100 nM) to preincubated enzyme/DNA mixtures giving a final reaction 
volume of 10 µL. The polymerase reactions with pols δ, η, κ, pol ι, and the 
combinations of pols κ/ι  and pols η/ι were initiated by the addition of dNTP 
with final concentrations of 120, 250, and 1000 nM. The final concentrations 
for the DNA polymerases were 24 nM of Kf–, 24 nM of pol II–, 40 nM of Dpo4, 
2 nM of pol δ, 2 nM of pol η, 2 nM of pol κ, 2 nM of pol ι, 2 nM of each pol η 
and pol ι for the combination of pols η/ι and 2 nM of each pol κ and pol ι  for 
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the combination of pols κ/ι. The final concentrations of the components for 
the enzyme reactions were 100 nM DNA duplex, 50 mM Tris-HCl (pH 7.8), 1 
mM dithiothreitol of (DTT), 50 µg bovine serum albumin (BSA) mL-1, 50 mM 
NaCl, and 5 mM MgCl2. The Kf– and pol II– reactions were run at room 
temperature for 10 min, the Dpo4 reactions were run at 37 °C  30 min and pol 
η, pol κ, pol ι and the combinations of pols η/ι  and pol κ/ι reactions were run 
at 37 °C for 10 min. The polymerase reactions with Kf–, pol II– and Dpo4 with 
primer/unadducted template were run at the same reaction conditions as the 
modified sequence, but with the two-fold less enzyme concentrations and 
reaction time. The polymerase reactions with pols δ, η, κ, pol ι , and the 
combinations of pols κ/ι  and pols η/ι with primer/unadducted template were 
run at the same reaction conditions as the modified sequence, but with the 
two-fold less enzyme concentrations. The polymerase reactions were 
quenched with 70 µL of 20 mM EDTA in 95% formamide (v/v) containing 
xylene cyanol and bromophenol blue dyes and heated at 95 °C for 10 min. 
Aliquots (6 µL) were separated by electrophoresis on a denaturing gel 
containing 8.0 M urea and 16% acrylamide (w/v) (from a 19:1 
acrylamide/bisacrylamide solution, AccuGel, National Diagnostics, Atlanta, 
GA) with 80 mM Tris borate buffer (pH 7.8) containing 1 mM EDTA. The gel 
was exposed to a PhosphorImager screen (Imaging Screen K, Bio-Rad) 
overnight. The bands were visualized with a PhosphorImaging system (Bio-
Rad, Molecular Imager FX) using the manufacturer’s Quantity One software, 
version 4.3.0. 
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Full-Length Extension Assay with All Four dNTP's 
A 32P-labeled primer was annealed to either an unmodified or an 
modified template and extended in the presence of all four dNTP’s. The final 
dNTP concentration for the reactions with Kf–, pol II–, and Dpo4 was 10, 50, 
and 100 nM each. The reactions with pols δ, κ, η and the combinations of 
pols κ/ι and pols η/ι were initiated by the addition of dNTP with final 
concentrations of 120, 250, and 1000 nM. Each reaction was initiated by 
adding the mixture of dNTPs to preincubated enzyme/DNA mixtures in a 
mixture of 100 nM DNA duplex, 50 mM Tris-HCl (pH 7.8), 1 mM DTT, 50 µg 
BSA mL-1, 50 mM NaCl, and 5 mM MgCl2, giving a final reaction volume of 10 
µL. The enzymes final concentrations were 24 nM Kf–, 24nM pol II–, 40 nM  
Dpo4, 2 nM pol δ, 2 nM pol η, 2 nM pol κ, 2 nM pol ι, 2 nM of each pol η and 
pol ι for the combination of pols η/ι and 2 nM of each pol κ and pol ι for the 
combination of pols κ/ι. The Kf– and pol II– polymerase reactions were run at 
room temperature for 10 min, the Dpo4 reactions were run at 37 °C for 30 min 
and the polymerase reactions with pols δ, η, κ , ι and the combination of pols 
η/ι and pols κ/ι reactions were run at 37 °C for 10 min. The polymerase 
reactions with Kf–, pol II– and Dpo4 with primer/unadducted template were run 
at the same reaction conditions as the modified sequence, but with the two-
fold less enzyme concentrations and reaction time. The polymerase reactions 
with pols δ, η, κ, pol ι, and the combinations of pols κ/ι and pols η/ι with 
primer/unadducted template were run at the same reaction conditions as the 
modified sequence, but with the two-fold less enzyme concentrations. The 
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polymerase reactions were quenched by the addition of 70 µL of 20 mM 
EDTA in 95% formamide (v/v) containing xylene cyanol and bromophenol 
blue dyes and heated at 95°C for 10 min. Aliquots (6 µL) were separated by 
electrophoresis on a denaturing gel containing 8.0 M urea and 16% 
acrylamide (w/v) (from a 19:1 acrylamide/bisacrylamide solution, AccuGel, 
National Diagnostics, Atlanta, GA) with 80 mM Tris borate buffer, pH 7.8, 
containing 1 mM EDTA. Gels were exposed to a PhosphorImager screen 
(Imaging Screen K, Bio-Rad) overnight. The bands were visualized with a 
PhosphorImaging system (Bio- Rad, Molecular Imager FX) using the 
manufacturer’s Quantity One software, version 4.3.0. 
 
Steady-State Kinetics 
A 32P-labeled primer, annealed to either an unmodified or a modified 
template, was extended in the presence of a single dNTP. Reaction times 
varied from 5 to 30 min at 37 °C for Dpo4, pol η, pol κ, and room temperature 
for Kf– and pol II–. The molar ratio of primer-template/enzyme varied from 20:1 
to 5:1 for modified oligonucleotides and up to 40:1 for unmodified 
oligonucleotides. Reaction times, enzyme concentrations, dNTP 
concentrations were chosen so that the maximium product formation would 
be ∼ 20% of the substrate concentration. All reactions (10 µL final volume) 
were run at eight dNTP concentrations (in duplicate) and quenched with 70 
µL of 20 mM EDTA in 95% formamide (v/v) containing xylene cyanol and 
bromophenol blue dyes and heated at 95 °C for 10 min. Aliquots (6 µL) were 
separated by electrophoresis on denaturing gels containing 8.0 M urea and 
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16% acrylamide (w/ v) (from a 19:1 acrylamide/bisacrylamide solution, 
AccuGel, National Diagnostics, Atlanta, GA) with 80 mM Tris borate buffer 
(pH 7.8) containing 1 mM EDTA. The gel was exposed to a PhosphorImager 
screen (Imaging Screen K, Bio-Rad) overnight. The bands were visualized 
with a PhosphorImaging system (Bio-Rad, Molecular Imager FX) using the 
manufacturer’s Quantity One software, version 4.3.0. The steady-state rates 
versus dNTP concentration were fit using nonlinear regression (hyperbolic 
fits) in GraphPad Prism (version 4.0, GraphPad, San Diego, CA) for the 
estimation of kcat and Km values. 
 
LC-ESI/MS/MS Analysis of Oligonucleotide Products from Kf–, Pol II–, Dpo4, 
Pol η, Pol κ and the Combinations of Pols η/ι and κ/ι. 
 Kf–, pol II–, Dpo4,  pol η, pol κ,  and the combinations of pols η/ι and 
κ/ι reactions were performed for 6 h in 50 mM of Tris-HCl (pH 7.8), 100-500 
of nM DNA duplex containing the biotinated primer (2.54), 1 mM DTT, 50 µg 
BSA mL-1, 50 mM NaCl, and 5 mM MgCl2 (200 µL total reaction mixture). The 
reactions were performed with all four dNTP’s at 1 mM each and polymerase 
concentrations of 100 nM of Kf–, pol II– and Dpo4, and 40 nM of pol η, pol κ, 
and the combinations of pols η/ι and κ/ι. To this reaction mixtures streptavidin 
coated beads (0.5 ml of the streptavidin solution was centrifuged and 
subsequently washed 3 x 500 µL 100 mM of phosphate buffer (PS)  pH 7) 
and 600 µL of PS  pH 7 were added and the resulting suspension was set at 
a rotating shaker for 2 h. The streptavidin coated beads were washed with 1 
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mL H2O (3 x 333 µL). The UDG hydrolysis was conducted with 20 units of 
UDG in 500 µL solution of 50 mM of Tris-HCl, 1 mM of EDTA, and 1 mM of 
DTT for 4 h at 37 °C. The streptavidin coated beads were washed with H2O (3 
x 333 µL) and then heated in the presence of piperidine (final concentration of 
0.25 M) at 95 °C for 1 h. The liquid was decanted and the beads were 
washed with 200 H2O (3 x 200 µL). The combined water washes were 
lyophilized and then the residue was dissolved in water (70 µL). Aliquot (20 
µL) was taken and 0.0068 A260 units of the oligonucleotide 5′-
pCTTACGAGCCCCC-3′ (2.56) (standard) was added. MS analysis was 
performed in the Vanderbilt University facility on a Waters Acquity UPLC 
system (Waters, Milford, MA) connected to a Finnigan LTQ mass 
spectrometer (ThermoElectron) using an Acquity UPLC BEH C18 column (1 
µm, 1.0 mm x 100 mm). LC conditions were as follows: buffer A contained 10 
mM NH4CH3CO2 plus 2% CH3CN (v/v) and buffer B contained 10 mM 
NH4CH3CO2 plus 95% CH3CN (v/v). The following gradient program was used 
with a flow rate of 150 µL: initially 0% B; 3 min linear gradient to 3% B; 1.5 
min linear gradient to 20% B; 0.5 min linear gradient 100% B; isocratic at 
100% B for 0.5 min; 1 min linear gradient to 0% B; isocratic at 0% B for 3 min. 
The temperature of the column was maintained at 50 °C and the samples (10 
µL) were infused with an auto-sampler. The electrospray conditions were as 
follows: source voltage 4 kV, source current 100 µA, auxiliary gas flow-rate 
setting 20, sweep gas flow-rate setting 5, sheath gas flow setting 34, capillary 
voltage -49 V, capillary temperature 350 °C, and tube lens voltage -90 V. 
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MS/MS conditions were as follows: normalized collision energy 35%, 
activation Q 0.250, and activation time 30 ms. Product ion spectra were 
acquired over the range m/z 345-2000. The ions were selected for CID 
analysis and the calculations of the CID fragmentations of the candidate 
oligonucleotide sequence were done using the Mono Oligo Mass Calculator 
(v. 2.6) from the Mass Spectrometry Group of Medicinal Chemistry at the 
University of Utah (http://library.med.utah.edu/masspec/). After the 
oligonucleotide sequence was identified, the proposed sequence was 
purchased from Midland Certified Reagents (Midland, TX) and subjected to 
the same LC-ESI/MS/MS analysis in order to compare the CID spectra. 
 
Construction of the Calibration Curves for the Measurements of the 
Percentage of Formation of the Full-length Extension Products 
The standard calibration curves were constructed using 5 to 7 
concentrations of the corresponding oligonucleotide (analyte) and a constant 
amount (0.0034 A260 units) of the 5’-pCTTCACGAGCCCCC-3’  (2.55) 
(standard). The analytes and the standard were purchased from Midland 
Certified Reagents (Midland, TX). The yield of formation of the corresponding 
analyte was calculated based on ratio amount (A260 units) of the full-extension 
product and the amount (A260 units) the biotinated primer used for the full-
length extension reaction. 
 
 
  167
References 
(1) Siebenlist, U. and Gilbert, W. (1980) Contacts between Escherichia 
coli RNA polymerase and an early promotor of phage T7. Proc. Natl. 
Acad. Sci. USA 77, 122-126. 
(2) Hayashibara, K. C. and Verdine, G. L. (1991) Template-directed 
interference footprinting of protein-guanine contacts in DNA. J. Am. 
Chem. Soc. 113, 5104-5106. 
(3) Rydberg, B. and Lindahl, T. (1982) Nonenzymatic methylation of DNA 
by the intracellular methyl group donor S-adenosyl-L-methionine is a 
potentially mutagenic reaction. EMBO J. 1, 211-216. 
(4) Barrows, L. R. and Magge, P. N. (1982) Nonenzymatic methylation of 
DNA by S-adenosylmethionine in vitro. Carcingenesis 3, 349-351. 
(5) Holliday, R. and Ho, T. (1998) Gene silencing and endogenous DNA 
methylation in mammalian cells. Mutat. Res. 400, 361-368. 
(6) Bartsch, H., Ohsima, H., Shuker, D. E. G., Pignatelli, B. and Calmes, 
S. (1990) Exposure of humans to endogenous N-nitroso compounds:  
implications in cancer etiology. Mutat. Res. 238, 255-267. 
(7) Kodama, M. and Saito, H. (1980) Formation of methylurea from 
methylamine and carbamyl phosphate: a possible environmental 
hazard. Cancer Lett. 10, 319-324. 
  168
(8) Vaughan, P. and Sedgwick, B. (1991) A weak adaptive response to 
alkylation damage of nitrosation. Environ. Mol. Mutagen. 15, 69-70. 
(9) Hecht, S. S. (1998) Biochemistry, biology, and carcinogenicity of 
tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11, 559-603. 
(10) Smith, G. B., Catonguay, A., Donnelly, P. J., Reid, K. R., Petsikas, D. 
and Massey, T. E. (1999) Biotransformation of the tobacco-specific 
carcinogen 4-(methylnitrosoamino)-1-(3-pyrridyl)-1-butanone (NNK) in 
freshly isolated human lung cells. Carcingenesis 20, 1809-1818. 
(11) Hecht, S. S. (1999) Tobacco smoke carcinogens and lung cancer. J. 
Natl. Cancer Inst. 91, 1194-1210. 
(12) Wogan, G. N., Hecht, S. S., Felton, J. S., Conney, A. H. and Loeb, L. 
A. (2004) Environmental and chemical carcinogenesis. Semin. Cancer 
Biol. 14, 473-486. 
(13) Vodicka, P. and Hemminki, K. (1988) Depurination and imidazole ring-
opening in nucleosides and DNA alkylated by styrene oxide. Chem. 
Biol. Interact. 68, 117-126. 
(14) Lindahl, T. and Nyberg, B. (1972) Rate of depirination of native 
deoxyribonucleic acid. Biochemistry 11, 3610-3618. 
  169
(15) Laval, J., Pierre, J. and Laval, F. (1981) Release of 7-methylguanine 
residues from alkylated DNA by extracts of Micrococcus luteus and 
Escherichia Coli. Proc. Natl. Acad. Sci. USA 78, 852-855. 
(16) Chetsanga, C. J. and Lindahl, T. r. (1979) Release of 7-methylguanine 
residues whose imidazole rings have been opened from damaged 
DNA by a DNA glycosylase from Escherichia coli. Nucleic Acids Res. 
1979, 3676-3684. 
(17) Beranek, D. T., Weiss, C. C., Evans, F. E., Chetsanga, C. J. and 
Kadlubar, F. F. (1983) Identification of N5-methyl-N5-formyl-2,5,6-
triamino-4-hydroxypyramidine as a major adduct in rat liver DNA after 
treatment with the carcinogens, N,N-dimethylnitrosoamine or 1,2-
dimethylhydrazine. Bioch. Biophys. Res. Comm. 110, 625-631. 
(18) Kadlubar, F. F., Beranek, D. T., Weiss, C. C., Evans, F. E., Cox, R. 
and Irving, C. C. (1984) Characterization of the purine ring-opened 7-
methylguanine and its persistence in rat bladder epithelial DNA after 
treatment with the carcinogen N-methylhitrosourea. Carcingenesis 5, 
587-592. 
(19) Hendler, S., Furer, E. and Srinivasan, P. R. (1970) Synthesis and 
chemical properties of monomers and polymers containing 7-
methylguanine and an investigation of their substrate or template 
properties for bacterial deoxyribonucleic acid or ribonucleic acid 
polymerases. Biochemistry 9, 4141-4153. 
  170
(20) Barbarella, G., Tugnoli, V. and Zambianchi, M. (1991) Imidazole ring-
opening of 7-methylguanosine at physiological pH. Nucleosides 
Nucleotides 10, 1759-1769. 
(21) Darzynkiewicz, E., Labadi, I., Haber, D., Burger, K. and Lonneberg, H. 
(1988) 7-Methylguanine nucleotides and their structural analogs; 
protolytic equlibria, complexing with magnesium(II) ion and kinetics for 
alkaline opening of the imidazole ring. Acta Chem. Scand. B42, 86-92. 
(22) Greenberg, M. M., Hantosi, Z., Wiederholt, C. J. and Rithner, C. D. 
(2001) Studies on N4-(2-deoxy-D-pentofuranosyl)-4,6-diamino-5-
formamidopyrimidine (Fapy:dA) and N6-(2-deoxy-D-pentofuranosyl)-6-
diamino-5-formamido-4-hydroxypyrimidine (Fapy:dG). Biochemistry 40, 
15856-15861. 
(23) Raoul, S., Bardet, M. and Cadet, J. (1995) Gamma irradiation of 2'-
deoxyadenosine in oxygen-free aqueous solutions: identification and 
conformational features of formamidopyrimidine nucleoside 
derivatives. Chem. Res. Toxicol. 8, 924-933. 
(24) Tomasz, M., Lipman, R., Lee, M. S., Verdine, G. L. and Nakanishi, K. 
(1987) Reaction of acid-activated mitomycin C with calf thymus DNA 
and model guanines: Elucidation of the base-catalyzed degradation of 
N7-alkylguanine nucleosides. Biochemistry 26, 2010-2027. 
  171
(25) Berger, M. and Cadet, J. (1985) Isolation and characterization of the 
radiation-induced degradation products of 2'-deoxyguanisine in 
oxygen-free aqeouos solutions. Z. Naturforsch. 40B, 1519-1531. 
(26) Haraguchi, K. and Greenberg, M. M. (2001) Synthesis of 
oligonucleotides containing Fapy.dG (N6-(2-deoxy-alpha,beta-D-
erythro-pentofuranosyl)-2,6-diamino-4-hydroxy-5- 
formamidopyrimidine). J. Am. Chem. Soc. 123, 8636-8637. 
(27) Bergdorf, L. T. and Carrel, T. (2002) Synthesis, stability and 
conformation of the formamidopyrimidine G DNA lesion. Chem. Eur. J. 
8, 293-301. 
(28) Chetsanga, C. J. and Makaroff, C. (1982) Alkaline opening of 
imidazole ring of 7-methylguanosine. 2. Further studies on reaction 
mechanisms and products. Chem. Biol. Interact. 41, 235-249. 
(29) Box, H. C., Ligam, K. T., French, J. B., Potienko, G. and Alderfer, J. L. 
(1981) 13C NMR characterization of alkyalted derivatives of guanosine, 
adenosine, and cytidine. Carbohydr., Nucleosides, Nucleotides 8, 189-
195. 
(30) Boiteux, S., Belleney, J., Roques, B. P. and Laval, J. (1984) Two 
rotameric forms of open ring 7-methylguanine are present in alkylated 
polynucleotides. Nucleic Acids Res. 12, 5429-5439. 
  172
(31) Chetsanga, C. J., Bearie, B. and Makaroff, C. (1982) Alkaline opening 
of imidazole ring of 7-methylguanosine. 1. Analysis of the resulting 
pyrimidine derivatives. Chem. Biol. Interact. 41, 217-233. 
(32) Hemminki, K., Peltonen, K. and Vodicka, P. (1989) Depurination from 
DNA of 7-methylguanine, 7-(2-amonoethyl)-guanine and ring-opened 
7-methylguanines. Chem. Biol. Interact. 70, 289-303. 
(33) Lin, J.-K., Miller, J. A. and Miller, E. C. (1977) 2,3-Dihydro-2-(guan-7-
yl)-3-hydroxy-aflatoxin B1 a major acid hydrolysis product of aflatoxin 
BB1-DNA or -ribosomal RNA adducts formed in hepatic microsome-
mediated reactions and in rat liver microsomes. Cancer Res. 37, 4430-
4438. 
(34) Chetsanga, C. J. and Mavunga, I. (1986) Chemical reclosure of 
opened imidazole ring of guanine. Chem. Biol. Interact. 58, 117-123. 
(35) Kohn, K. W. and Spears, C. L. (1967) Stabilization of nitrogen-mustard 
alkylations and inter-strand crosslinks in DNA by alkali. Biochim. 
Biophys. Acta 145, 734-741. 
(36) Barak, R., Vincze, A., Bel, P., Dutta, S. P. and Chedda, G. B. (1993) 
Mass spectrometric investigation of the presence of 7-methyl ring-
opened guanine derivatives in urine. Chem. Biol. Interact. 86, 29-40. 
(37) Oleykowski, C. A., Mayernik, J. A., Lim, S. E., Groopman, J. D., 
Grossman, L., Wogan, G. N. and Yeung, A. T. (1993) Repair of 
  173
aflatoxin B1 DNA adducts by the UvrABC endonuclease of Escherichia 
coli. J. Biol. Chem. 268, 7990-8002. 
(38) Smela, M. E., Hamm, M. L., Henderson, P. T., Harris, C. M., Harris, T. 
M. and Essigmann, J. M. (2002) The aflatoxin B1 formamidopyrimidine 
adduct plays a major role in causing the types of mutations observed in 
human hepatocellular carcinoma. Proc. Nat. Acad. Sci. USA 99, 6655-
6660. 
(39) Bailey, E. A., Iyer, R. S., Stone, M. P., Harris, T. M. and Essigmann, J. 
M. (1996) Mutational properties of the primary aflatoxin B1-DNA 
adduct. Proc. Natl. Acad. Sci. USA 93, 1535-1539. 
(40) Boiteux, S. and Laval, J. (1983) Imidazole open ring 7-methylguanine: 
an inhibitor of DNA synthesis. Bioch. Biophys. Res. Comm. 110, 552-
558. 
(41) Tchou, J., Kasai, H., Shibutani, S., Chung, M. H., Laval, J., Grollman, 
A. P. and Nishimura, S. (1991) 8-Oxoguanine (8-hydroxyguanine) DNA 
glycosylase and its substrate specificity. Proc. Natl. Acad. Sci. USA 88, 
4690-4694. 
(42) Tudek, B., Grąziewicz, M., Kazanova, O., Zastawny, T. H., Obtułowicz, 
T. and Laval, J. (1999) Mutagenic specificity of imidazole ring-opened 
7-methylpurines  in m13mp18 phage DNA. Acta Biochim. Pol. 46, 785-
800. 
  174
(43) Ezza-Nikpay, K. and Verdine, G. V. (1992) Aberrantly methylated DNA: 
site-specific introduction of N7-methyl-2'deoxyguanosine into the 
Dickerson/Drew dodecamer. J. Am. Chem. Soc. 114, 6562-6563. 
(44) Asagoshi, K., Yamada, T., Okada, Y., Terato, H., Ohyama, Y., Seki, S. 
and Ide, H. (2000) Recognition of formamidopyrimidine by Escherichia 
coli and mammalian thymine glycol glycosylases. Distinctive paired 
base effects and biological and mechanistic implications. J. Biol. 
Chem. 275, 24781-24786. 
(45) Asagoshi, K., Yamada, T., Terato, H., Ohyama, Y., Monden, Y., Arai, 
T., Nishimura, S., Aburatani, H., Lindahl, T. and Ide, H. (2000) Distinct 
repair activities of human 7,8-dihydro-8-oxoguanine DNA glycosylase 
and formamidopyrimidine DNA glycosylase for formamidopyrimidine 
and 7,8-dihydro-8-oxoguanine. J. Biol. Chem. 275, 4956-4964. 
(46) Asagoshi, K., Terato, H., Ohyama, Y. and Ide, H. (2002) Effects of a 
guanine-derived formamidopyrimidine lesion on DNA replication. J. 
Biol. Chem. 277, 14589–14597. 
(47) Haraguchi, K., Delaney, M. O., Wiederholt, C. J., Sambandam, A., 
Hantosi, Z. and Greenberg, M. M. (2002) Synthesis and 
characterization of oligodeoxynucleotides containing 
formamidopyrimidine lesions and nonhydrolyzable analogues. J. Am. 
Chem. Soc. 124, 3263-3269. 
  175
(48) Jiang, Y. L., Wiederholt, C. J., Patro, J. N., Haraguchi, K. and 
Greenberg, M. M. (2005) Synthesis of oligonucleotides containing 
Fapy·dG (N5-(2-deoxy-,-D-erythropentofuranosyl)-2,6-diamino-4-
hydroxy-5-formamidopyrimidine) using a 5'-dimethoxytrityl dinucleotide 
phosphoramidite. J. Org. Chem. 70, 141-149. 
(49) Tudek, B., Boiteux, S. and Laval, J. (1992) Biological properties of 
imidazole ring-opened N7-methylguanine in M13mp18 phage DNA. 
Nucleic Acids Res. 20, 3079-3084. 
(50) O'Connor, T. R., Boiteux, S. and Laval, J. (1988) Ring-opened 7-
methylguanine residues in DNA are a block to in vitro DNA synthesis. 
Nucleic Acids Res. 16, 5879-5894. 
(51) McBride, L. J., Kierzek, R., Beaucage, S. L. and Caruthers, M. H. 
(1986) Nucleotide chemistry. 16. Amidine protecting groups for 
oligonucleotide synthesis. J. Am. Chem. Soc. 108, 2040-2048. 
(52) Elmquist, C. E., Stover, J. S., Wang, Z. and Rizzo, C. J. (2004) Site-
specific synthesis and properties of oligonucleotides containing C8-
deoxyguanosine adducts of the dietery mutagen IQ. J. Am. Chem. 
Soc. 126, 11189-11201. 
(53) Brown, K. B., Deng, Z. J., Iyer, S. R., Iyer, G. L., Voehler, M. W., 
Stone, M. P., Harris, C. M. and Harris, T. M. (2006) Unraveling the 
aflatoxin-FAPy conundrum: structural basis for differential replicative 
  176
processing of isomeric forms of the foramidopyrimidine-type DNA 
adduct of aflatoxin B1. J. Am. Chem. Soc. 128, 15188-15199. 
(54) Birk, C., Voss, J. and Wirsching, J. (1997) Preparation, structural 
elucidation and reactions of benzyl 2'-deoxy-3,5-di-O-methyl-1,4-dithio-
L-treo-pentofuranoside and synthesis of the corresponding 2'-deoxy-4'-
thionucleosides. Carbohydr. Res. 304, 239-247. 
(55) Harris, C. M. and Harris, T. M. unpublished data. 
(56) Mastihubova, M. and Biely, P. (2004) Deoxy and deoxyfluoro 
analogues of acetylated methyl  β-D-xylopyranoside substrates for 
acetylxylan esterases. Carbohydr. Res. 339, 2101-2110. 
(57) Napolitano, R., Janel-Bintz, R., Wagner, J. and Fuchs, P. P. (2000) All 
three SOS-inducible DNA polymerases (Pol II, Pol IV and Pol V) are 
involved in induced mutagenesis. EMBO J. 19, 6259-6265. 
(58) Goodman, M. F., Woodgate, R. and Rangarajan, S. (1999) A 
phenotype for enigmatic DNA polymerase II in replication restart in UV-
radiated E. coli. Proc. Natl. Acad. Sci. USA, 96, 9224-9229. 
(59) Yang, W. (2003) Damage repair DNA polymerases Y. Curr. Opin. 
Struct. Biol. 13, 23-30. 
(60) Boudsocq, F., Iwai, S., Hanaoka, F. and Woodgate, R. (2001) 
Sulfolobus solfataricus P2 DNA polymerase IV (Dpo4): an archaeal 
  177
DinB-like DNA polymerase with lesion-bypass properties akin to 
eukaryotic pol η. Nucleic Acids Res. 29, 4607-4616. 
(61) Maga, G., Villani, G., Tillement, V., Stucki, M., Locateli, G. A., Frouin, 
I., Spadari, S. and Hubscher, U. (2001) Okazaki fragment processing: 
modulation of the strand displacement activity of DNA polymerase δ by 
the concerted action of replication protein A, proliferating cell nuclear 
antigen, and flap endonuclease-1. Proc. Natl. Acad. Sci. USA 98, 
14298-14303. 
(62) Washington, M. T., Johson, R. E., Prakash, S. and L., P. (2000) 
Accuracy of thymine-thymine dimer bypass by Saccharomyces 
cerevisiae DNA polymerase η. Proc. Natl. Acad. Sci. USA 97, 3094-
3099. 
(63) Johnson, R. E., Kondratick, C. M., Prakash, S. and Prakash, L. (1999) 
hRAD30 mutations in the variant form of xeroderma pigmentosum. 
Science 285, 263-265. 
(64) Masutani, C., Kusumoto, R., Yamada, A., Dohmoe, N. and Yokoi, M. 
(1999) The XPV (xeroderma pigmentosum variant) gene encodes 
human DNA polymerase η. Nature 399, 700-704. 
(65) Haracska, L., Yu, S. L., Johnson, R. E., Prakash, L. and Prakash, S. 
(2000) Efficient and accurate replication in the presence of 7,8-dihydro-
8-oxoguanine by DNA polymerase η. Nat. Genet. 25, 458-461. 
  178
(66) Kalam, M. A., Haraguchi, K., Chandani, S., Loechler, E. L., Moriya, M., 
Greenberg, M. M. and Basu, A. K. (2006) Genetic effects of oxidative 
DNA damages: comparative mutagenesis of the imidazole ring-opened 
formamidopyrimidines (Fapy lesions) and 8-oxo-purines in simian 
kidney cells. Nucleic Acids Res. 34, 2305-2315. 
(67) Johnson, R. E., Prakash, S. and Prakash, L. (2000) The human DINB1 
gene encodes the DNA polymerase Pol η. Proc. Natl. Acad. Sci. USA 
97, 3838-3843. 
(68) Haracska, L., Prakash, L. and Prakash, S. (2002) Role of human DNA 
polymerase κ as an extender in translesion synthesis. Proc. Nat. Acad. 
Sci. USA 99, 16000-16005. 
(69) Washington, M. T., Minko, I. G., Johnson, R. E., Wolfle, W. T., Harris, 
T. M., Lloyd, R. S., Prakash, S. and Prakash, L. (2004) Efficient and 
error-free replication past a minor-groove DNA adduct by the 
sequential action of human DNA polymerases ι and κ. Mol. Cell  Biol. 
24, 5687-5693. 
(70) Johnson, R. E., Washington, M. T., Haracska, L., Prakash, S. and 
Prakash, L. (2000) Eukaryotic polymerases ι and ζ act sequentially to 
bypass DNA lesions. Nature 406, 1015-1019. 
(71) Haracska, L., Johnson, R. E., Unk, I., Phillips, B. B. and Hurwitz, J. 
(2001) Targeting of human DNA polymerase ι to the replication 
  179
machinery via interaction with PCNA. Proc. Natl. Acad. Sci. USA 98, 
14256-14261. 
(72) Washington, M. T., Johnson, R. E., Prakash, L. and Prakash, S. (2004) 
Human DNA polymerase ι utilizes different nucleotide incorporation 
mechanisms dependent upon the template base. Mol. Cell. Biol. 24, 
936–943. 
(73) Stover, J. S., Chowdhury, G., Zang, H., Guengerich, F. P. and Rizzo, 
C. J. (2006) Translesion synthesis past the C8- and N2-
deoxyguanosine adducts of the dietary mutagen 2-amino-3-
methylimidazo[4,5-f]quinoline in the NarI recognition sequence by 
prokaryotic DNA polymerases. Chem. Res. Toxicol. 19, 1506-1517. 
(74) Ling, H., Boudsocq, F., Woodgate, R. and Yang, W. (2001) Crystal 
structure of a Y-family DNA polymerase in action: a mechanism for 
error-prone and lesion-bypass replication. Cell 107, 91-102. 
(75) Oka, N. and Greenberg, M. M. (2005) The effect of the 2-amino group 
of 7,8-dihydro-8-oxo-2'-deoxyguanosine on translesion synthesis and 
duplex stability. Nucleic Acids Res. 33, 1637-1643. 
(76) Wiederholt, C. J. and Greenberg, M. M. (2002) Fapy.dG instructs 
Klenow exo(-) to misincorporate deoxyadenosine. J. Am. Chem. Soc. 
124, 7278-7279. 
  180
(77) Choi, J.-Y., Stover, J. S., Angel, K. C., Chowdhury, G., Rizzo, C. J. and 
Guengerich, F. P. (2006) Biochemical basis of genotoxicity of 
heterocyclic arylamine food mutagens: Human DNA polymerase η 
selectively produces a two-base deletion in copying the N2-guanyl 
adduct of 2-amino-3-methylimidazo[4,5-f]quinoline but not the C8-
adduct at the NarI G3 site. J. Biol. Chem. 281, 25297-25306. 
(78) Derome, A. E. and Williamson, M. P. (1990) Rapid-pulsing artifacts in 
double-quantum-filtered COSY. J. Magn. Reson. 88, 177-185. 
(79) Jeener, J., Meier, B. H., Bachmann, P. and Ernst, R. R. (1979) 
Investigation of exchange processes by two-dimensional NMR 
spectroscopy. J. Chem. Phys. 71, 4546-4553. 
(80) Wagner, R. and Berger, S. (1996) Gradient-selected NOESY- a 
fourfold reduction of the measurement time for the NOESY experiment. 
J. Magn. Reson. 123, 119-121. 
(81) Bax, A. and Davis, D. G. (1985) MLEV-17-based two-dimensional 
homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 
65, 355-360. 
(82) Willker, W., Leibfritz, D., Kerssebaum, R. and Bermel, W. (1993) 
Gradient selection in inverse heteronuclear correlation spectroscopy. 
Magn. Reson. Chem. 31, 287-292. 
  181
(83) Wang, H., Zuiderweg, E. R. R. and Glick, G. D. (1995) Solution 
structure of a disulfide cross-linked DNA hairpin. J. Am. Chem. Soc. 
117, 2981-2991. 
(84) Goddard, T. D. and Kneller, D. G. SPARKY 3.11, University of 
California, San Francisco. 
(85) Zang, H., Goodenough, A. K., Choi, J.-Y., Irimia, A., Loukachevitch, L. 
V., Kozekov, I. D., Angel, K. C., Rizzo, C. J., Egli, M. and Guengerich, 
F. P. (2005) DNA adduct bypass polymerization by Sulfolobus 
solfataricus DNA polymerase Dpo4. Analysis and crystal structures of 
multiple base-pair substitution and frameshift products with the adduct 
1,N2-ethenoguanine. J. Biol. Chem. 280, 29750-29764. 
(86) Lowe, L. G. and Guengerich, F. P. (1996) Steady-state and pre-
steadystate kinetic analysis of dNTP insertion opposite 8-oxo-7, 8-
dihydroguanine by Escherichia coli polymerases I exo- and II exo-. 
Biochemistry 35, 9840-9849. 
 
 
  182
CHAPTER III 
 
FORMATION OF (2-OXOETHYL)-FAPy-dGuo DNA ADDUCT 
 
Introduction 
 
Reactivity of Vinyl Chloride (3.01) Towards DNA 
Vinyl chloride (3.01) is an industrial chemical that is used widely for the 
preparation of polyvinyl chloride and copolymers. It is a hepatocarcinogen 
epidemiologically linked to hepatic angiosarcomas in humans and experimentally 
linked to the same tumors in rodents (1-4). Vinyl chloride (3.01) is epoxidized by 
cytochrome P450 2E1 to 2-chlorooxirane (3.02), the ultimate carcinogenic 
species, which rapidly rearranges to 2-chloroacetaldehyde (3.03) (Figure 3-01) 
(5). 
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Figure 3-01. Epoxidation of vinyl chloride (3.01) to 2-chlorooxirane (3.02) by 
cytochrome P450 E1. 
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2-Chlorooxirane (3.02) reacts extensively with DNA whereas 2-
chloroacetaldehyde (3.03) reacts mainly with proteins. 2-Chlorooxirane (3.02) 
alkylates DNA at N1, N2, N3, and N7 positions of dGuo moieties (3.04) in DNA to 
form the corresponding 2-oxoethyl adducts 3.05 - 3.08. The oxoethyl adducts on 
N1 and N3 adducts cyclize to give the 1,N2- and N2,3-etheno adducts 3.09 and 
3.11, respectively; the N2 adduct cyclizes to form the 8-hydroxy-5,6,7,8-
tetrahydropyrimido[1,2-a]purin-10(3H)-one (3.10); the N7 oxoethyl adduct 3.08 
undergoes depurination resulting in N7-(2-oxoethyl)-Gua (3.12) (Figure 3-02). 
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Figure 3-02. 2-Oxoethyl alkylation products at the N1, N2, N3 and N7 
positions of the dGuo moieties (3.04) in DNA. 
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Alkylation reaction also occurs at N3 position of dCyd (3.13) and at N1 
position of dAdo (3.14) to give 2-oxoethyl derivatives 3.15 and 3.16; these 
adducts also cyclize to form 3,N4-ε-dCyd (3.17) and 1,N6-ε-dAdo (3.18) adducts 
(Figure 3-03).  
 
 
3.02
Cl
O
3.13
1,N6-ε-dAdo
N
N
NH2
O
N
NN
N
NH2
DNA
DNA
3.02
Cl
O
3.14
(3.17)
N
N
HN
O
DNA
N
NN
N
HN
DNA
(3.18)
3,N4-ε-dCyd3.15
N
N
NH2
O
N
NN
N
NH2
DNA
DNA
3.16
O
O
 
Figure 3-03. 2-Oxoethyl alkylation products at the N3 positions of the dCyt (3.13) 
and at N1 position of dAdo (3.14) moieties in DNA. 
 
 
 
Mutagenicity of the Vinyl Chloride (3.01) Induced DNA Adducts 
In the reaction of 2-chlorooxirane (3.02) with DNA, N7-(2-oxoethyl)-Gua 
adduct (3.12) predominates, representing ~99% of the product mixture. 
Nevertheless, the etheno adducts (3.09 - 3.11, 3.17 and 3.18) are generally 
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considered to be biologically more important than the N7-(2-oxoethyl)-Gua 
adduct (3.12), because the latter has been reported to be non-mutagenic (6), 
whereas the etheno species are miscoding in vitro (7-10) and both mutagenic 
and highly persistent in vivo (11). Although the carcinogenicity of vinyl chloride 
(3.01) is usually ascribed to the etheno adducts, a confounding factor is that the 
etheno adducts are present in the cells of laboratory animals and humans that 
have not been exposed to vinyl chloride (3.01) or other vinyl monomers that 
might be capable of forming etheno adducts (12). The endogenous etheno 
derivatives are believed to arise from oxidative degradation products of 
unsaturated lipids, in particular from the epoxides of α,β-unsaturated aldehydes 
(13). In support of this hypothesis, the levels of etheno derivatives rise 
significantly in liver samples in which oxidative stress is present, for example 
patients with alcoholic fatty liver, Wilson’s disease, and hemochromatosis. Thus, 
a central question is why relatively low levels of exposure to vinyl chloride (1.01) 
would generate sufficiently high concentrations of  etheno adducts to create a 
substantial risk of  inducing malignancies when background levels of these 
adducts are already present in normal hepatic cells.  One needs to examine the 
possibility that some other, as yet unexamined, 2-chlorooxirane adduct is the 
primary cause of the angiosarcomas resulting from vinyl chloride (3.01) 
exposure, with the main qualification being that the adduct could not also be 
formed by reactions of epoxidized enals and thus not present in unexposed cells. 
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Formation of (2-Oxoethyl)-FAPy-dGuo Adduct (3.19) 
 We have hypothesized that formamidopyrimidine 3.19 ((2-oxoethyl)-FAPy-
dGuo) may be formed via basic hydrolysis of the imidazole ring of the N7 adduct 
3.08 and could contribute to the mutagenicity of vinyl chloride (3.01) (Figure 3-
04). Detection of the (2-oxoethyl)-FAPy-dGuo lesion (3.19) in biological samples 
has never been reported. Neither has the synthesis of the nucleoside nor the 
base been reported. However, FAPy-dGuo lesions involving other N7-alkyllated 
guanine derivatives, discussed in Chapter I and II, have been characterized in 
biological samples and prepared by chemical routes. 
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Figure 3-04. Possible formation of (2-oxoethyl)-FAPy-dGuo adduct (3.19) via 
basic hydrolysis of the imidazole ring of the N7-(2-oxoethyl)-dGuo cationic 
species 3.08. 
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The failure of investigators to observe the (2-oxoethyl)-FAPy-dGuo lesion 
(3.19) might reflect the complex chemistry of FAPy-dGuo adducts. As discussed 
in Chapter II, an opening and reclosure of the deoxyribose ring of a FAPy-dGuo 
nucleoside can generate a mixture of α- and β-furanose and pyranose 
nucleosides. N5-Alkylated FAPy-dGuo adducts have also a hindered rotation 
around the C5-N5 bond leading to atropisomers. Slow reorientation of the planar 
formamide creates geometrical isomers. The various isomeric forms are 
frequently separable but still able to interconvert leading to the nucleoside having 
poor chromatographic behavior. Even at the FAPy-Gua base level atropisomers 
and geometrical isomers can exist. The N7 adducts of dGuo that have been 
investigated so far have little or no mutagenic activity, but several of the 
corresponding FAPy-dGuo lesions have been found to be strongly promutagenic 
(Figure 3-05). The unsubstituted FAPy-dGuo species (3.20) formed by oxidation 
of guanine is mutagenic in mammalian systems (14). The dominant form of the 
AFB1-FAPy-dGuo lesion (3.21) is potently mutagenic in E. coli and more 
mutagenic than the corresponding N7-cationic-dGuo adduct (15). 
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Figure 3-05. Structures of the FAPy-dGuo (3.20), AFB1-FAPy-dGuo (3.21) and 
MeFAPy-dGuo (3.22) lesions. 
  
 
 However, in contrast to these results, the MeFAPy-dGuo lesion (3.22) 
derived from the N7-methyl derivative of dGuo has been reported to be a strong 
block to replication by the Klenow fragment exo- but bypass, to the extent that it 
occurs, is with high fidelity (16). Our results, described in Chapter II, with 
prokaryotic DNA polymerases also showed that MeFAPy-dGuo lesion (3.22) is 
highly mis-coding, but this does not necessary reflect its mutagenic potential 
since the initial incorporation of dCTP opposite the adduct is preferentially 
extended. In contrast the in vitro bypass and extension past the MeFAPy-dGuo 
lesion (3.22), described also in Chapter II, with eukaryotic DNA polymerases 
showed that the MeFAPy-dGuo lesion (3.22) is bypassed and extended in both 
error-free and error-prone manner. The question still remains of whether the 
MeFAPy-dGuo lesion (3.22) is mutagenic in living organisms.  
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Results and Discussion 
 
Preliminary Results from the Reaction of 2-Acetoxyoxirane (3.27) and dGuo  
(3.30) 
2-Chlorooxirane (3.02) is usually prepared by photochemical chlorination 
of ethylene oxide (3.23) with t-butyl hypochlorite (3.24) (17, 18) (Figure 3-06). It is 
difficult to obtain 2-chlorooxirane (3.02) in pure form, because trace amounts of 
HCl, which may be present as a contaminant, can catalyze rearrangement to 2-
chloroacetaldehyde (3.03). For this reason, we chose to use 2-acetoxyoxirane 
(3.27) as a surrogate, although it likely to be less reactive with dGuo (3.30) and is 
also prone to hydrolysis. However, the acetic acid, which may contaminate the 2-
acetoxyoxirane (3.27) is a less potent catalyst of rearrangement than HCl. 
Substantial excesses of the epoxide (3.27) would be required to obtain 
reasonable yields of the N7 adduct.  
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Figure 3-06. Synthesis of 2-chlorooxirane (3.02) from ethylene oxide (3.23). 
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We found that 2-acetoxyoxirane (3.27) could be conveniently prepared by 
epoxidation of vinyl acetate (3.25) with dimethyl dioxirane (3.26) (Figure 3-07). 
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Figure 3-07. Synthesis of 2-acetoxyoxirane (3.27) from vinyl acetate (3.25). 
 
 
Several solvent mixtures were investigated for the reaction of dGuo (3.30) 
with 2-acetoxyoxirane (3.27). Dimethyl sulfoxide (DMSO) was examined first 
because an aprotic polar solvent favors the N7-alkylation of dGuo by stabilizing 
the transition state in the formation of the cationic adduct. HPLC analysis of the 
DMSO reaction mixture showed the major product was N7-(2-oxoethyl)-Gua 
(3.12). In addition, glyoxal-dGuo (3.31), 1,N2-ε-dGuo (3.09) and the N2,3-ε-Gua 
(3.11a) were observed (Figure 3-08 and 3-09); their identity was confirmed by co-
injection with authentic standards. We were unable to detect the (2-oxoethyl)-
FAPy-dGuo species (3.19). The cationic adduct (3.08) may have deglycosylated 
due to the presence of acetic acid arising from hydrolysis of the 2-acetoxyoxirane 
(3.27) by adventitious moisture. The (2-oxoethyl)-FAPy-dGuo (3.19) was not 
detected, which is attributed to the absence of hydroxide; an equivalent of 
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hydroxide is required to achieve the imidazole ring-opening reaction.  
 
 
 
Figure 3-08. HPLC traces of the reaction mixture of 2-acetoxyoxirane 
(3.27) with dGuo (3.30) 
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Figure 3-09. Formation of the N2,3-ε-Gua (3.11a). 
 
 
Glyoxal (3.29) was a by-product of the adduction reaction, leading to 
formation of the glyoxal adduct 3.31 of dGuo (Figure 3-10). Glyoxal (3.29) arises 
by oxidation of 2-acetoxyoxiarane (3.27) and/or glycolaldehyde (3.28), which is 
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the decomposition product of the 2-acetoxyoxirane (3.27). We have proposed 
that the latter oxidation is mediated by DMSO (19, 20). Both reactions require 
molecular oxygen. In subsequent reactions, the formation of glyoxal (3.29) and 
its dGuo adduct 3.31 was suppressed by carrying out the reactions under an 
inert atmosphere and using degassed solvents. 
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Figure 3-10. Oxidation of glycolaldehyde (3.28) and 2-acetoxyoxirane (3.27) to 
glyoxal (3.29); the later reacts with dGuo (3.30) to form glyoxal-dGuo (3.31) 
adduct. 
 
 
In the next experiment, dGuo (3.30) and 2-acetoxyoxirane (3.27) were 
incubated in DMSO for 20 min, after which the DMSO was removed in vacuo, pH 
7.0 phosphate buffer was added in an effort to convert the cationic adduct to the 
(2-oxoethyl)-FAPy-dGuo derivative (3.19), and further reaction was monitored by 
reverse phase HPLC. N7-(2-oxoethyl)-Gua (3.12) was identified as the major 
product. When the reaction of dGuo (3.30) and 2-acetoxyoxirane (3.27) was 
done in phosphate buffers at pH’s ranging from 7.0 to 9.0, once again only N7-(2-
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oxoethyl)-Gua (3.12) was detected.  
We recognized the possibility that (2-oxoethyl)-FAPy-dGuo nucleoside 
(3.19) might have complex chromatographic behavior such that the product could 
be overlooked. Prior investigations of MeFAPy-dGuo nucleosides have shown 
that they exist as mixtures of isomeric forms. In the nucleosides, the 
carbohydrate moiety undergoes ring-opening and reclosure leading to mixtures 
of α and β-anomers of furanosides and pyranosides. Furthermore, hindered 
rotation around the C5-N5 bond can lead to slowly equilibrating atropisomers. 
Slow reorientation of the formamide linkage can create chromatographically 
separable geometrical isomers. This potential mixture of isomers can be 
simplified somewhat by analyzing the FAPy-Gua rather than the nucleoside 
although the potential remains for the product to be a mixture of geometrical 
isomers. Thus, the focus of the study shifted to the use of 0.5 M NaOH as the 
base with the work-up procedure for subsequent reactions involving 
deglycosylation under acidic conditions (2 h at pH 4-5 and room temperature). 
LC-ESI/MS/MS analysis of the acid hydrolysates gave a chromatographic peak 
having a molecular ion at m/z 212, which is consistent with [M + H]+ of the (2-
oxoethyl)-FAPy-Gua (3.35). The N7-(2-oxoethyl)-Gua (3.12) as a hydrated form 
also gives a molecular ion at m/z 212. An independent synthesis of the N7-(2-
oxoethyl)-Gua (3.12) was performed (21, 22) and the species was analyzed by 
LC-ESI/MS/MS. The MS/MS analysis of the N7-(2-oxoethyl)-Gua (3.12) showed 
a different pattern of fragmentation than the observed fragmentation of the 
tentatively assigned (2-oxoethyl)-FAPy-Gua (3.35).  
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Synthesis and Spectral Properties of (2-Oxoethyl)-FAPy-Gua (3.35)
To establish the structure of the base, tentatively assigned as the (2-
oxoethyl)-FAPy-Gua (3.35), an independent synthesis was developed as shown 
in Figure 3-11 to provide an authentic sample for the MS analysis of ring opening 
of N7 adduct 3.19. The synthetic approach that was taken involved preparation of 
N5-allyl-FAPy-dGuo (3.32), which promised to be relatively straightforward, 
followed by transformation of it to (2-oxoethyl)-FAPy-Gua (3.35). N7-Alkylation of 
dGuo (3.30) with allyl bromide was achieved in good yield. The cationic adduct 
was treated with sodium hydroxide to give N5-allyl-FAPy-dGuo (3.32) in an 
overall 41% yield after purification. Purification was complicated by the fact that 
3.32 was a complex product mixture for the reasons discussed above. To 
simplify the mixture, acid-catalyzed deglycosylation was performed to give the 
N5-allyl-FAPy-Gua (3.33) in high yield. Dihydroxylation of 3.33 using OsO4 gave 
diol 3.34 in 85% yield. Oxidative cleavage of the diol 3.34 with NaIO4 at neutral 
pH was achieved in 79% yield to give the desired product.  
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Figure 3-11. Synthesis of the cyclized (2-oxoethyl)-FAPy-Gua (3.36). 
 
 
HPLC analysis immediately after periodate oxidation gave a broad peak 
centered at about 5 min which was tentatively assigned as (2-oxoethyl)-FAPy-
Gua (3.35) (Figure 3-12, Panel A). When the sample was allowed to stand, the 
chromatographic behavior changed to give two sharp peaks of similar intensity, 
eluting at tR 2.89 min and 3.57 min, along with a broad peak between them 
(Figure 3-12, Panel B); however, when normal phase chromatographic system 
was used for 3.35 the peak shape was satisfactory (Figure 3-12, Panel C). 
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 Figure 3-12. HPLC traces of compound(s) 3.35. A) Reverse phase HPLC 
traces of compound 3.35 after periodate cleavage of 3.34; B) Reverse phase 
HPLC traces of compound 3.35 after 1h in water; C) Normal phase HPLC 
traces of compound 3.35 after 1h in water. 
 
 
This change occurred over a period of 1 h but was rapid if a trace of acid 
was added to the sample. The sharp peaks were collected individually at –78 °C 
and subsequently re-analyzed by HPLC. Each peak gave a similar 
chromatogram (Figure 3-12, Panel B), which suggested that the two species 
were interconverting on the time scale of the separation. Subsequently, the two 
components were collected as a single fraction. 
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Solubility and kinetic constraints precluded obtaining NMR spectra on the 
initially formed product of the peroxide oxidation. NMR studies on the equilibrated 
products were carried out in D2O containing trichloroacetic acid which was 
required to obtain adequate solubility. The product was assigned as 
carbinolamine 3.36 arising by reaction of the aldehyde of 3.35 and the C4-amino 
group of the pyrimidione on the basis of 1H, 13C, COSY, NOESY, and HSQC 
spectra described below (the NMR spectra are available in the Appendix). The 
two interconverting chromatographic components which are designated 3.36a 
and 3.36b are assigned as involving slow reorientation of the formyl moiety of the 
formamide (Figure 3-13). This assignment is consistent with earlier assignments 
for other N5-alkylated FAPy-Guo adducts. There was no evidence for uncyclized 
aldehyde species 3.35 in the 1H spectrum, which would have given an aldehyde 
signal in the range 9.0 - 10.0 ppm. The formyl protons for 3.36a and 3.36b were 
observed at 8.56 and 7.89 ppm, respectively; in both cases the methine proton 
appeared as a broad triplet at 5.17 ppm (Figure 3-13). The methylene signals of 
3.36b appeared at 3.11 and 3.76 ppm, whereas those of 3.36a appeared at 2.73 
and 4.42 ppm. It is noteworthy that the difference in chemical shifts for the 
methylene protons of 3.36b is much smaller that the difference 3.36a. 
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Figure 3-13. Structures of the two interconverting chromatographic components 
designated as the 3.36a and 3.36b of the carbinolamine 3.36. 
 
 
Strong geminal coupling was observed between the methylene protons 
(13.4 Hz in 3.36b and 18 Hz in 3.36a) and weak vicinal coupling (1.8 Hz) to the 
methine protons. The COSY spectrum showed correlations among the three 
signals for each streoisomer. The fact that the vicinal coupling constants are 
small and equal for both isomers indicates that the preferred conformation of 
each is a half chair having the hydroxyl group in the axial position leading to 
torsional angle between the methine proton and the each of the methylene 
protons of approximately 60°. Had the product actually been the hydrated form 
for of aldehyde 3.35, the preferred conformation would place the formamide 
across from one of the hydroxyl groups and adjacent to the other. Thus, the 
torsional angle of the methine proton with one of the methylene protons would 
have been 180° and with other 60° leading to one vicinal coupling being large 
and the other small. 
The NOESY spectrum of 3.36b showed correlation of the formamide 
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proton with one of the methylene protons (3.11 ppm) allowing this isomer to be 
assigned as having Z conformation with the formyl proton proximal to the 
methylene group. No correlation was observed to the other methylene proton of 
3.36a. For 3.36a, the half-chair conformation of the ring places the formyl group 
much close to the equatorial proton of the methylene group to the axial proton. 
Consequently, we can assign the signal at 3.11 ppm to the equatorial proton and 
the one at 3.76 ppm to the axial. No correlation was observed of the formyl 
proton of 3.36a with either the methylene protons, which is consistent with an E 
configuration for the formamide. The large difference between the chemical shifts 
of the methylene protons of 3.36a versus the much smaller difference between 
the shifts of 3.36b is consistent with the carbonyl group of 3.36a to shielding the 
equatorial proton of 3.36a. 
The 13C chemical shifts were correlated with the proton spectrum via an 
HSQC spectrum. The spectra of 3.36a and 3.36b were very similar with the 
exception that the methylene carbon of 3.36b was 5.68 ppm farther downfield 
than the methylene carbon of 3.36a (42.32 versus 48.10 ppm). This is consistent 
with the methylene carbon of 3.36a lying in the shielding cone of the carbonyl 
group. 
The NOESY spectrum clearly showed a weak cross-peak between the 
formyl proton signals of phase opposite to those of the NOE signals. It can be 
assigned to chemical exchange involving reorientation of the formyl group on the 
time scale of the NMR experiment and is consistent with the observation that 
3.36a and 3.36b are in equilibrium on the time scale of the HPLC separation.  
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A detailed analysis was made of the mass spectrum of 3.36, acquired by 
LC-ESI/MS/MS, in an attempt to develop a sensitive assay for the compound. It 
eluted as a reasonably sharp peak from a normal phase column with a molecular 
ion [M + H]+ at m/z 212. Fragmentation of the molecular ion at 15% relative 
energy (RE) gave a product ion of m/z 184, which is assigned as lost of CO. 
Increasing the RE to 25% gave two product ions of m/z 184 and m/z 166; the 
latter ion is assigned as loss of H2O from m/z 184. Further fragmentation of m/z 
184 at 20% RE gave a product ion of m/z 166, and when 30% RE was used, only 
a product ion of m/z 166 was observed (Figure 3-14). 
 
 
 
Figure 3-14. MS/MS fragmentation of the (2-oxoethyl)-FAPy-Gua 3.36; A) MS 
spectrum of the major product ion transitions m/z 212 → 184 at 20% RE; B) MS2 
spectrum of the ion transition m/z 184 → 166 at 30% RE. 
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As monitoring of the m/z 212 → 184 transition was not diagnostic for our 
purpose, we chose to use the 30% RE in our MS2 parameters to give only the 
m/z 166 product ion. MS3 fragmentation was carried on the m/z 166 product ion 
at 35% RE. This led to the formation of a major product ion m/z 149, due to loss 
of ammonia, plus several less intense product ions at m/z 138 and m/z 124, 
representing losses of CO and NC-NH2 respectively, from the m/z 166 ion (Figure 
3-15). 
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Figure 3-15. MS3 profile of molecular ion peak with m/z 166, derived from 
(2-oxoethyl)-FAPy-Gua (3.36) standard at 35% RE.  
 
 
Based on these MS fragmentations, an LC-ESI/MS/MS method was 
developed for detection of (2-oxoethyl)-FAPy-Gua (3.36) consisting of a full scan 
followed by fragmentation of the m/z 212 molecular ion at 25% RE to give 
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product ions m/z 166 and m/z 184, then in a third event m/z 212 was fragmented 
at 30% RE to give only m/z 166, which was further fragmented at 35% RE. 
Possible structures of the product ions are shown in Figure 3-16. 
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Figure 3-16. Proposed assignments of mass spectrometric products ions 
derived from MS/MS fragmentation of the (2-oxoethyl)-FAPy-Gua (3.36). 
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Conversion of (2-Oxoethyl)-FAPy-Gua (3.36) into Pyrimidopyrazine (3.38) 
The (2-oxoethyl)-FAPy-Gua (3.36) was heated at 60 °C for 2 days in the in 
the D2O/CCl3COOD solution that had been used for NMR measurements. HPLC 
analysis showed the appearance of a single compound, eluting at tR 5.18 min 
(Figure 3-17).  
 
 
 
Figure 3-17. Characterization of pyramidopyrazine 3.38. A) HPLC traces of 
pyramidopyrazine 3.38. B) Comparison of the UV spectra of (2-oxoethyl)-FAPy-
Gua (3.36) (---) and pyramidopyrazine (3.38) (—) 
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Based on the 1H and 13C NMR data, all of which were acquired under 
acidic conditions, this compound was identified as dihydropteridinone (3.37) 
(Figure 3-11). However, 3.37 was only stable under strongly acidic conditions; 
under neutral conditions 3.37 underwent air oxidation to pyrimidopyrazine 3.38, 
which was identified by comparison with an authentic sample prepared by a 
published procedure (23). Compounds 3.37 and 3.38 were readily distinguished 
by their MS and NMR. However, the oxidation of 3.37 to 3.38 occurred readily 
(24-27); HPLC and LC-ESI/MS/MS of compound 3.37 under neutral conditions 
showed only the presence of 3.38. 
 
 
Reaction of 2-Acetoxyoxirane (3.27) with dGuo (3.30) and Oligonucleotide  
(3.39) Followed by Treatment with 0.5 M NaOH 
The next reactions were carried out with dGuo (3.30) and 2-
acetoxyoxirane (3.27) in dry degassed DMSO.  After treatment with 0.5 M NaOH 
and acid hydrolysis (pH 4 at 25 °C for 2 h) of the glycosyl bond, the samples 
were analyzed by LC-ESI/MS/MS using the aforementioned MS method. The 
analyses showed that (2-oxoethyl)-FAPy-Gua (3.36) was formed (Figure 3-18, 
Panel A). When the acid hydrolysis step was performed for 2 h at 60 °C, LC-
ESI/MS/MS analysis showed the presence of 3.38 together with remaining 3.36. 
In order to investigate the formation of 3.36 further, a self-complementary 
oligomer (5′-AGGCGCCT-3′, 8mer) (3.39) having two adjacent dGuo residues 
was incubated with 2-acetoxyoxirane (3.27) in degassed DMSO. This sequence 
was chosen due to the enhanced nucleophilicity of the N7 position of the dGuo 
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moieties in duplex DNA. After base treatment and acidic work-up (pH 4 at 25 °C 
for 2 h), LC-ESI/MS/MS analysis showed the formation of the 3.36 (Figure 3-18, 
Panel B).  
 
 
 
 Figure 3-18. MS3 profile of molecular ion peak with m/z 166, derived from (2-
oxoethyl)-FAPy-Gua (3.36) at 35% RE; A) the reaction product mixture of dGuo 
(3.30) and 2-acetoxyoxirane (3.27) in dry degassed DMSO, followed by 
treatment with 0.5 M NaOH; B) the reaction product mixture of oligonucleotide 
(3.39) and 2-acetoxyoxirane (3.27) in dry degassed DMSO, followed by 
treatment with 0.5 M NaOH.  
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The percentages of formation of the (2-oxoethyl)-FAPy-Gua (3.36) from 
the reaction of dGuo (3.30) and ds-DNA (3.39) with 2-acetoxyoxirane (3.27) were 
determined by the LC-ESI-MS/MS method based on the calibration curve shown 
in Figure 3-19. The d3-(2-oxoethyl)-FAPy-Gua (3.40) was synthesized as an 
internal standard according to Figure 3-10 using d5-allyl bromide (Figure 3-20). 
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Figure 3-19. The calibration curve for the (2-oxoethyl)-FAPy-Gua (3.36) and its 
corresponding deuterated standard d3-(2-oxoethyl)-FAPy-Gua (3.40). 
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Figure 3-20. The structure of the d3-(2-oxoethyl)-FAPy-Gua (3.40). 
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Employing 150-fold excess of the 2-acetoxyoxirane (3.27), the reaction 
dGuo (3.30) gave ∼ 4% yield of 3.36, while the yield was less than 1% for the 
reaction of 330-fold excess of 2-acetoxyoxirane (3.27) with the oligonucleotide 
3.39 (Table 1). 
 
 
Substrate Solvent Time (min) Yield of 2.36 (%) 
    15 3 
dGuo (3.30) DMSO 30 4 
    60 4.5 
   15 0.3 
5'-AGGCGCCT-3' (3.39) DMSO 30 1 
    60 0.7 
 
Table 1. Yields of formation of (2-oxoethyl)-FAPy-Gua (3.36) when dGuo (3.30) 
or 5′-AGGCGCCT-3′ (3.39) were treated with 2-acetoxyoxirane (3.27). 
 
 
 
Reaction of 2-Acetoxyoxirane (3.27) and dGuo (3.30) in Phosphate Buffers 
The reaction of dGuo (3.30) and 2-acetoxyoxirane (3.27) was examined in 
degassed phosphate buffers at pH ranging from 7.0 to 9.0, followed by acid 
hydrolysis. HPLC analysis of the acid hydrolates showed that the N7-(2-
oxoethyl)-Gua (3.12) was the major product. The ESI-LC/MS/MS analysis of the 
hydrolates showed that (2-oxoethyl)-FAPy-Gua (3.36) was not formed.  
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Reaction of 2-Chlorooxirane (3.02) with dGuo (3.30) 
We next examined the reaction of dGuo (3.30) and 2-chlorooxirane (18) 
(3.02) in dry degassed DMSO or DMF, followed by base treatment and acid 
hydrolysis. The LC-ESI/MS/MS analysis showed that (2-oxoethyl)-FAPy-Gua 
(3.36) was not formed, presumably due to the reaction of the solvents with 2-
chlorooxirane (3.02). To avoid this, other solvents, such as THF or CH2Cl2 were 
used. Since the solubility of dGuo (3.30) in these solvents is very low, 3,5-
protected dGuo 3.41 was used instead (Figure 3-21). 
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Figure 3-21. Reaction of the 2-chlorooxirane (3.02) and the 3,5-diprotected 
dGuo 3.41. 
 
 
The LC-ESI/MS/MS analysis showed that (2-oxoethyl)-FAPy-Gua (3.26) 
was not formed, which could be a result of the use of 100-fold excess of 2-
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chlorooxirane (3.02). The excess of 2-chlorooxirane (3.02) may cause alkylation 
of the O6 position of 3.42 to form the N7,O6-di-(2-oxoethyl)-dGuo species (3.43) 
(Figure 3-21). The N7,O6-di-(2-oxoethyl)-dGuo species (3.43) is much more 
prone to deglycosylation than to hydroxide ring-opening. Thus, 2-chlorooxirane 
(3.02) was incubated with an excess of the 3.41, and the reaction mixture was 
either treated with aqueous sodium hydroxide, followed by acid hydrolysis or only 
subjected to acid hydrolysis in order to detect the possible formation of the 
N7,O6-di-(2-oxoethyl)-Gua (3.43a), which species if treated with base could lose 
the O6-2-oxoethyl group to form N7-(2-oxoethyl)-Gua (3.12). The LC-ESI/MS/MS 
analysis of both mixtures showed no evidence for the formation of the (2-
oxoethyl)-FAPy-Gua (3.36) nor the N7,O6-di-(2-oxoethyl)-Gua species (3.43a). 
It was suggested that the difference of the reactivity of 2-chlorooxirane 
(3.02) and 1-acetoxyoxirane (3.27) could be due to the counter anion of the N7-
dGuo cationic species, the chloride versus the acetoxy ion, respectively. The 
acetoxy group is a stronger base and will better support the formation of the N7-
(2-oxoethyl)-dGuo cationic species than the chloride group. In order to test this, 
the reaction of 2-chlorooxirane (3.02) and 3.41 was performed in the presence of 
tetrabutylammonium acetate, which could provide the necessary acetate base. 
The LC-ESI/MS/MS analysis of the reaction mixture showed that (2-oxoethyl)-
FAPy-Gua (3.36) was not formed. 
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Reaction of 2-Chloroacetaldehyde (3.03) with dGuo (3.30) 
dGuo (3.30) was incubated with 2-chloroacetaldehyde (3.03) (50 % wt. in 
water) in DMSO and the reaction was monitored by reverse phase HPLC and 
LC-ESI/MS/MS. The HPLC analysis after 4 h showed the formation of a single 
species with a long retention time (19.5 min), which was identified by NMR as the 
carbinolamine 3.44 (Figure 3-22). The stability of the carbinolamine was 
investigated in 0.1 M NaOH, DMSO and 0.1 M HCl. 
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Figure 3-22. Reaction of dGuo (3.30) and 2-chloroacetaldehyde (3.02) in a 
mixture of DMSO/H2O = 1:1. 
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When compound 3.44 was treated with 0.1 M NaOH this led to the formation of 
3.45, which is formed by initial attack of the N1 at C-Cl and displacement of the 
chlorine (Figure 3-23, Panel A). Compound 3.45 underwent dehydratation and 
tautomerization resulting 1,N2-ε-dGuo (3.09) (Figure 3-23, Panel B). The 
identities of both 3.45 and 3.09 were confirmed by co-injection with authentic 
standards. 
 
 
 
Figure 3-23. HPLC traces of the product(s) formed from carbinolamine 3.44 
when treated with 0.1 M NaOH; A) HPLC traces of pure carbinolamine 3.44; B) 
HPLC traces of the formation of 3.45; C) HPLC traces of the 1,N2-ε-dGuo (3.09) 
formed via dehydratation of 3.45 and further tautomerization.  
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The carbinolamine 3.44 was unstable in DMSO and decomposed to N2,3-
ε-Guo (3.11a) and dGuo (3.30) (Figure 3-24, Panel A). Treatment of 
carbinolamine 3.44 with acid for a period of 10 min, gave rise to N2,3-ε-Gua 
(3.11a) and dGuo (3.30) (Figure 3-24, Panel B). A mixture of N2,3-ε-Gua (3.11a) 
guanine (3.46) and carbinolamine 3.47 was observed after 3 h (Figure 3-24, 
Panel C). 
If the reaction of 2-chloroacetaldehyde (3.03) and dGuo (3.30) was 
allowed to take place for more than 8 hours, the formation of N2,3-ε-Gua (3.11a), 
guanine (3.46) and carbinolamine 3.47 (Figure 3-24, Panel D) were observed. 
The formation of carbinolamine 3.47 may also be attributed to the hydrolysis of 
dGuo (3.30) to guanine (3.46), which reacts with the excess of 2-
chloroacetladehyde (3.03). The LC-ESI/MS/MS analysis of the reaction mixture 
of 2-chloroacetaldehyde (3.03) and dGuo (3.30) did not show that (2-oxoethyl)-
FAPy-Gua (3.36) was formed.  
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 Figure 3-24. HPLC traces of the reaction of 2-chloroacetaldehyde (3.03) and 
dGuo (3.30); A) HPLC traces of the decomposition of carbinolamine 3.44 to 
dGuo (3.30) and N2,3-ε-Gua (3.11a) in DMSO; B) HPLC traces of the acid 
hydrolysis of carbinolamine 3.44 for a period of 10 min; C) HPLC traces of the 
acid hydrolysis of carbinolamine 3.44 for a period of 3 h; D) HPLC traces of the 
reaction of 2-chloroacetladehyde (3.03) and dGuo (3.03) after 8 h. 
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Summary 
We have hypothesized that (2-oxoethyl)-FAPy-dGuo (3.19) lesion may be 
formed via basic hydrolysis of the imidazole ring of the N7-(2-oxoethyl) alkylated 
dGuo (3.08) and could contribute to the mutagenicity of vinyl chloride (3.01) and 
related species (Figure 3-25 and 3-26). To identify the formation of the (2-
oxoethyl)-FAPy-dGuo (3.19) lesion, an independent synthesis was developed to 
provide an authentic sample of the corresponding FAPy-Guo 3.35. The spectral 
analysis of 3.35 showed that this species exists as the carbinolamine 3.36, which 
is arising by reaction of the aldehyde of 3.35 and the amino group on the C4 of 
the pyrimidione (Figure 3-25). 
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Figure 3-25. Structures of the N7-(2-oxoethyl)-dGuo cationic species (3.08), (2-
oxoethyl)-FAPy-dGuo (3.19), (2-oxoethyl)-FAPy-Gua (3.35) and carbinolamine 
3.36. 
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The carbinolamine 3.36 consists of two interconverting species identified 
as a geometric isomers arising by the rotation of the formyl group. The (2-
oxoethyl)-FAPy-Gua (3.35), was detected when 2-acetoxyoxirane (3.27), a 
surrogate for 2-chlorooxirane (3.02), was used to treat dGuo (3.30) and 
oligonucleotide (3.39) followed by treatment with 0.1 M NaOH and subsequent 
acid hydrolysis (Figure 3-17). When 2-chlorooxirane (3.01) was used as an 
alkylating agent, the (2-oxoethyl)-FAPy-Gua (3.35) was not detected. 
We also investigated the reaction of dGuo (3.30) with 2-
chloroacetaldehyde (3.03), a metabolite of 2-chlorooxirane (3.02), to form (2-
oxoethyl)-FAPy-Gua (3.35). The spectral analysis of the product mixture showed 
that the N5-alkylated FAPy-Gua (3.35) was not formed; instead the carbinolamine 
3.44 was formed (Figure 3-26). 
 
 
O
Cl
2-chlorooxirane
(3.02)
O
Cl
2-chloroacetaldehyde
(3.03)
O
OAc
2-acetoxyoxirane
(3.27)
NH
NN
N
O
NH2
dR
dGuo
(3.30)
5'-AGGCGCCT-3'
3.39
NH
NN
N
O
NH
dR
OH
Cl
3.44  
Figure 3-26. Structures of the 2-chloroxirane (3.02), 2-chloroacetaldehyde 
(3.03), 2-acetoxyoxirane (3.27), dGuo (3.30), oligonucleotide (3.39) and 
carbinolamine (3.44). 
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Experimental Procedures 
 
Materials and Methods 
All commercial chemicals were of the highest quality available and used 
without further purification. 
 
NMR Spectra 
 1H NMR spectra were recorded at 400 or 500 MHz in D2O, acetone-d6 or 
DMSO-d6; 13C NMR spectra were recorded at 125 MHz. The two-dimensional 
nuclear Overhauser/chemical exchange spectroscopy experiments (NOESY) 
were performed on a 500 MHz spectrometer with the water peak suppressed by 
presaturation. A total of 4096 scans were collected using a spectral width of 5000 
Hz. The acquisition, pre-acquisition delay, and mixing times were 204 ms, 2 s, 
and 600 ms, respectively.  
 
Chromatography  
HPLC analysis was carried out on a gradient HPLC (Beckman 
Instruments; System Gold Software) equipped with pump module 125 and 
photodiode array detector module 168. For monitoring reactions by HPLC, a C-
18 reverse phase column (YMC ODS-AQ, 250 х 4.6 mm, flow rate 1.5 mL/min 
and Phenomenex Gemini-C18, 250 х 4.6 mm, flow rate 1.5 mL/min) was 
employed with the effluent monitored at 254 nm. Sample purifications were 
carried out using C-18 reverse phase columns either by HPLC (Phenomenex 
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Gemini-C18 column, 250 х 10 mm, flow rate 5 mL/min and YMC ODS-AQ, 250 х 
10 mm, flow rate 5 mL/min) or by medium pressure chromatographic system 
(Biotage SP1, Charlottesville, VA) using  Biotage C18-HS-(12 + M) with a flow 
rate 12 mL/min.  Effluent composition from both systems was monitored at 254 
nm. 
Gradient A: 0.1 M aqueous ammonium formate buffer (A) and acetonitrile 
(B); initially 99% A; 15 min linear gradient to 90% A; 5 min linear gradient to 80% 
A; isocratic at 80% A for 5 min; 3 min linear gradient to 20% A; isocratic at 20% A 
for 3 min; 3 min linear gradient to 99% A (initial conditions).  
Gradient B: 0.1 M aqueous ammonium formate buffer (A) and methanol 
(B); initially 99% A; 10 min linear gradient to 60% A; 2 min linear gradient to 20% 
A; isocratic at 20% A for 2 min; 3 min linear gradient to 99% A (initial conditions).  
Gradient C: 0.02 M phosphate buffer (A) and methanol (B); initially 97% A; 
10 min linear gradient to 87% A; 2 min linear gradient to 20% A; isocratic at 20% 
A for 2 min; 3 min linear gradient to 97% A (initial conditions). 
Gradient D: 0.1 M aqueous ammonium formate buffer (A) and acetonitrile 
(B); isocratic at 100% A for 20 min; 40 min linear gradient to 70% A; 5 min linear 
gradient to 0% A;  isocratic at 0% A for 10 min; 15 linear gradient to 100% A 
(initial conditions).  
Gradient E: water (A) and acetonitrile (B); initially 99% A; linear gradient to 
90% A for 15 min; 5 min linear gradient to 80% A; isocratic at 80% A for 5 min;  
3min linear gradient to 20% A; isocratic at 20% A for 2 min; linear gradient to 
99% A (initial conditions). 
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Normal phase HPLC analysis of (2-oxoethyl)-FAPy-Gua (3.36) was 
performed with Phenomenex Luna 5 µ Silica column (150 mm x 2 mm, flow rate 
0.60 mL/min). Effluent composition was monitored at 254 nm. Gradient F: 
acetonitrile (A) and  38.8% acetonitrile, 60% H2O, 0.2% AcOH, 1% (1M) 
ammonium acetate (B); isocratic at 99% A for 3 min; 3 min linear gradient to 0% 
A; isocratic at 0% A for 11 min; 2 min  linear gradient to 99% A , isocratic at 99% 
A for 9 min (initial conditions). 
 
Mass Spectrometry  
FAB mass spectra (low and high resolution) were obtained at the Mass 
Spectrometry Facility at the University of Notre Dame (Notre Dame, IN) using a 
matrix of nitrobenzyl alcohol. 
LC-ESI/MS/MS was performed on a DecaXP ion trap instrument 
(ThermoFinnigan, San Jose, CA) using an Agilent 1100 A pump system (Agilent, 
Foster City, USA). Detection and quantification of the (2-oxoethyl)-FAPy-Gua 
species (3.36) were carried out on a Phenomenex Luna 5 µ Silica column (150 
mm x 2 mm). Buffer A consisted of 96.8% ACN, 2% H2O, 0.2% AcOH, 1% (1M) 
ammonium acetate; buffer B consisted of 38.8% acetonitrile, 60% H2O, 0.2% 
AcOH, 1% (1M) ammonium acetate. The following gradient program was used 
with a flow rate of 0.35 mL/min: isocratic at 99% A for 3 min; 3 min linear gradient 
to 0% A; isocratic at 0% A for 5 min; 1 min linear gradient to 99% A; isocratic at 
99% A for 8 min (initial conditions). The (2-oxoethyl)-FAPy-Gua species (3.36) 
eluted at 7.27 min. Samples were injected using an autosampler. ESI conditions: 
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source voltage 4 kV, N2 sheath gas setting 64 units, N2 auxiliary sweep gas 
setting 11 units, capillary voltage 3 V, capillary temperature 300 °C, tube lens 
offset 0 V. A method consisting of three scan events was used: 1) full scan, 2 
microscans, ion accumulation time 200 ms, m/z [100.00-500.00]; 2) selected 
reaction monitoring (SRM): 1 microscan, spectral width 2, ion accumulation time 
50 ms, MS m/z 212.10 @25 [165.50-166.50, 183.50-184.50]; 3) MS3 1 
microscan, spectral width 2, ion accumulation time 200 ms, m/z 212.10 → m/z 
166 @ 35 [100-170]. 
 
Reaction of dGuo (3.30) and 2-Acetoxyoxirane (3.27) in Phosphate Buffers 
dGuo:H2O (3.30) (0.485 mg, 0.0017 mmol) in degassed phosphate buffers 
(pH 7, pH 8 or pH 9) (200 μL) was treated with 2-acetoxyoxirane (3.27) (0.26 
mmol, 24 μL) at room temperature. The progress of the reaction was monitored 
by HPLC using gradient E and the LC-ESI/MS/MS method for the detection of (2-
oxoethyl)-FAPy-Gua (2.36).  
 
 
Reaction of dGuo (3.30) and 2-Acetoxyoxirane (3.27) in DMSO 
dGuo:H20 (3.30) (0.5 mg, 0.00175 mmol) in dry, degassed DMSO (100 
μL) was treated with 2-acetoxyoxirane (3.27) (0.26 mmol, 24 μL) at room 
temperature. The progress of the reaction was monitored by HPLC using 
gradient E and the LC-ESI/MS/MS method for the detection of (2-oxoethyl)-
FAPy-Gua (2.36). 
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Reaction of dGuo (3.03) and 2-Acetoxyoxirane (3.27) in DMSO Followed by 
Treatment with 0.5 M NaOH 
dGuo:H2O (3.30) (0.462 mg, 0.0016 mmol) in dry, degassed DMSO (100 
μL) was treated with 2-acetoxyoxirane (3.27) (0.24 mmol, 22 μL) at room 
temperature. Aliquots (25 μL) were withdrawn at 15, 30, and 60 min and treated 
with 0.5 M NaOH (200 μL) for 3 min. HCl (10 μL, 6 M) was then added to these 
solutions to lower the pH to 4.0-5.0; the mixtures were allowed to stand at room 
temperature for 1.5 h. The mixtures were spiked with measured quantities 
(0.3019 µg) of d3-3.40 as an internal standard and analyzed by LC-ESI/MS/MS 
(10 μL samples). Quantitation involved comparison of peak areas for signals at 
m/z 212 in the full scan spectra with the respective signals derived from d3-3.40, 
which appeared at m/z 215. 
 
Reaction of the Oligonucleotide 5′-AGGCGCCT-3′ (3.39) with 2-
Acetoxyoxirane (3.27) in DMSO Followed by Treatment with 0.5 M NaOH 
The oligonucleotide (3.39) (25 A260 units) dissolved in degassed DMSO 
(300 μL) was treated with 2-acetoxyoxirane (3.27) (10 μL) at room temperature. 
Aliquots (25 μL) were withdrawn at 15, 30 and 60 min and treated with 0.5 M 
NaOH (200 μL) for 3 min. HCl (<10 μL, 6 M) was added to these solutions to 
lower the pH to 4.0-5.0; the mixtures were allowed to stand at room temperature 
for 2.0 h. Quantitation was accomplished as described above using d3-3.40 as 
the internal standard. Samples (10 μL) were analyzed by LC-ESI/MS/MS. 
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Preparation of d3-(2-Oxoethyl)-FAPy-Gua (3.40) and Construction of the 
Calibration Curve 
The d3-(2-oxoethyl)-FAPy-Gua (3.40) was synthesized using d5-allyl 
bromide according to the procedure for the synthesis of the unlabeled sample 
(procedure to follow). Its structure was confirmed by 1H NMR, MS and UV. EI 
analysis showed the anticipated molecular ion peak at m/z 215.  The standard 
calibration curve was constructed using nine concentrations of the undeuterated 
analyte (30 to 3000 ng/mL injected) and a constant amount of the deuterated 
standard (0.3019 µg). The calibration graph showed good linearity (R2 = 0.9962). 
 
2-Acetoxyoxirane (3.27)  
Vinyl acetate (1.04 mL, 0.017 mmol) (3.25) was added dropwise to an 
acetone solution of dimethyl dioxirane (28) (375 mL, 0.05 M) (3.26) at -78 °C. 
The mixture was allowed to warm up to room temperature. After stirring for 1 h, 
the mixture was concentrated under vacuum (70 – 80 Torr). The distillation was 
stopped after the volume had been reduced by ~30%. The remaining solution 
was dried with anhydrous K2CO3 for 15 min at 0 °C, filtered and distilled (80°C, 
70 – 80 Torr) to give 1.8 g of 2-acetoxyoxirane (3.27) (78%). 1H NMR (acetone-
d6): δ 5.36 (dd, 1H, J = 2.4 Hz, J = 1.2 Hz), 2.72 (dd, 1H, J = 2.4 Hz, J = 4.4 Hz), 
2.69 (dd, 1H, J = 1.2 Hz, J = 4.4 Hz), 1.94 (s, 3H).  
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N-[2-Amino-6-[(2-deoxy-β-D-erythro-pentopyranosyl)amino]-3,4-dihydro-4-
oxo-5-pyrimidinyl]-N-(2-propenyl)-formamide (3.32) 
dGuo:H2O (3.30) (300 mg, 1.12 mmol) was dissolved in 10 mL of 
degassed DMSO. Allyl bromide (1.94 ml, 22.40 mmol) was added dropwise and 
the reaction mixture was stirred at room temperature for 3 h. Excess allyl 
bromide was removed in vacuo and the residue was treated with aqueous NaOH 
(30 mL, 1 M) for 1 h. The reaction was monitored with an YMC ODS-AQ column 
(gradient A) and purified by Biotage SP1 chromatography (gradient D) to afford 
3.32 (150 mg, 41% yield). 1H NMR (DMSO-d6) mixture of isomers: δ 10.69 
(broad s, 1H, amide), 7.76-7.69 (multiple s, 1H, CHO), 7.06 (d, 1H, NH, J = 7.6 
Hz), 6.64 (broad s, 2H, NH2), 5.77-5.74 (m, 1H, =CH ), 5.42-5.35 (m, 1H, H-1’), 
5.14-4.97 (m, 3H, OH-3’, =CH2), 4.70-4.43 (m, 1H, OH-5’), 4.10-3.85 (m, 3H, H-
3’, CH2-N), 3.78-3.65 (m, 1H, H-4’), 3.67-3.24 (m, 2H, H-5’), 1.93-1.71 (m, 2H, H-
2’). HRMS (FAB+) m/z calcd for C13H20N5O5 [M + H]+ 326.1464, found 326.1449. 
 
N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-(2-propenyl)-formamide 
(3.33) 
Compound 3.32 (130 mg, 0.39 mmol) was heated in aqueous HCl (1M, 
5mL) for 2 h at 60 °C. The reaction was monitored with an YMC ODS-AQ column 
(gradient A) and purified with the Biotage SP1 chromatograph (gradient D) to 
afford 3.33 (75 mg, 92% yield). 1H NMR (DMSO-d6) first isomer: δ 11.50 (broad 
s, 1H, amide) 8.34 (s, 1H, CHO), 6.36-6.30 (broad s, 4H, NH2), 5.81-5.71 (m, 1H, 
=CH, J = 8 Hz), 5.11-5.03 (m, 2H, =CH2), 4.03-3.97 (m, 2H, CH2-N); second 
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isomer: δ 11.35 (broad s, 1H, amide) 7.74 (s, 1H, CHO), 6.14-6.00 (broad s, 4H, 
NH2), 5.70-5.68 (m, 1H, =CH, J = 8 Hz), 4.99-4.95 (m, 2H, =CH2), 3.90-3.78 (m, 
2H, CH2-N). HRMS (FAB+) m/z calcd for C8H12N5O2 [M + H]+ 210.0991, found 
210.0997. 
 
N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-(2,3-dihydroxypropyl)-
formamide (3.34)  
A solution of 3.33 (70 mg, 0.33 mmol) in water (0.3 mL) was added to a 
mixture of water (1 mL), acetone (0.5 mL), N-methylmorpholine-N-oxide (46.39 
mg, 0.39 mmol) and of OsO4 (~ 1 mg). The reaction mixture was stirred overnight 
at room temperature then the solvents were evaporated in vacuo. Progress of the 
reaction was monitored with an YMC ODS-AQ column (gradient B).  The product 
was purified by Biotage SP1 chromatography (gradient D) to afford 3.34 (69 mg, 
85% yield). 1H NMR (DMSO-d6) mixture of isomers: δ 12.00 (broad s, 1H, 
amide), 8.07-7.74 (s, 1H, CHO), 6.70-6.50 (broad s, 2H, NH2), 6.43-6.20 (broad 
s, 2H, NH2), 4.02-3.99 (m, 1H, CH2OH), 3.77-3.75 (m, 1H, CH2OH), 3.53-3.48 
(m, 1H, CHOH), 3.35-3.25 (m, 2H, CH2N). HRMS (FAB+) m/z calcd for 
C8H14N5O4 [M + H]+ 244.1046, found 244.1058. 
 
2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-oxopteridine-5(6H)-carbaldehyde 
((2-oxoethyl)-FAPy-Gua) (3.36) 
Compound 3.34 (60 mg, 0.25 mmol) was dissolved in water (1 mL), then 
treated with aqueous NaIO4 solution (16 mL, 20 mM in 0.05 M phosphate buffer, 
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pH 7) for 45 min at room temperature. The reaction was monitored and purified 
by HPLC using a Phenomenex Gemini-C18 column (gradient C; Solvent system 
B consisted of 0.1 M aqueous ammonium formate buffer) to afford 3.36 as a 
mixture of the geometrical isomers. Compound 3.36 was liophilized several times 
with water to remove the ammonium formate (42 mg, 79% yield). 1H NMR (500 
MHz, D2O, 10% CCl3COOD) isomer 3.36b: δ 7.89 (s, 1H, CHO), 5.17 (broad tr, 
1H, CHOH), 3.76 (dd, 1H, CH2, J1 = 1.8 Hz, J2 = 13.4 Hz), 3.11 (dd, 1H, CH2, J1 
= 1.8 Hz, J2 = 13.4 Hz); isomer 3.36a: δ 8.56 (s, 1H, CHO), 5.17 (broad tr, 1H, 
CHOH), 4.42 (dd, 1H, CH2, J1 = 1.8 Hz, J2 = 18.0 Hz), 2.73 (dd, 1H, CH2, J1 = 1.8 
Hz, J2 = 18.0 Hz). 13C NMR (125 MHz, D2O, 10% CCl3COOD) isomer 3.36b: δ 
163.55, 158.13, 154.25, 153.45, 91.72, 72.70, 42.32; isomer 3.36a: δ 165.42, 
158.79, 155.25, 153.84, 93.04, 72.70, 48.10. HRMS (FAB+) m/z calcd for 
C7H10N5O3 [M + H]+ 212.0784, found 212.0793; UV (H2O) λmax 290 nm. 
 
2-Amino-5,8-dihydro-4(3H)-pteridinone (3.37)  
Compound 3.36 (5 mg, 0.023 mmol) was dissolved in D2O (0.5 mL) 
containing CCl3COOD (0.05 mL). The solution was heated in an NMR tube for 2 
d at 60 °C to give 3.37. The reaction was monitored (gradient C) by HPLC using 
a Phenomenex Gemini-C18 column. 1H NMR (500 MHz, D2O, 10% CCl3COOD): 
δ 8.85 (d, 1H, J = 2.32 Hz), 8.78 (d, 1H, J = 2.32 Hz); 13C NMR (125 MHz, D2O, 
10% CCl3COOD): δ 165.75, 160.00, 150.09, 147.83, 144.32, 128.22. HRMS 
(FAB+) m/z calcd for C6H8N5O [M + H]+ 166.0729, found 166.0701.  
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2-Amino-4-hydroxypyrimido[4,5-b]pyrazine (3.38) 
Compound 3.38 was synthesized as previously described (23). The HPLC 
analysis was performed by HPLC using a Phenomenex Gemini-C18 column 
(gradient C). 1H NMR (500 MHz, D2O, 10% CCl3COOD): δ 7.48 (d, 1H, J = 2.25 
Hz), 7.39 (d, 1H, J = 2.25 Hz); 13C NMR (125 MHz, D2O, 10% CCl3COOD): δ 
159.83, 151.85, 150.99, 147.65, 143.90, 127.90. HRMS (FAB+) m/z calcd for 
C6H6N5O [M + H]+ 164.0572, found 164.0565; UV (H2O), λmax 270, 343 nm. 
 
N2-(2-Chloro-1-hydroxy-ethyl)-(2-deoxy-β-D-erythro-pentopyranosyl)-
guanine (3.44)  
dGuo:H2O (3.30) (20 mg, 0.070 mmol) dissolved in DMSO (220 μL) was 
treated with 2-chloroacetaldehyde (3.03) (50 % wt in water, 0.35 mmol, 54.95 μL) 
for 2 h at room temperature. The product was purified by reverse phase HPLC 
using YMC ODS-AQ column and gradient E. 1H NMR (400MHz, DMSO-d6): δ 
10.65 (broad s, 1H, amide), 8.01 (s, 1H, H-8), 6.87 (m, 1H, NH), 6.19-6.16 (m, 
1H, H1’), 5.64-5.61 (m, 1H, CHOH), 4.35-4.33 (m, 1H, H3’), 3.82-3.73 (m, 1H, 
H4’), 3.72-3.70 (m, 2H, CH2Cl), 3.54-3.58 (m, 2H, H5’), 2.60-2.55 (m, 1H, H2’), 
2.25-2.19 (m, 1H, H2’). HRMS (FAB+) m/z calcd for C12H16ClN5O5 [M + H]+ 
345.0840, found 345.0835. 
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Stability Studies on the Carbinolamine (3.44) 
Carbinolamine (3.44) (0.1 mg) was dissolved in aqueous NaOH (300 µL, 
0.1 M), DMSO (300 µL) or HCl (300 µL, 0.1 M) and the reaction mixtures was 
stirred at room temperature. Aliquots were withdrawn and analyzed by HPLC 
using YMC ODS-AQ column and gradient E.  
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Appendix I: 
 
1H, 13C, COSY and 31P NMR Spectra 
for Chapter II 
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1H NMR of N-3-[(dimethylamino)methylene]-(5’-O-[bis(4-methoxy 
phenyl)phenylmethyl-2’-deoxy-β-D-erythro-
pentofyranosyl)amino]-3,4-dihydro-4-oxo-5-pyrimidinyl]-N-
(methyl)-formamide (2.35) 
 234
 COSY NMR of N-3-[(dimethylamino)methylene]-(5’-O-[bis(4-
methoxyphenyl)-phenylmethyl-2’-deoxy-β-D-erythro-pento 
fyranosyl)-amino]-3,4-dihydro-4-oxo-5-pyrimidinyl]-N-(methyl)-
formamide (2.35) 
 235
 1H NMR of N-3-[(dimethylamino)methylene]-3’O-[(2-cyanoethyl)-
(N,N-diisopropyl)phosphoroamidite-(5’-O-[bis(4-methoxyphenyl)-
phenylmethyl-2’-deoxy-β-D-erythro-pentofyranosyl)amino]-3,4-
dihydro-4-oxo-5-pyrimidi-nyl]-N-(methyl)-formamide (2.36) 
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 COSY NMR of N-3-[(dimethylamino)methylene]-3’O-[(2-
cyanoethyl)-(N,N-diisopropyl)phosphoroamidite-(5’-O-[bis(4-
methoxyphenyl)phenylmethyl-2’-deoxy-β-D-erythro-
pentofyranosyl)amino]-3,4-dihydro-4-oxo-5-pyrimidi-nyl]-N-
(methyl)-formamide (2.36) 
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31PP NMR of N-3-[(dimethylamino)methylene]-3’O-[(2-cyanoethyl)-
(N,N-diisopropyl)phosphoroamidite-(5’-O-[bis(4-methoxy 
phenyl)phenylmethyl-2’-deoxy-β-D-erythro-
pentofyranosyl)amino]-3,4-dihydro-4-oxo-5-pyrimidi-nyl]-N-
(methyl)-formamide (2.36 
 238
  
1H NMR of N-[(1,2-dideoxy-D-erythro-pentitol)2-amino]-3,4-
dihydro-4-oxo-5-pyrimidinyl]-6-amino-N-(methyl)-formamide (2.50) 
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COSY NMR of N-[(1,2-dideoxy-D-erythro-pentitol)2-amino]-3,4-
dihydro-4-oxo-5-pyrimidinyl]-6-amino-N-(methyl)-formamide (2.50) 
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 13C NMR of N-[(1,2-dideoxy-D-erythro-pentitol)2-amino]-3,4-
dihydro-4-oxo-5-pyrimidinyl]-6-amino-N-(methyl)-formamide (2.50) 
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Appendix II: 
 
MALDI-TOF Mass Spectra 
for Chapter II 
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LC-ESI/MS analysis of trinucleotide of 5'-A-(MeFAPy-dGuo)-C-3' 
(2.38a); A) Select ion profile of 2.38a with m/z 900.20; B) The 
molecular mass of the 2.38a.  
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LC-ESI/MS analysis of trinucleotide of 5'-A-(MeFAPy-dGuo)-C-3' 
(2.38b); A) Select ion profile of 2.388 with m/z 900.07; B) The 
molecular mass of the 2.38b.  
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5'-TCAT-(MeFAPy-dGuo)-GAATCCTTACGAGCATCGCCCCC-3'  
(2.52a, furanose) 
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 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTACGAGCATCGCCCCC-3' 
(2.52b, pyranose) 
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 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-3' pyranose  
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 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-3' furanose 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.43a, furanose) 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.43b, pyranose) 
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5’-CTT-(MeFAPy-dGuo)-TT-3’ (2.37a, furanose) 
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 5’-CTT-(MeFAPy-dGuo)-TT-3’ (2.37b, pyranose) 
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Appendix III 
 
NMR spectra of 5′-A-(MeFAPy-dGuo)-C-3′ 
for Chapter II 
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 NMR of 5′-A-(MeFAPy-dGuo)-C-3′ (2.38a, furanose) 
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Group   Atom  Nuc    Shift   SDev  Assignments 
     
   1A1    31P  31P   -0.065  0.005        2  
   1A1    C1'  13C   86.027  0.000        1  
   1A1    C2'  13C   37.367  0.008        2  
   1A1    C3'  13C   77.114  0.000        1  
   1A1    C4'  13C   86.926  0.000        1  
   1A1    C5'  13C   61.866  0.000        1  
   1A1    H1'   1H    6.350  0.004          4  
   1A1    H2'   1H    2.678  0.005          3  
   1A1    H2''   1H    3.006  0.008          3  
   1A1    H3'   1H    4.909  0.005           6 
   1A1    H4'   1H    4.324  0.003           3 
   1A1    H5'   1H    3.780  0.002           2 
   1C3    C1'  13C   85.419  0.000        1  
   1C3    C2'  13C   39.350  0.003        2  
   1C3    C3'  13C   70.370  0.000        1  
   1C3    C4'  13C   85.013  0.000        1  
   1C3    C5'  13C   69.464  0.000        1  
   1C3    H1'   1H    6.220  0.003           4 
   1C3    H2'   1H    2.192  0.005           3 
   1C3   H2''   1H    2.328  0.006           3  
   1C3    H3'   1H    4.490  0.002           5 
   1C3    H4'   1H    4.104  0.006           3 
   1C3     H5   1H    5.958  0.000          1  
   1C3    H5'   1H    3.888  0.003           2 
   1C3     H6   1H    7.776  0.000           1 
  1mf2    31P  31P   -0.187  0.000         1 
  1mf2    C1'  13C   81.375  0.000         1 
  1mf2    C2'  13C   37.543  0.012         2 
  1mf2    C3'  13C   75.368  0.000         1 
  1mf2    C4'  13C   81.998  0.000         1 
  1mf2    H1'   1H    5.893  0.004           4 
  1mf2    H2'   1H    2.106  0.003           3 
  1mf2   H2''   1H    2.471  0.008           3 
  1mf2    H3'   1H    4.735  0.007           6 
  1mf2    H4'   1H    4.247  0.001           4 
  1mf2    H5'   1H    3.932  0.000           1 
  1mf2   H5''   1H    4.041  0.000           1 
   2A1    31P  31P   -0.220  0.001         2 
   2A1    C1'  13C   85.353  0.000         1 
   2A1    C2'  13C   37.423  0.000         1 
   2A1    C3'  13C   76.704  0.000         1 
   2A1    C5'  13C   61.415  0.000         1 
   2A1    H1'   1H    6.404  0.000           3 
   2A1   H2''   1H    2.857  0.002           3  
   2A1    H3'   1H    4.948  0.001           6 
   2A1    H4'   1H    4.334  0.001           2 
   2A1    H5'   1H    3.810  0.000           3 
   2C3    C1'  13C   85.305  0.000         1 
 255
   2C3    H1'   1H    6.143  0.002             4 
   2C3    H2'   1H    2.186  0.000             1 
   2C3   H2''   1H    2.312  0.000           1  
   2C3    H3'   1H    4.480  0.000             1 
  2mf2    31P  31P   -0.646  0.009        2  
  2mf2    C1'  13C   82.098  0.000           1 
  2mf2    C2'  13C   37.547  0.000           1 
  2mf2    C3'  13C   76.096  0.000           1 
  2mf2    C4'  13C   83.276  0.000           1 
  2mf2    C5'  13C   65.181  0.000           1 
  2mf2    H1'   1H    5.677  0.003             3 
  2mf2   H2''   1H    2.175  0.001             3 
  2mf2    H3'   1H    4.706  0.003             5 
  2mf2    H4'   1H    4.179  0.001             4 
  2mf2    H5'   1H    3.937  0.002             2 
  2mf2   H5''   1H    3.988  0.001             2 
   3C3    H1'   1H    6.079  0.002             3 
   3C3    H2'   1H    2.135  0.000             1 
   3C3   H2''   1H    2.345  0.000            1  
   3C3    H3'   1H    4.480  0.000             2 
   3C3    H4'   1H    4.022  0.000             1 
  3mf2    C4'  13C   82.587  0.000           1 
  3mf2    C5'  13C   64.902  0.000           1 
  3mf2    H1'   1H    5.935  0.000             1 
  3mf2    H3'   1H    4.724  0.009             2 
  3mf2    H4'   1H    4.302  0.001             4 
  3mf2    H5'   1H    3.923  0.000             1 
  3mf2   H5''   1H    4.012  0.005             3 
 
13C NMR of 5′-A-(MeFAPy-dGuo)-C-3′ (2.38a, furanose) 
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Group   Atom  Nuc    Shift   SDev  Assignments 
     
   1A1    C1'  13C   84.863  0.000      1  
   1A1    C2'  13C   38.136  0.004      2  
   1A1    C3'  13C   76.258  0.000      1  
   1A1    C4'  13C   86.703  0.000      1  
   1A1    C5'  13C   61.633  0.000      1  
   1A1    H1'   1H    6.431  0.002       4  
   1A1    H2'   1H    2.742  0.007       3  
   1A1    H2''   1H    2.830  0.005       3  
   1A1    H3'   1H    4.941  0.007        7  
   1A1    H4'   1H    4.385  0.000        1  
   1A1    H5'   1H    3.777  0.001        2  
  2mf1    C1'  13C   85.384  0.000      1  
  2mf1    C2'  13C   39.652  0.039      2  
  2mf1    C3'  13C   70.779  0.000      1  
  2mf1    C4'  13C   68.230  0.000      1  
  2mf1    C5'  13C   66.119  0.002      2  
  2mf1    H1'   1H    5.914  0.003       5  
  2mf1    H2'   1H    2.038  0.001       3  
  2mf1   H2''   1H    2.278  0.006       4  
  2mf1    H3'   1H    4.343  0.003       6  
  2mf1    H4'   1H    4.031  0.008       5  
  2mf1    H5'   1H    3.679  0.000       2  
  2mf1   H5''   1H    4.079  0.002        2  
  2mf2    C1'  13C   74.637  0.000      1  
  2mf2    C2'  13C   34.679  0.007      2  
  2mf2    C3'  13C   70.975  0.000      1  
  2mf2    C4'  13C   69.687  0.000      1  
  2mf2    C5'  13C   69.429  0.000      1  
  2mf2    H1'   1H    5.535  0.002       4  
  2mf2    H2'   1H    2.027  0.003       3  
  2mf2    H2'   1H    2.027  0.003       4  
  2mf2    H2'   1H    2.027  0.003       5  
  2mf2    H2'   1H    2.027  0.003       6  
  2mf2    H2'   1H    2.027  0.003       7  
  2mf2    H2'   1H    2.027  0.003       8  
  2mf2    H2'   1H    2.027  0.003       9  
  2mf2    H2'   1H    2.027  0.003      10  
  2mf2    H2'   1H    2.027  0.003      11  
  2mf2    H2'   1H    2.027  0.003      12  
  2mf2    H2'   1H    2.027  0.003      13  
  2mf2    H2'   1H    2.027  0.003      14  
  2mf2    H2'   1H    2.027  0.003      15  
  2mf2    H2'   1H    2.027  0.003      16  
  2mf2    H2'   1H    2.027  0.003      17  
  2mf2    H2'   1H    2.027  0.003      18  
  2mf2    H2'   1H    2.027  0.003      19  
  2mf2    H2'   1H    2.027  0.003      20  
  2mf2    H2'   1H    2.027  0.003      21  
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  2mf2    H2'   1H    2.027  0.003      22  
  2mf2    H2'   1H    2.027  0.003      23  
  2mf2    H2'   1H    2.027  0.003      24  
  2mf2    H2'   1H    2.027  0.003      25  
  2mf2    H2'   1H    2.027  0.003      26  
  2mf2    H2'   1H    2.027  0.003      27  
  2mf2    H2'   1H    2.027  0.003      28  
  2mf2    H2'   1H    2.027  0.003      29  
  2mf2    H2'   1H    2.027  0.003      30  
  2mf2    H2'   1H    2.027  0.003      31  
  2mf2    H2'   1H    2.027  0.003      32  
  2mf2    H2'   1H    2.027  0.003      33  
 
 
13C NMR of 5′-A-(MeFAPy-dGuo)-C-3′ (2.38b, furanose) 
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Appendix IV 
 
MALDI-TOF Sequencing 
for Chapter II 
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5'-TCAT-(MeFAPy-dGuo)-GAATCCTTACGAGCATCGCCCCC-3' 
(2.52a, furanose) with Phosphodiesterase II 
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 5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' furanose with 
Phosphodiesterase I 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' furanose with 
Phosphodiesterase II 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3'  (2.42a, furanose) with 
Phosphodiesterase I 
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 5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.43b ,pyranose) with 
Phosphodiesterase II 
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 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-3' (furanose) with 
Phosphodiesterase II 
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5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-3' (pyranose) with 
Phosphodiesterase II 
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Appendix V 
 
Enzyme Digestion of MeFAPy-dGuo containing 
oligonucleotides for Chapter II 
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Enzyme digestion of A: 5’-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3’ 
(2.43a, furanose); B: 5’-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3’ 
(2.43b, pyranose) 
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Enzyme digestion of A: 5’-TCAT-(MeFAPy-dGuo)-GAATCCTTCCC 
CC-3’ (furanose); B: 5’-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-
3’ (pyranose)  
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Enzyme digestion of A: 5’-TCAT-(MeFAPy-dGuo)-GAATCCTTACG 
AGCATCGCCCCC-3’ (2.52a, furanose); B: : 5’-TCAT-(MeFAPy-
dGuo)-GAATCCTTACGAGCATCGCCCCC-3’  (2.52b, pyranose)  
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Enzyme digestion of A: 5’-CTT-(MeFAPy-dGuo)-TT-3’ (2.37a, 
furanose); B:  5’-CTT-(MeFAPy-dGuo)-TT-3’ (2.37b, pyranose) 
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Appendix VI 
 
Stability of MeFAPy-dGuo containing 
oligonucleotides (2.42a and 2.42b) for Chapter II 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in water 
for 2 days 
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 5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in water 
for 5 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in water 
for 1h at 90 °C 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in 
buffer for 2 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in 
buffer for 5 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in 
buffer for 10 min at 90 °C 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in 
buffer for 30 min at 90 °C 
 
 
 279
 
 
5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in 
buffer for 1h at 90 °C 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42b, pyranose) in water 
for 2 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42b, pyranose) in water 
for 5 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42b, pyranose) in buffer 
for 2 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42b, pyranose) in buffer 
for 5 days 
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5'-CCTCTTC-(MeFAPy-dGuo)-CTCTC-3' (2.42a, furanose) in water 
with Na(CN)BH3 for 2 days 
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Appendix VII 
 
HPLC and CZE Traces 
for Chapter II 
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CZE analysis of 5'-CTT-(MeFAPy-dGuo)-TT-3' (2.27); A) CZE traces 
of 2.27a (furanose form); B CZE traces of 2.27b (pyranose form); 
C) CZE traces of the co-injection of 2.27a and 2.27b. 
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CZE (A) and HPLC (B) traces of 5'-TCAT-(MeFAPy-dGuo)-
GAATCCTTCCCCC-3' (furanose form). 
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CZE analysis of 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCCCCC-3'; 
A) CZE traces of the furanose form; B) CZE traces of the pyranose 
form; C) CZE traces of the co-injection of the furanose and 
pyranose forms. 
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CZE analysis of 5'-TCAT-(MeFAPy-dGuo)-GAATCCTTCGAGCATC 
GCCCCC-3' 92.52A). 
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Appendix VIII 
 
LC-ESI/MS/MS Sequencing 
for Chapter II 
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CID fragmentation of commercially obtained sequence  
5′-pTCCATGA-3′ 
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CID fragmentation of commercially obtained sequence  
5′-pTCTATGA-3′ 
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CID fragmentation of commercially obtained sequence  
5′-pTCGATGA-3′ 
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CID spectrum of the molecular ion peak m/z 1099.25 of the DPO4 
full-length extension product, identified as 5′-pTCGATGA-3′, past 
the MeFAPy-dGuo lesion in oligonucleotide 2.52a using primer 
5′GGGGGCGATGCTCGTAAGGATTCG-3’ (2.58). 
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CID spectrum of the molecular ion peak m/z 1090.68 of the DPO4 
full-length extension product, identified as 5′-pTCAATGA-3′, past 
the MeFAPy-dGuo lesion in oligonucleotide 2.52a using primer 
5′GGGGGCGATGCTCGTAAGGATTCA-3’ (2.56). 
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CID spectrum of the molecular ion peak m/z 1086.83 of the DPO4 full-length 
extension product, identified as 5′-pTCTATGA-3′, past the MeFAPy-dGuo 
lesion in oligonucleotide 2.52a using primer 
5′GGGGGCGATGCTCGTAAGGATTCT-3’ (2.57). 
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Sequence : 
TCC ATGA  
5'p - DNA[7mer] - 3'OH 
C:2  T:2  A:2  G:1   
monoisotopic mass, negative mode 
 
CID FRAGMENTS 
 
    n   ch      a-B           w            y               d-H2O 
 
    1   -1                   330.059   250.093     303.037 
        -2                                                      151.015 
    2   -1   481.040   659.111   579.145     592.083 
        -2   240.016   329.051   289.068      295.538 
        -3                                                      196.689 
    3   -1   770.086   963.157   883.191     881.129 
        -2    384.539   481.074   441.091     440.061 
        -3   256.023   320.380   293.725      293.038 
        -4                                                      219.526 
    4   -1  1059.132  1276.214  1196.248  1194.187 
        -2      529.062   637.603   597.620   596.589 
        -3      352.372   424.733   398.077   397.390 
        -4      264.027   318.297   298.306   297.790 
        -5                                                      238.031 
    5   -1  1372.189  1565.260  1485.294  1498.232 
        -2     685.590   782.126   742.143    748.612 
        -3     456.724   521.081   494.426    498.739 
        -4     342.291   390.559   370.567    373.802 
        -5     273.631   312.245   296.252    298.840 
        -6                                                      248.865 
    6   -1  1676.235  1854.306  1774.340  1827.285 
        -2     837.613   926.649   886.666    913.138 
        -3     558.073   617.430   590.775    608.423 
        -4     418.302   462.820   442.829    456.065 
        -5     334.440   370.055   354.061    364.650 
        -6     278.532   308.211   294.883    303.707 
        -7                                                      260.176 
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Sequence :  
TCT ATG A  
5'p - DNA[7mer] - 3'OH 
C:1  T:3  A:2  G:1   
monoisotopic mass, negative mode 
 
CID FRAGMENTS 
 
    n   ch      a-B           w           y               d-H2O 
 
    1   -1                  330.059   250.093       303.037 
        -2                                                       151.015 
    2   -1   481.040   659.111   579.145      592.083 
        -2    240.016   329.051   289.068      295.538 
        -3                                                       196.689 
    3   -1   770.086   963.157   883.191      896.129 
        -2    384.539   481.074   441.091      447.560 
        -3    256.023   320.380   293.725      298.037 
        -4                                                       223.276 
    4   -1  1074.131  1276.214  1196.248  1209.186 
        -2     536.561   637.603   597.620     604.089 
        -3     357.372   424.733   398.077     402.390 
        -4     267.777   318.297   298.306     301.540 
        -5                                                      241.031 
    5   -1  1387.189  1580.260  1500.294  1513.232 
        -2     693.090   789.626   749.643      756.112 
        -3     461.724   526.081   499.426      503.738 
        -4     346.041   394.309   374.317      377.552 
        -5     276.631   315.245   299.252      301.840 
        -6                                                      251.365 
    6   -1  1691.234  1869.306  1789.340  1842.284 
        -2     845.113   934.149   894.166      920.638 
        -3     563.073   622.430   595.774      613.423 
        -4     422.052   466.570   446.579      459.815 
        -5     337.440   373.055   357.061      367.650 
        -6     281.032   310.711   297.383      306.207 
        -7                                                        262.319 
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Sequence :  
TCA ATG A  
5'p - DNA[7mer] - 3'OH 
C:1  T:2  A:3  G:1   
monoisotopic mass, negative mode 
 
CID FRAGMENTS 
 
    n   ch      a-B            w         y                d-H2O 
 
    1   -1                  330.059   250.093       303.037 
        -2                                                       151.015 
    2   -1   481.040   659.111   579.145      592.083 
        -2    240.016   329.051   289.068      295.538 
        -3                                                       196.689 
    3   -1   770.086   963.157   883.191      905.141 
        -2    384.539   481.074   441.091      452.066 
        -3    256.023   320.380   293.725      301.041 
        -4                                                       225.529 
    4   -1  1083.143  1276.214  1196.248  1218.198 
        -2     541.067   637.603   597.620      608.595 
        -3     360.375   424.733   398.077     405.394 
        -4     270.029   318.297   298.306     303.793 
        -5                                                       242.833 
    5   -1  1396.200  1589.271  1509.305  1522.244 
        -2     697.596   794.132   754.149      760.618 
        -3     464.728   529.085   502.430      506.742 
        -4     348.294   396.562   376.570      379.805 
        -5     278.433   317.048   301.054      303.642 
        -6                                                        252.867 
    6   -1  1700.246  1878.317  1798.351  1851.296 
        -2     849.619   938.655   898.672      925.144 
        -3     566.076   625.434   598.778      616.426 
        -4     424.305   468.823   448.832      462.068 
        -5     339.243   374.857   358.864      369.453 
        -6     282.534   312.213   298.885      307.709 
        -7                                                        263.607 
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Sequence :  
TCG ATG A  
5'p - DNA[7mer] - 3'OH 
C:1  T:2  A:2  G:2   
monoisotopic mass, negative mode 
 
CID FRAGMENTS 
 
    n   ch      a-B            w            y             d-H2O 
 
    1   -1                   330.059   250.093        303.037 
        -2                                                         151.015 
    2   -1   481.040   659.111   579.145        592.083 
        -2    240.016   329.051   289.068        295.538 
        -3                                                         196.689 
    3   -1   770.086   963.157   883.191        921.136 
        -2    384.539   481.074   441.091        460.064 
        -3    256.023   320.380   293.725        306.373 
        -4                                 229.528 
    4   -1  1099.138  1276.214  1196.248   1234.193 
        -2     549.065   637.603   597.620       616.592 
        -3     365.707   424.733   398.077       410.725 
        -4     274.028   318.297   298.306       307.792 
        -5                                                         246.032 
    5   -1  1412.195  1605.266  1525.300  1538.239 
        -2     705.593   802.129   762.146      768.615 
        -3     470.059   534.417   507.761      512.074 
        -4     352.293   400.560   380.569      383.803 
        -5     281.632   320.247   304.253      306.841 
        -6                                 255.533 
    6   -1  1716.241  1894.312  1814.346  1867.291 
        -2     857.616   946.652   906.669      933.141 
        -3     571.408   630.765   604.110      621.758 
        -4     428.304   472.822   452.830      466.066 
        -5     342.442   378.056   362.063      372.652 
        -6     285.200   314.878   301.551      310.375 
        -7                                                        265.892 
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Appendix IX 
 
Steady-state Kinetics 
for Chapter II 
 
 
 
 
 
 
 
 
 302
 Steady-State kinetics for Kf– with dCTP(A), dTTP ( B), dGTP(C) 
and dATP (D) 
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Steady-State kinetics for Dpo4- with dCTP(A), dTTP ( B), dGTP(C) 
and dATP (D) 
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Steady-State kinetics for Pol lI– with dCTP(A), dTTP ( B), dGTP(C) 
and dATP (D) 
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Steady-State kinetics for pol η with dCTP(A), dTTP ( B), dGTP(C) 
and dATP (D) 
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Steady-State kinetics for pol κ with dCTP(A), dGTP ( B) and 
dTTP(C) 
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Appendix X 
 
1H, 13C, COSY, NOESY, HMBC and HSQC NMR Spectra  
for Chapter III 
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1H NMR of N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-(2-
propenyl)-formamide (3.33) 
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COSY NMR of N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-
(2-propenyl)-formamide (3.33) 
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1H NMR of N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-(2,3-
dihydroxypropyl)-formamide (3.34)  
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 COSY NMR of N-(2,6-Diamino-3,4-dihydro-4-oxo-5-pyrimidinyl)-N-
(2,3-dihydroxypropyl)-formamide (3.34)  
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1H NMR of 2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-oxopteridine-
5(6H)-carbaldehyde (3.36) 
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COSY NMR of N-3-[(dimethylamino)methylene]-3’O-[(2-cyanoethyl)-
(N,N-diisopropyl)phosphoroamidite-(5’-O-[bis(4-methoxyphenyl)-
phenylmethyl-2’-deoxy-β-D-erythro-pentofyranosyl)amino]-3,4-
dihydro-4-oxo-5-pyrimidi-nyl]-N-(methyl)-formamide (2.36) 
 
 314
 
13C NMR of 2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-oxopteridine-
5(6H)-carbaldehyde(3.36) 
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 HMBC NMR of 2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-
oxopteridine-5(6H)-carbaldehyde (3.36) 
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 NOESY NMR of 2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-
oxopteridine-5(6H)-carbaldehyde(3.36) 
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 HSQC NMR of 2-Amino-3,4,7,8-tetrahydro-7-hydroxy-4-
oxopteridine-5(6H)-carbaldehyde(3.36) 
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1H NMR of 2-Amino-5,8-dihydro-4(3H)-pteridinone (3.37) 
 319
 COSY NMR of 2-Amino-5,8-dihydro-4(3H)-pteridinone (3.37) 
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13C NMR of 2-Amino-5,8-dihydro-4(3H)-pteridinone (3.37) 
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1H NMR of 2-Amino-4-hydroxypyrimido[4,5-b]pyrazine (3.38) 
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13C NMR of 2-Amino-4-hydroxypyrimido[4,5-b]pyrazine (3.38) 
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1H NMR of N7-(2-Propenyl)-guanine 
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 COSY NMR of N7-(2-Propenyl)-guanine 
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1H NMR of N2-(2-Chloro-1-hydroxy-ethyl)-(2-deoxy-β-D-erythro-
pentopyranosyl)-guanine (3.43)  
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 COSY NMR of N2-(2-Chloro-1-hydroxy-ethyl)-(2-deoxy-β-D-
erythro-pentopyranosyl)-guanine (3.43)  
 327
